Cover Page for Protocol 
 
Sponsor name:  [CONTACT_3454] A/S 
NCT number [STUDY_ID_REMOVED] 
Sponsor trial ID: NN9068-4229 
Official title of study: A clinical trial comparing glycaemic control and safety of 
insulin degludec/liraglutide (IDegLira) versus insulin glargine 
(IGlar) as add-on therapy to SGLT2i in subjects with type 2 diabetes mellitus 
Document date: 22-March-[ADDRESS_1268786] of contents
Protocol - version 2.0.......................................... ............................................................... .................
Protocol amendment 1 - Spain ..................................... ............................................................... ......
Protocol amendment 2 - Global ................................... ............................................................... ......CONFIDENTIALDate: Novo Nordisk
Version:
Status:IDegLira
Trial ID: NN9068-4229Clinical Trial Report
Appendix 16.1.1 0DUFK  2018

)LQDO
16.1.1 Protocol and protocol amendmentsCONFIDENTIAL
30Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 1 of 107
Protocol
Trial ID: NN9068-4229
DUALTMIX - Add-on to SGLT2i
A clinical trial comparing glycaemic control and safety 
of insulin degludec/liraglutide (IDegLira) versus insulin 
glargine (IGlar) as add-on therapy to SGLT2i in 
subjects with type 2 diabetes mellitus 
Trial phase: 3b
Protocol originator
, 
Insulin & Diabetes Outcomes 
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties. 
 
 
 
 
Redacted protocol 
Includes redaction of personal identifiable information only. 
 
 
 
. 
 
 
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268787] re placement......................................................................................................... ............27
6.8 Rationale for trial population.............................................................................................. .........27
7 Milestones.................................................................................................................... .............................29
8 Methods and assessments ....................................................................................................... ................30
8.1 Visit procedures ............................................................................................................ ...............30
8.1.1 Fasting requirements..................................................................................................31
8.1.2 Screening (V1)...........................................................................................................3 2
8.1.3 Screening failures ......................................................................................................32
8.1.4 Randomisation (V2)...................................................................................................33
8.1.5 Follow-up contacts (FU1 and FU2) ...........................................................................[ADDRESS_1268788] ................................................................34
8.1.8 Withdrawal of consent...............................................................................................35CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268789] related information................................................................................................. .........36
8.3.1 Demography...............................................................................................................3 6
8.3.2 Concomitant illness a nd medical history ...................................................................36
8.3.3 Diabetes history and diab etes complications: ............................................................37
8.3.4 Hypoglycaemia una wareness.....................................................................................37
8.3.5 Concomitant medication............................................................................................37
8.3.6 Smoking status (t obacco use).....................................................................................38
8.4 Assessments for efficacy.................................................................................................... ..........38
8.4.1 Body measurements...................................................................................................38
8.4.2 Blood samples for efficacy ........................................................................................38
8.4.3 Fasting plasma gl ucose (FPG) ...................................................................................39
8.4.4 Self-measured plas ma glucose (SMPG) ....................................................................39
8.5 Assessments for safety...................................................................................................... ...........40
8.5.1 Adverse events (AEs) ................................................................................................40
8.5.2 Hypoglycaemic epi[INVESTIGATOR_1841] ...........................................................................................408.5.3 Physical examination .................................................................................................43
8.5.4 Vital Signs............................................................................................................... ...43
8.5.5 Electrocardiogr am (ECG) ..........................................................................................[ADDRESS_1268790] co mpliance.......................................................................................................... ............46
9 Trial supplies ................................................................................................................ ...........................47
9.1 Trial products.............................................................................................................. .................47
9.2 Labelling ................................................................................................................... ...................48
9.3 Storage ..................................................................................................................... ....................48
9.4 Drug accountability and destruction ......................................................................................... ...49
9.5 Auxiliary supplies.......................................................................................................... ..............49
10 Interactive web respo nse system  (IWRS)....................................................................................... .......50
11 Randomisation  procedure ...................................................................................................... ................50
12 Adverse events,  technical c omplaints and pr egnancies ......................................................................51
12.1 Definitions ................................................................................................................ ...................51
12.2 Reporting of a dverse events................................................................................................ .........54
12.3 Follow-up of adverse events ................................................................................................ ........57
12.4 Technical complaints and tec hnical complaint samples ..............................................................57
12.4.1 Reporting of techn ical complaints .............................................................................57
12.4.2 Collection, storage and shipment of technical complaint samples ............................58
12.5 Pregnancies ................................................................................................................ ..................58
12.5.1 Pregnancies in  female subjects ..................................................................................58
12.5.2 Pregnancies in female partners of male subjects (only applicable for US)................60
12.6 Precautions and/or overdose ................................................................................................. .......61
12.7 Committees related to safety............................................................................................... .........62
12.7.1 Novo Nordisk sa fety committee ................................................................................62CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 4 of 107
12.7.2 Event adjudicati on committee (E AC)........................................................................62
13 Case report forms............................................................................................................ ........................64
13.1 Corrections to cas e report forms........................................................................................... .......64
13.2 Case report form flow...................................................................................................... ............65
14 Monitoring procedures ........................................................................................................ ...................66
15 Data man agement.............................................................................................................. ......................68
16 Computerised  systems......................................................................................................... ....................68
17 Statistical considerations ................................................................................................... .....................69
17.1 Sample size calculation.................................................................................................... ............70
17.2 Definition of analysis sets................................................................................................ ............72
17.3 Primary endpoint........................................................................................................... ...............73
17.3.1 Primary statistical anal ysis primary estimand............................................................73
17.3.2 Sensitivity analyse s primary es timand.......................................................................75
17.3.3 Primary statistical analysi s secondary estimand ........................................................76
17.3.4 Sensitivity analyses secondary es timand ...................................................................76
17.4 Secondary endpoints........................................................................................................ ............76
17.4.1 Confirmatory seconda ry endpoints............................................................................76
17.4.2 Supportive seconda ry endpoints ................................................................................80
17.5 Health economics and/or pa tient reported outcomes ...................................................................[ADDRESS_1268791] during trial ........................................................................................ .......93
18.5 Premature termination of th e trial and/or trial site....................................................................... 94
19 Protocol compliance.......................................................................................................... ......................95
20 Audits and inspections ....................................................................................................... .....................95
21 Critical documents ........................................................................................................... .......................96
22 Responsibilities ............................................................................................................. ...........................98
23 Reports and publications..................................................................................................... ...................99
23.1 Communication of results................................................................................................... .........99
23.1.1 Authorship ............................................................................................................... 100
23.1.2 Site-specific publication(s) by [CONTACT_1697](s) .........................................................100
23.2 Investigator access to data and review of results .......................................................................100
24 Retention of clinical trial documentation.................................................................................... ........101
24.1 Retention of clinical trial documentation.................................................................................. .101
25 Institutional Review Boards/Independent Ethics Committees and regulatory authorities............102
26 Indemnity stateme nt .......................................................................................................... ...................103
27 References ................................................................................................................... ...........................104CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 5 of 107
Appendices and attachments to the protocol
!Appendix A: Titration Guideline
!Appendix B: Events with additional data collection and events requiring adjudication
!Appendix C: Monitoring of calcitonin
!Attachment  I – Global list of key staff and relevant departments and suppliers
Table of Figures
Page
Figure 5–1 Trial Design ......................................................................................................... ...................21
Figure 12–1 Initial reporting of AEs............................................................................................ ...............56
Figure 17–1 Novo Nordisk cla ssification of hypoglycaemia......................................................................85
Figure 17–2 ADA classifi cation of hypogl ycaemia................................................................................. ...86
Table of Tables
Page
Table 9–1 Investigati onal medicinal products................................................................................... ......47
Table 9–2 Storage conditions for investigational medicinal products.....................................................48
Table 17–1 Power for various rates of disc ontinuation .......................................................................... ...72CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268792] aspartate aminotransferase GLP-1 glucagon-like peptide-1 
BG blood glucose HbA
1c glycosylated haemoglobin
BMI body mass index hCG human Chorionic Gonadotropi[INVESTIGATOR_904183]-
EPI[INVESTIGATOR_904184]’s Brochure
CR copy reference ICH GCPI[INVESTIGATOR_904185]. Guideline for Good 
Clinical Practice 
CRF case report form IDeg insulin degludec
CTR clinical trial report IDegLira insulin degludec/liraglutide
DPP4i dipeptidyl peptidase-4 inhibitors IDMS isotope-dilution mass spectrometry DUN dispensing unit number IGlar insulin glargineEAC Event Adjudication Committee IMPs investigational medicinal products  
EASDEuropean Association for the Study 
of DiabetesIRB/IECInstitutional Review 
Board/Independent Ethics 
Committee 
ECG electrocardiogram IWRS interactive web response system
eCRF electronic case report form J2R jump to reference
eGFR estimated Glomerular Filtration Rate LDL low-density lipoproteinEoT end of treatment LLOQ lower limit of quantificationEMA European Medicines Agency LSFV last subjects first visit
FAS full analysis set MACEmajor adverse cardiovascular 
events
FDA U.S. Food and Drug Administration MI myocardial infarction
FPG fasting plasma glucose NIMPsnon-investigational medicinal 
products  CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268793] measureTSH thyroid stimulating hormoneTTT treat to targetUTN Universal Trial Number
VLDL very-low-density lipoproteinCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 8 of 107
1 Summary
Objectives and endpoints:
Primary objective
To confirm the effect of insulin degludec/liraglutide (IDegLira) in terms of glycaemic control in 
subjects with type 2 diabetes mellitus (T2DM) on previous treatment with sodium-glucose co-
transporter 2 inhibitors (SGLT2i) ± oral an ti-diabetic drug (OAD) therapy. This is done by 
[CONTACT_904240] 1cafter 26 weeks to a non-inferiority
margin of 0.3% for IDegLira versus insulin glargine (IGlar), both in combination with SGLT2i ±OAD.
Primary endpoint
Change from baseline in HbA
1c after 26 weeks.
Key secondary objectives
To confirm superiority of IDegLira versus IGlar after 26 weeks  in subjects with T2DM on previous 
treatment with SGLT2i ± OAD therapy in terms of one or more of the following:
!Weight change
!Treatment-emergent hypoglycaemic epi[INVESTIGATOR_1841] (severe or blood glucose [BG]confirmed
symptomatic)
!Glycaemic control
!Insulin dose
To compare the effect and safety of IDegLira versus IGlar after 26 weeks.
Key secondary endpoints
The key secondary endpoints are:
!Change from baseline in body weight after 26 weeks
!Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_904186] 26 weeks
!Insulin dose, total daily dose (U) after 26 weeks
!Responder after 26 weeks (Yes/No) for HbA 1c< 7.0%
!Change from baseline after 26 weeks in fasting plasma glucose (FPG)
!Number of treatment-emergent adverse events during 26 weeks
Trial design:
This is a 26-week randomised, active-controlled, multicentre, multinational, two-arm parallel, open-
label, treat-to-target trial (TTT) in subjects with T2DM. Subjects inadequately controlled on OAD CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268794] include SGLT2i 
either as monotherapy, or in combinations with metformin ± dipeptidyl peptidase-4 inhibitor 
(DPP4i) ± pi[INVESTIGATOR_051]. If a subject is treated with DPP4i these have to be discontinued at 
randomisation. Subjects on fixed dose combinations of SGLT2i and DPP4i should be shifted to the 
corresponding SGLT2i, whereas fixed dose combinations of SGLT2i and metformin should be 
continued. Pi[INVESTIGATOR_904187], except those treated with dapagliflozin. The trial 
will compare IDegLira to IGlar as an add-on to treatment with SGLT2i ± OAD. Inadequately 
controlled T2DM is defined as an HbA 1clevel of 7.0-11.0%, both inclusive.
Trial population:
Planned number of subjects to be randomised and started on trial products is 416.
Key inclusion criteria
!Male or female, age ≥18 years at the time of signing informed consent
!Subjects diagnosed (clinically) with type 2 diabetes mellitus
!HbA 1c7.0-11.0% [53-97 mmol/mol] (both inclusive) by [CONTACT_111405]
!Body mass index (BMI) ≥20 kg/m2and < 40 kg/m2
!Insulin naïve subjects; however short term insulin treatment for a maximum of 14 days prior to
the day of screening is allowed, as well as prior insulin treatment for gestational diabetes
!A stable daily dose for at least 90 days prior to the day of screening of any SGLT2i in
monotherapy or in combination with metformin ± DPP4i ± pi[INVESTIGATOR_051]. Use of pi[INVESTIGATOR_904188]
!Receipt of any investigational medicinal product within 90 days prior to screening
!Use of any OADs (other than SGLT2i in monotherapy or in combination with metformin or
DPP4i or pi[INVESTIGATOR_904189]) within 90 days prior to the day of
screening
!Use of glucagon-like peptide-1 (GLP-1) receptor agonist (e.g., exenatide or liraglutide) within
90 days prior to the day of screening
!Acute decompensation of glycaemic control requiring immediate intensification of treatment to
prevent severe metabolic dysregulation (e.g., diabetes ketoacidosis) in the previous 90 days
prior to the day of the screening
!Subjects presently classified as being in NYHA Class III or IV1
!Renal impairment estimated Glomerular Filtration Rate < 60 mL/min/1.73 m2as per CKD-EPI
(Chronic Kidney Disease Epi[INVESTIGATOR_10444])CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 10 of 107
!Impaired liver function, defined as ALT ≥2.5 times upper normal limit at screening
!Known or suspected hypersensitivity to trial product(s) or related products
Key efficacy assessments:
!HbA 1c
!Body weight
Key safety assessments: 
!Hypoglycaemic epi[INVESTIGATOR_1841]
!Adverse events (AEs)
Trial products:
!IDegLira 100 units/mL + 3.6 mg/mL, a fixed ratio of IDeg (100 units/mL) and liraglutide (3.6
mg/mL) solution provided in a 3 mL pre-filled PDS290 pen-injector for subcutaneous (s.c.)
injection
!IGlar (Lantus®) 100 units/mL solution for injection in a pre-filled pen (SoloStar®) for s.c.
injection
The subject’s de-facto cost of SGLT2i and metformin (mono- or fixed dose combination products) 
will be reimbursed in accordance with local legislation and Ethics Committee approval.   CONFIDENTIAL
Protocol UTN: U1111-1168-9343 Date: 20 November 2015 Status: Final Novo Nordisk
Trial ID: NN9068-[ADDRESS_1268795] No.: 2015-001596-48 Version: 2.0 Page: 11 of 107
2 Flow chart
Trial Periods Screen Rand Treatment EoT Follow-up Pre-disc1
Trial site visit (V)
Phone contact (P)2V1 V2 P3 V4 P5 V6 P7 V8 P9 V10P11
P12
P13 V14P15
P16
P17 V18P19
P20
P21 V22P23
P24
P25 V26P27
P28
P29
P30
P31 V32FU1
V33FU2
P34 PX V32A
Timing of visit (weeks)≤ [ADDRESS_1268796] 
trial 
productEvery 
4 
weeks 26
Visit window (days) ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±[ADDRESS_1268797] RELATED
INFO/ASSESSMENTS
Informed consent X
In/exclusion criteria X X
Randomisation X
Pre-discontinuation of 
trial productX X X X X X X X X X X X X X X X X X
Rescue criteria X X X X X X X X X X X X X X
Withdrawal of consent X X X X X X X X X X X X X X X X X X X X4X
Demography5X
Concomitant illness X
Medical history X
Diagnosis of diabetes X
Diabetes complications X
1Subjects discontinuing trial product prematurely will be asked to attend the end of treatment (EoT) visit and the two follow up  visits after discontinuation corresponding to V32, V33 and 
P34. After the follow-up period the subject should have phone contacts scheduled every 4 weeks (PX) until the additional premat ure discontinuation follow-up visit (V32A) performed at 
week 26. See section 8.1.[ADDRESS_1268798] prematurely.
5Collection of sex and date of birth, race and ethnicity only if applicable by [CONTACT_1769].
Protocol UTN: U1111-1168-9343 Date: 20 November 2015 Status: Final Novo Nordisk
Trial ID: NN9068-[ADDRESS_1268799] No.: 2015-001596-48 Version: 2.0 Page: 12 of 107
Trial Periods Screen Rand Treatment EoT Follow-up Pre-disc1
Trial site visit (V)
Phone contact (P)2V1 V2 P3 V4 P5 V6 P7 V8 P9 V10P11
P12
P13 V14P15
P16
P17 V18P19
P20
P21 V22P23
P24
P25 V26P27
P28
P29
P30
P31 V32FU1
V33FU2
P34 PX V32A
Timing of visit (weeks)≤ [ADDRESS_1268800] 
trial 
productEvery 
4 
weeks 26
Visit window (days) ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±[ADDRESS_1268801], please enter “0” in the eCRF
8Body weight should be measured fasting except at V1, see section 8.1.[ADDRESS_1268802] attend visits fasting, see section 8.1.1
Protocol UTN: U1111-1168-9343 Date: 20 November 2015 Status: Final Novo Nordisk
Trial ID: NN9068-[ADDRESS_1268803] No.: 2015-001596-48 Version: 2.0 Page: 13 of 107
Trial Periods Screen Rand Treatment EoT Follow-up Pre-disc1
Trial site visit (V)
Phone contact (P)2V1 V2 P3 V4 P5 V6 P7 V8 P9 V10P11
P12
P13 V14P15
P16
P17 V18P19
P20
P21 V22P23
P24
P25 V26P27
P28
P29
P30
P31 V32FU1
V33FU2
P34 PX V32A
Timing of visit (weeks)≤ [ADDRESS_1268804] 
trial 
productEvery 
4 
weeks 26
Visit window (days) ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±3
Self measured plasma 
glucose (SMPG)
Once daily10X X X X X X X X X X X X X X
9-point profile11X X X
SAFETY
Adverse events X X X X X X X X X X X X X X X X X X X X X X X12X12
Hypoglycaemic epi[INVESTIGATOR_1841] X X X X X X X X X X X X X X X
Technical complaints X X X X X X X X X X X X X X X
ECG X X13
Eye examination X14X15
Physical examination X X
Vital signs X X X X
Biochemistry X X X X X X
Haematology X X X X
Hormones (calcitonin) X X X X
Urinalysis 
(albumin:creatinine ratio)X X X
10Subjects should measure "self measured plasma glucose" prior to breakfast. Diabetes medication should be withheld until after t he SMPG measurement.
119-point profile should be measured within one week prior to the site visit (on a day where unusual strenuous exercises is not a nticipated).
12Only AE information for potential major adverse cardiovascular events (MACE) and SAE information will be collected
13ECG obtained within [ADDRESS_1268805] the screening assessment if resul ts are available for evaluation at V2. 
15Eye examination performed within 2 weeks prior to V32 is acceptable if results are available for evaluation at V32.
Protocol UTN: U1111-1168-9343 Date: 20 November 2015 Status: Final Novo Nordisk
Trial ID: NN9068-[ADDRESS_1268806] No.: 2015-001596-48 Version: 2.0 Page: 14 of 107
Trial Periods Screen Rand Treatment EoT Follow-up Pre-disc1
Trial site visit (V)
Phone contact (P)2V1 V2 P3 V4 P5 V6 P7 V8 P9 V10P11
P12
P13 V14P15
P16
P17 V18P19
P20
P21 V22P23
P24
P25 V26P27
P28
P29
P30
P31 V32FU1
V33FU2
P34 PX V32A
Timing of visit (weeks)≤ [ADDRESS_1268807] 
trial 
productEvery 
4 
weeks 26
Visit window (days) ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±3
Urine dipstick X X X
Pregnancy test16X (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) X
OTHER ASSESSMENTS
Barriers in Diabetes 
Treatment questionnaireX
PRO questionnaires
TRIM-D X X X
SF-36v2 X X X
TRIAL MATERIAL
Dispensing trial product X X X X X X X
IWRS call X X X X X X X X X
Dosing dates17X X
Drug accountability X X X X X X X X
REMINDERS
Hand-out ID card X
Discontinue DPP4i X
Training in trial product 
and pen handling.X X X X X X X
16For women of childbearing potential a blood sample pregnancy test must be performed at V1 and V32. Additionally, a urine pregna ncy test should be performed at site if pregnancy is 
suspected or if a menstrual period is missed. If the subject reports missing menstrual period at a phone contact, the subject wi ll have to attend the site for an unscheduled visit as soon as 
possible to have an urine pregnancy test performed. If positive a confirmatory serum hCG test should be sent to the central lab oratory. If required by [CONTACT_1769], pregnancy test may be 
performed regularly.
17First and last dates and doses as recorded in patient diaries.
Protocol UTN: U1111-1168-9343 Date: 20 November 2015 Status: Final Novo Nordisk
Trial ID: NN9068-[ADDRESS_1268808] No.: 2015-001596-48 Version: 2.0 Page: 15 of 107
Trial Periods Screen Rand Treatment EoT Follow-up Pre-disc1
Trial site visit (V)
Phone contact (P)2V1 V2 P3 V4 P5 V6 P7 V8 P9 V10P11
P12
P13 V14P15
P16
P17 V18P19
P20
P21 V22P23
P24
P25 V26P27
P28
P29
P30
P31 V32FU1
V33FU2
P34 PX V32A
Timing of visit (weeks)≤ [ADDRESS_1268809] 
trial 
productEvery 
4 
weeks 26
Visit window (days) ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±[ADDRESS_1268810] in 
BG meterX
Attend visit fasting X X X X X X X
Make appointment for eye 
examinationX
Sign off Casebook X18X
End of trial 
(subject completion)X18X
18Not applicable for subjects that have prematurely discontinued trial product.
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 16 of 107
3 Background information and rationale for the trial
The trial will be conducted in compliance with this protocol, ICH GCP2and applicable regulatory 
requirements, and in accordance with the Declaration of Helsinki3. 
In this document, the term investigator refers to the individual responsible for the overall conduct of the clinical trial at a trial site.
3.[ADDRESS_1268811] demonstrated the importance of maintaining good glycaemic control to reduce the risk of long-term complications associated with diabetes
5,6.The initial step in management of T2DM 
includes lifestyle intervention and treatment with OADs, often with metformin as a first choice. 
Given the progressive nature of T2DM, anti-diabetic therapi[INVESTIGATOR_904190]-treatment may need intensification over time, and more anti-diabetic therapi[INVESTIGATOR_904191], often two OADs. If the glycaemic target is not achieved or sustained with this treatment, several treatment options exist such as intensifying with insulin treatment, GLP-[ADDRESS_1268812] treatment as separate injections has led to the inclusion of this treatment combination in the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) position statement on management of hyperglycaemia in T2DM
4,7,8.
IDeg is a long-acting basal insulin and the active ingredient used in Tresiba®, which has been 
approved for use in amongst others the [LOCATION_003], European Union (EU) and Japan. For more details on IDeg see current Investigator’s Brochure (IB)
9and any updates hereof and locally approved 
labelling in countries where this is available.
Liraglutide is an analogue native (human) GLP-[ADDRESS_1268813] and the active ingredient used in 
Victoza®, which is approved amongst others in Australia, Canada, China, EU, Japan and the US for 
the treatment of adults with T2DM to achieve glycaemic control. For more details on liraglutide, 
please see the local approved labelling for Victoza®. 
IDegLira (the combination of IDeg and Liraglutide) is a solution for s.c. injection for treatment of 
T2DM with once daily (OD) use. It is to be initiated and titrated to achieve adequate glycaemic 
control in a similar way as basal insulin therapy. The basal insulin and GLP-1 analogue 
combination provides complimentary effects of the two compounds on fasting and postprandial 
glycaemic control in a single injection. IDegLira is on the market as Xultophy∀and has been 
approved for use amongst others in EU. Efficacy and safety of IDegLira has been demonstrated in 
previous randomised clinical trials (NN9068-3697, NN9068-3912, NN9068-3951, NN9068-3851 
and NN9068-3952) and is currently being evaluated in the randomised clinical trials NN9068-4056CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 17 of 107
and NN9068-4185. In all finalised clinical trials, IDegLira has shown to effectively improve the 
glycaemic control of the subjects, and no unexpected safety issues were identified. For more information, see the IDegLira NN9068 IB
10current version or any updates hereof. 
The basal insulin and GLP-1 analogue combination brings complementary effects of the two
compounds on fasting (IDeg and liraglutide) and postprandial (liraglutide) glycaemic control. The 
addition of liraglutide to IDeg reduces the requirement of exogenous insulin (i.e. insulin sparing 
effect) hence minimising the risk of hypoglycaemia and weight gain often associated with insulin 
treatment. The inherent weight reducing effect of liraglutide further contributes to the favourable
weight profile of the combination drug compared to basal insulin treatment. Furthermore, given the 
glucose dependent effect of liraglutide, liraglutide reduces postprandial glucose excursions while 
reducing the risk of unwanted lowering of inter-prandial or fasting glucose.
IGlar (Lantus®) is a long-acting insulin analogue, indicated for treatment of diabetes mellitus in 
combination with oral antidiabetic agents. For further details, please refer to the Summary of 
Product Characteristics (SmPC)11for IGlarand the [LOCATION_002] (U.S.) Label Information12.
For an assessment of benefits and risks of the trial, see section 18.1.
3.2 Rationale for the trial
Recently, a new OAD class has been introduced on the market, the SGLT2i. The mode of action of 
SGLT2i is to inhibit renal re-absorption of glucose in the renal cortex, thereby [CONTACT_904241]
13.Treatment with SGLT2i is also associated with a 
lowering of systolic blood pressure of ~5 mmHg and a weight reduction in the range of 1–3 kg14,15.
SGLT2i act independently of other diabetes treatment modalities, and combination therapy with most of the current therapi[INVESTIGATOR_904192]. In line with this, SGLT2i in fixed dose combinations with 
various OADs, e.g., metformin and DPP4i are approved for use.However, as with current OAD 
regimens, it must be expected that a number of patients with T2DM treated with SGLT2i will need intensification of glycaemic control after a certain period of treatment.
This protocol describes a clinical trial aiming to demonstrate effect and safety of IDegLira versus 
IGlar as an add-on to SGLT2i ± OAD treatment in subjects with T2DM uncontrolled on this OAD 
treatment. IGlar has been chosen as a comparator as it is currently a widely used basal insulin.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268814] of IDegLira in terms of glycaemic control in subjects with T2DM on previous 
treatment with SGLT2i ± OAD therapy. This is done by [CONTACT_904242] 1cafter 26 weeks to a non-inferiority margin of 0.3% for IDegLira versus IGlar, 
both in combination with SGLT2i ± OAD.
Secondary objectives
To confirm superiority of IDegLira versus IGlar after 26 weeks in subjects with T2DM on previous 
treatment with SGLT2i ± OAD therapy in terms of one or more of the following:
!Weight change
!Treatment-emergent hypoglycaemic epi[INVESTIGATOR_1841] (severe or blood glucose [BG]confirmed
symptomatic)
!Glycaemic control
!Insulin dose
To compare the effect and safety of IDegLira versus IGlar after 26 weeks.
4.2 Endpoints
4.2.1 Primary endpoint
Change from baseline in HbA 1cafter 26 weeks.
4.2.2 Secondary endpoints
[IP_ADDRESS] Confirmatory secondary endpoints
The confirmatory secondary endpoints are:
!Change from baseline in body weight after 26 weeks
!Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_904186] 26 weeks
!Insulin dose, total daily dose (U), after 26 weeks
[IP_ADDRESS] Supportive secondary endpoints
Supportive secondary efficacy endpoints:
!Responder after 26 weeks (Yes/No) for:
oHbA 1c< 7.0% *CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 19 of 107
oHbA 1c< 7.0% without weight gain
oHbA 1c < 7.0% without treatment-emergent severe or BG confirmed symptomatic
hypoglycaemic epi[INVESTIGATOR_339663] 12 weeks of treatment
oHbA 1c< 7.0% without treatment-emergent severe or BG confirmed symptomatic
hypoglycaemic epi[INVESTIGATOR_339663] 12 weeks of treatment and without weight gain
oHbA 1c≤ 6.5%
oHbA 1c ≤ 6.5% without weight gain
oHbA 1c≤ 6.5% without treatment-emergent severe or BG confirmed symptomatic
hypoglycaemic epi[INVESTIGATOR_339663] 12 weeks of treatment
oHbA 1c≤ 6.5% without treatment-emergent severe or BG confirmed symptomatic
hypoglycaemic epi[INVESTIGATOR_339663] 12 weeks of treatment and without weight gain
!Change from baseline after 26 weeks in:
oWaist circumference
oFasting plasma glucose (FPG)*
!Fasting lipid profile
oCholesterol
oLow-density lipoprotein cholesterol (LDL cholesterol)
oHigh-density lipoprotein cholesterol (HDL cholesterol)
oVery-low-density lipoprotein cholesterol (VLDL cholesterol)
oTriglycerides
oFree fatty acids
!Self-measured plasma glucose (SMPG) 9-point profile
o9-point profile
oMean of the 9-point profile
oPrandial plasma glucose increments (from before meal to [ADDRESS_1268815], lunch and
dinner). The mean increment over all meals will be derived as the mean of all available
meal increments
!Vital signs
oSystolic and diastolic blood pressure
Supportive secondary safety endpoints:
!Number of treatment-emergent adverse events during 26 weeks*
!Number of treatment-emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic
epi[INVESTIGATOR_51953] 26 weeks
!Number of treatment-emergent hypoglycaemic epi[INVESTIGATOR_513381] 26
weeks
!Change from baseline in clinical evaluation after 26 weeks:
oElectrocardiogram (ECG)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 20 of 107
oEye examination
oPhysical examination
oPulse rate
!Change from baseline in laboratory assessments after 26 weeks:
oBiochemistry
oHaematology
oCalcitonin
oUrine albumin/creatinine ratio
Supportive secondary health economics endpoints:
!Change from baseline in patient reported outcomes (PROs) after 26 weeks:
oSummary scores of medical outcomes study 36-item short form (SF-36v2)[ADDRESS_1268816] measure for diabetes (TRIM-D)17
* Key supportive secondary endpoint prospectively selected for disclosure (e.g. clinicaltrials.gov
and EudraCT)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 21 of 107
5 Trial design
5.1 Type of trial
This is a 26-week randomised, active-controlled, multicentre, multinational, two-arm parallel, open-
label, TTT trial in subjects with T2DM. Subjects inadequately controlled on treatment with SGLT2i 
± OAD will be eligible for the trial. The trial will compare IDegLira to IGlar as an add-on to 
treatment with SGLT2i ± OAD. Inadequately controlled T2DM is defined as an HbA 1clevel of 7.0-
11.0 % (53-97 mmol/mol) (both inclusive).
A total of 416 subjects will be randomized using IWRS in a 1:1 manner to either of the two trial
arms, IDegLira (OD) or IGlar (OD). 
Figure 5–1 Trial Design
The total trial duration will be approximately 32 weeks, consisting of a 2 week screening period, a 
26-week treatment period, and two follow-up contacts (FU1 and FU2). FU1 is scheduled 7 days (+3 
days) after last dose of trial product, and FU2 is scheduled 30 days (+3 days) after last dose of trial 
product. The purpose of FU1 and FU2 are to collect all treatment-emergent adverse events (AEs).
5.2 Rationale for trial design
Based on experience from previous insulin titration trials a duration of 26 weeks is sufficient to 
reach a stable HbA 1clevel, i.e. minimum of 12 weeks in maintenance period and to obtain sufficient 
data for efficacy and safety evaluation.
The multinational approach is chosen to ensure that the results are applicable for subjects with 
different race and ethnicity, and to ensure that local regulatory requirements are fulfilled for a 
marketing approval.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268817] SMPG values and thereby [CONTACT_904243] 1cresults. 
The primary endpoint, HbA 1c, is being assessed at a central laboratory, thus avoiding assessment 
bias. 
The trial is open-label, as blinding the trial and including placebo would require a double dummy 
design with two s.c. injections, which is deemed to pose an unacceptable burden to the subjects and 
increase the trial design complexity, thereby [CONTACT_904244], discontinuing treatment prematurely or being non-compliant.
5.3 Treatment of subjects
Subjects with T2DM treated with SGLT2i and OAD(s) in accordance with the inclusion and 
exclusion criteria are eligible for the trial. When randomised the subjects will get one of the 
investigational medicinal products (IMPs) described below in combinations with previous SGTL2i 
± OAD. Pre-trial OAD treatments must include SGLT2i according to current local label, either as 
monotherapy, or in combination with metformin ± DPP4i ± pi[INVESTIGATOR_051]. If a subject is treated with 
DPP4i these have to be discontinued at randomisation. Subjects on fixed dose combinations of 
SGLT2i and DPP4i should be shifted to the corresponding SGLT2i included in the original fixed 
dose combinations of SGLT2i and DPP4i. Pre-trial SGLT2i and metformin treatment should be 
continued at unchanged pre-trial doses throughout the trial, unless there is a safety concern. 
Pi[INVESTIGATOR_904187], except those treated with dapagliflozin, and pre-trial doses 
should be unchanged during the trial, unless there is a safety concern.
!IDegLira added to OAD therapy (SGLT2i ± OAD):IDegLira will be given s.c. once daily. 
The recommended starting dose of IDegLira is 10 dose steps (10 units insulin degludec/0.36 
mg liraglutide). IDegLira will be titrated twice weekly according to a predefined titration 
algorithm, see appendix A ,with a maximum dose of 50 dose steps (50 units insulin 
degludec/1.8 mg liraglutide) aiming to reach a pre-breakfast SMPG target between 4.0 – 5.0
mmol/L (72 – 90 mg/dL).
!IGlar added to OAD therapy (SGLT2i ± OAD):IGlar will be given s.c. oncedaily. IGlar 
should be administered according to the approved label. The recommended starting dose of 
IGlar is 10 units and will be titrated twice weekly according to a predefined titration 
algorithm, see appendix A , with no maximum dose aiming to reach a pre-breakfast SMPG 
target between 4.0 – 5.0 mmol/L (72 – 90 mg/dL).
The IMPs used in this trial are described in section 9.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268818] at the discretion of the investigator. 
5.5 Rationale for treatment
IDegLira will be investigated in this trial to demonstrate efficacy and safety, when added to SGTL2i 
± OAD in T2DM subjects, inadequately controlled on SGTL2i ± OAD. If a subject is treated with 
DPP4i these have to be discontinued at randomisation, as IDegLira cannot be combined with 
DPP4i.
IGlar has been chosen as comparator as it is currently a widely used basal insulin.  
The TTT approach will be applied after randomisation in order to optimise glycaemic control 
throughout the trial. 
All subjects in both arms will continue with SGTL2i ± OAD at pre-trial doses. In case of a safety 
concern the dose(s) may be reduced or temporarily interrupted at the discretion of the investigator. 
SGTL2i ± OAD treatment must follow the current locally approved label and any local 
recommendations present at the time of conducting the trial. 
The duration of [ADDRESS_1268819] at steady state.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 24 of 107
6 Trial population
6.1 Number of subjects 
Number of subjects planned to be randomised and started on trial products: 416 
Number of subjects expected to complete the trial (on trial product): [ADDRESS_1268820] be answered “yes”. 
1. Informed consent obtained before any trial-related activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability for 
the trial.
2. Male or female, age ≥18 years at the time of signing informed consent.
3. Subjects diagnosed (clinically) with type 2 diabetes mellitus.
4. HbA 1c7.0-11.0% (53-97 mmol/mol) (both inclusive) by [CONTACT_111405].
5. BMI≥20 kg/m2and < 40 kg/m2.
6. Insulin naïve subjects; however short term insulin treatment for a maximum of 14 days prior to 
the day of screening is allowed, as well as prior insulin treatment for gestational diabetes.
7. Oral antidiabetic treatment:
a. SGLT2i: Subjects must have been on a stable daily dose of any SGLT2i ( ≥ half of 
the maximum approved dose according to current local label or maximum tolerated 
dose as documented in subject medical record, or minimum recommended 
maintenance* dose according to current local label) for at least 90 days prior to the 
day of screening.
b. Combination therapy: Stable daily dose of SGLT2i as outlined above in combination 
with stable daily dose(s) of metformin ± DPP4i is allowed:
i. Metformin ( ≥[ADDRESS_1268821]) for at least 90 days prior to the day of screening.
ii. DPP4i ( ≥half of the maximum approved dose according to local label or 
maximum tolerated dose as documented in subject medical record) for at 
least [ADDRESS_1268822] 90 days prior to the day of screening are 
also allowed. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 25 of 107
c. Pi[INVESTIGATOR_051]: Stable daily dose ( ≥ half of the maximum approved dose according to
local label or maximum tolerated dose as documented in subject medical record) for
at least [ADDRESS_1268823] is treated with
SGLT2i as outlined above, except in subjects treated with dapagliflozin.
* E.g. 100 mg Invokana® (canagliflozin) is recommended, but [ADDRESS_1268824] be answered "no".
1. Known or suspected hypersensitivity to trial product(s) or related products.
2. Previous participation in this trial. Participation is defined as signed informed consent.
3. Receipt of any investigational medicinal product within [ADDRESS_1268825]-feeding or intends to become pregnant or is of child-bearing
potential and not using adequate contraceptive methods (adequate contraceptive measures as
required by [CONTACT_17993]).
5. Use of any OADs (other than SGLT2i in monotherapy or in combination with metformin or
DPP4i or pi[INVESTIGATOR_904189]) within [ADDRESS_1268826] (e.g., exenatide or liraglutide) within 90 days prior to the day of
screening.
7. Acute decompensation of glycaemic control requiring immediate intensification of treatment to
prevent severe metabolic dysregulation (e.g., diabetes ketoacidosis) in the previous 90 days
prior to the day of the screening.
8. Family or personal history of multiple endocrine neoplasia type 2 or medullary thyroids
carcinoma.
9. Screening calcitonin ≥50 ng/L.
10. History of pancreatitis (acute or chronic).
11. Any of the following: myocardial infarction, stroke or hospi[INVESTIGATOR_904193]/or
transient ischaemic attack within the past 180 days prior to the day of screening.
12. Subjects presently classified as being in NYHA Class III or IV.
13. Planned coronary, carotid or peripheral artery revascularisation at the day of screening.
14. Renal impairment eGFR < 60 mL/min/1.73 m2as per CKD-EPI.
15. Impaired liver function, defined as ALT ≥ 2.5 times upper normal limit at screening.
16. Inadequately treated blood pressure as defined as Class 2 hypertension or higher (systolic ≥160
mmHg or diastolic ≥100 mmHg) at screening.
17. Anticipated initiation or change in concomitant medications for more than [ADDRESS_1268827] weight or glucose metabolism (e.g., orlistat, thyroid
hormones, corticosteroids).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268828] 5 years (except basal and squamous
cell skin cancer and in-situ carcinomas).
20. History of diabetic ketoacidosis.
21. Any disorder, except for conditions associated with diabetes, which in the investigator’s opi[INVESTIGATOR_904194]’s safety or compliance with the protocol.
6.[ADDRESS_1268829] meets rescue criteria or if the following applies:
!If the investigator suspects acute pancreatitis, all drugs suspected to relate to this condition must
be discontinued until confirmatory tests have been conducted and appropriate treatment should
be initiated
Trial product must be permanently discontinued if the following applies:
!Included in the trial in violation of the inclusion and/or exclusion criteria
!Pregnancy or intention to become pregnant
!Participation in other clinical trials throughout the trial
!In case the calcitonin value is ≥ 50 ng/L. Please see Appendix C
!Initiation or significant change in concomitant medications (in excess of 14 days) which in the
investigator’s opi[INVESTIGATOR_513387]
!Subjects that are diagnosed with acute pancreatitis (as a minimum 2 of 3: characteristic
abdominal pain, amylase and/or lipase > 3x upper normal range or characteristic findings on
ultrasound, computerised axial tomography /magnetic resonance imaging)
Permanent premature discontinuation of treatment with trial product will not lead to subject 
withdrawal from the trial. Trial product may be permanently discontinued at the discretion of the 
investigator due to a safety concern, unacceptable tolerability, or if a subject is judged to be non-
compliant with trial procedures. 
6.[ADDRESS_1268830] SMPG values taken on three consecutive days or if any of the FPG samples 
analysed by [CONTACT_826683]:
!15.0 mmol/L (270 mg/dL) from baseline to week 6
!13.3 mmol/L (240 mg/dL) from week 7 to week 12
!11.1 mmol/L (200 mg/dL) from week [ADDRESS_1268831] should 
be called for a confirmatory FPG measurement as soon as possible. The FPG sample should be CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268832] randomised in the trial in violation of the inclusion and/or exclusion criteria but not 
exposed to trial product must be withdrawn from the trial, and should not attend further visits.
A subject randomised in the trial in violation of the inclusion and/or exclusion criteria and exposed 
to trial product must discontinue treatment with trial product, but will not be withdrawn from the 
trial and will be followed as “premature discontinued of trial product” described in section 8.1.[ADDRESS_1268833] procedures 
performed according to the EoT visit and the two follow-up contacts (see section 2).
Please see section 8.1.[ADDRESS_1268834] will not be replaced.
6.8 Rationale for trial population 
The target population for this trial is insulin naïve subjects with T2DM inadequately controlled on 
SGLT2i treatment ± OAD treatment. The following types of anti-diabetic pre-trial therapy are 
allowed: SGLT2i monotherapy or SGLT2i in combination with metformin ± DPP4i ± pi[INVESTIGATOR_904195] a period of at least 90 days prior to screening (inclusion criteria 7). Since pi[INVESTIGATOR_904196]. Subjects on DPP4i 
should discontinue this OAD treatment at randomisation. Thus the randomised subjects will be on 
either SGLT2i monotherapy or SGLT2i ± metformin ± pi[INVESTIGATOR_051], this treatment should be 
unchanged throughout the trial, unless there is a safety concern. 
To ensure a homogeneous SGLT2i-treated population, subjects may not be treated with other anti-
diabetic treatment (e.g., other OADs [such as sulfonylureas], or GLP-1 receptor agonists) within 90 
days of screening (exclusion criteria 4 and 5). Stable OAD treatment for at least [ADDRESS_1268835] of OAD treatment on trial endpoints, CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 28 of 107
including weight loss secondary to initiation of SGLT2i treatment, and to ensure a population 
tolerating SGLT2i treatment.
To ensure the safety of the subjects, subjects that are particularly vulnerable due to various illnesses
are excluded from participation. 
Eligible subjects are presenting with an HbA 1cin the range of 7.0-11.0% (both inclusive), while 
maintaining antidiabetic treatment with SGLT2i as described above. This HbA 1crange is chosen to 
include a representative T2DM population in need of further intensification without imposing an 
increased risk of hypoglycaemia for the subject.
BMI limits of ≥20 kg/m2and < 40 kg/m2are chosen to include as broad a population as possible 
while excluding under-weight individuals in risk of unsafe weight loss, and excluding morbidly 
obese individuals who may be extremely insulin resistant.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268836] Visit (FSFV) – Last Subject First 
Visit (LSFV): [ADDRESS_1268837] Visit (LSLV).
Recruitment:
Recruitment will be closed as soon as the total number of planned subjects to be randomised is 
achievable, taking the number of screened subjects and the screening failure rate into account. 
The screening and randomisation rate will be followed closely via IWRS in order to estimate when 
to stop screening. All investigators will be notified immediately when the recruitment period ends, 
after which no further subjects may be screened and the IWRS will be closed for further screening. 
All subjects included in the screening period and eligible for randomisation can be randomised.
Trial registration:
Information of the trial will be disclosed at clinicaltrials.gov and novonordisk-trials.com. According 
to the Novo Nordisk Code of Conduct for Clinical Trial Disclosure18,it will also be disclosed 
according to other applicable requirements such as those of the International Committee of Medical Journal Editors (ICMJE)
19,the Food and Drug Administration Amendment Act (FDAAA)20,
European Commission Requirements21,22and other relevant recommendations or regulations. If a 
subject requests to be included in the trial via the Novo Nordisk e-mail contact [CONTACT_36283], Novo Nordisk may disclose the investigator’s contact [CONTACT_18026]. As a result of increasing requirements for transparency, some countries require public disclosure of investigator names and their affiliations.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268838] the results. 
Timing of the site visits, telephone contacts, visit windows and the assessments to be performed are 
specified in the flow chart (see section 2).
Investigator assessments
Review of diaries, patient reported outcomes (PROs), laboratory reports, ECGs, eye examinations, 
physical examinations must be documented with the investigator´s dated signature [CONTACT_904289]/or in the subject´s medical records. The signed documents must be 
retained at the trial site as source documentation.
Visit schedule
It is the responsibility of the investigator to ensure that all site visits and phone contacts occur 
according to the flow chart (section 2). A phone contact [CONTACT_904245] a site visit, if needed. 
Date of visit and corresponding visit windows are always calculated in relation to V2 
(randomisation) except for V33 which should take place at least 7 days (+3 days) after last dose of 
trial product and phone contact [ADDRESS_1268839] 30 days (+3 days) after last dose 
of trial product.
Diaries
At each site visit the subjects will be provided with a new diary. The diary must be collected at the 
next site visit, and retained at the site as source data in accordance with section 14. However, after 
V32 the diary will only be collected at the first FU visit (V33), whereas diary data at the second FU 
contact (P34) will be collected per phone. Consequently, source data will be the notes written by [CONTACT_904246]’s medical record, and be based on an interview performed by [CONTACT_904247] (P34). 
The investigator is only allowed to record the following data in the diary: 
!Subject ID number
!Site contact [CONTACT_8972]
!Time and date of next visit or phone contact
!Prescribed dose of trial product
!Doses and values from SMPG measurements from previous diary, if required to complete next 
dose adjustment
!Review signatureCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268840] the following information in the diary: 
!Date, time and value of the daily pre-breakfast SMPG measurement(s)
!Date, time and value of the 9-point profile SMPG prior to V2, V18 and V32
!Date, time and dose of trial product each day
!Hypoglycaemic epi[INVESTIGATOR_1841] (see section 8.5.2 )
!Any medical issues
!Any changes to concomitant medication (see section 8.3.5 )
If the subject is not able to complete the diary themselves (taking exclusion criterion no. 21 into 
account) and need assistance from a third party to complete the diary, this must be stated in the 
subject’s medical records.
Based on the values from the SMPG measurements, the investigator/subject will assess whether trial product dose needs adjustment according to the titration guideline ( Appendix A ). 
The diary must be reviewed by [CONTACT_904248], including medical issues and
concomitant medication, are reported (see section 8.3.2 and 12). In addition, the investigator must 
consider whether the reported values from the SMPG measurements must be reported as 
hypoglycaemic epi[INVESTIGATOR_1841] (see section 8.5.2 ). 
The investigator or delegated staff should transcribe the diary data to the eCRF as soon as possible, 
preferable within 24 hours after each site visit/phone contact. Safety data from the diaries must be 
handled according to the timelines described in Figure 12–[ADDRESS_1268841] be documented either on the document and/or in the subject’s medical 
record. If clarification of entries or discrepancies in the diary is needed, the subject must be 
questioned and a conclusion made in the subject’s medical record. Care must be taken not to bias 
the subject.
8.1.[ADDRESS_1268842] and other glucose lowering agents should be withheld on the 
day of the visit until blood sampling and body weight (if applicable) have been performed. Any 
other prescribed medication should be taken as usual. If the subject attends a fasting visit in a non-
fasting state the blood sampling and body weight procedures should be re-scheduled within the visit 
window. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 32 of 107
8.1.2 Screening (V1)
Screening visit and all screening assessments must take place within 14 calendar days prior to 
randomisation (V2). 
Informed consent process
Prior to screening, the investigator must provide the subject with verbal and written information 
about the trial. Informed consent must be obtained before any trial related activity, see section 18.2.
The date of informed consent must be transcribed to the eCRF for all screened subjects. 
Screening
Screening of subjects will be registered by [CONTACT_112958] (see section 10). Each subject will be 
assigned a unique 6-digit subject number which will remain the same throughout the trial. The first 
three digits in the subject ID number will consist of the site number and the last three digits of the 
subject ID number will indicate the individual subject number. 
All inclusion and exclusion criteria must be reviewed and if any criteria cannot be assessed e.g. 
criteria related to results from blood sampling performed at screening or if a valid eye examination 
is missing, the investigator must ensure these are obtained for assessment of eligibility prior to the 
randomisation of the subject. 
At screening, subjects will be provided with a card stating that they are participating in a trial and 
giving contact [CONTACT_49761](es) and telephone number(s) of relevant trial site staff. Subjects should be 
instructed to return the card to the investigator at the last trial visit, or instructed to destroy the card 
after the last phone contact.
The investigator must keep a subject screening log, a subject identification code list and a subject 
enrolment log. The subject screening log and subject enrolment log may be combined in one list. 
8.1.[ADDRESS_1268843] for any reason is not eligible or are not randomised within 14 calendar days 
after the screening visit (V1), the subject will be considered a screening failure. For screening 
failures the screening failure form in the eCRF must be completed with the reason for not 
continuing in the trial. Serious and non-serious AEs from screening failures must be transcribed by 
[CONTACT_215546]. Follow-up of SAEs must be carried out according to section 12.3. 
Screening failures experiencing an AE that would otherwise qualify for adjudication (see section
12.7) will not be adjudicated as no trial product has been administered. 
A screening failure session must be made in the IWRS. The case book must be signed. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268844] or haemolysed and analysis is not possible at the central laboratory. 
8.1.4 Randomisation (V2) 
Randomisation must NOT take place more than 14 calendar days after V1 (screening). All results 
from screening assessments, including laboratory results, ECG and eye examination must be 
available and reviewed by [CONTACT_904249]/exclusion criteria must be carefully 
reviewed to ensure the subject is eligible prior to the randomisation. 
Randomisation of subjects will be done using the IWRS (see sections 10and 11).
At V2, the subject will be supplied with trial product, receive training in trial product and pen 
handling, and given directions for use verbally and in writing. For further information on trial 
product please see section 9. The subject should take the first dose of trial product at V2 after the 
randomisation is done if possible, or on the day after randomisation. The date and dose of the first 
dose of trial product should be recorded in the diary and the eCRF. 
DPP4i must be discontinued at randomisation and subjects on fixed dose combinations of SGLT2i 
and DPP4i should be shifted to a corresponding dose of SGLT2i.
8.1.5 Follow-up contacts (FU1 and FU2)
FU1 should be scheduled 7 days (+ 3 days) after last dose of trial product and FU2 should be 
scheduled 30 days (+ 3 days) after last dose of trial product. At FU1 information on antidiabetic 
treatment, any AEs and hypoglycaemic epi[INVESTIGATOR_904197]32 must be collected and 
recorded in the eCRF. At FU2 information on antidiabetic treatment and any AEs occurring since 
V32 must be collected and recorded in the eCRF.
8.1.6 Unscheduled visits
Unscheduled visits can be performed at any time at the discretion of the investigator. An 
unscheduled visit should be performed if:CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 34 of 107
!An AE occurs that needs further attention
!Additional laboratory samples are needed due to an AE requiring special forms in the eCRF
(see section [IP_ADDRESS] )
!A confirmatory pregnancy test is needed
!A blood re-sampling related to a specific visit (if not possible to schedule the re-sampling
within the visit window). Only if initial blood sample for some reason was not able to be
analysed
!Confirmatory FPG test for rescue criteria evaluation
For the above an unscheduled visit form must be completed in the eCRF, indicating the reason for 
the visit. 
An unscheduled visit form should not be completed if the subject attends the trial site for a blood re-
sampling within the visit window. Instead a requisition form must be completed with the visit 
number the re-sampling refers to and the data must be entered to the eCRF for the corresponding 
visit. Also, additional trial product dispensing or auxiliary supply does not require the use of the 
unscheduled visit form. Additional dispensing session should be made in the IWRS prior to 
additional trial product dispensing.
8.1.[ADDRESS_1268845] prematurely due to any of the rescue criteria (see section 6.5),
criteria for premature discontinuation of trial product (see section 6.4) or at subjects own will,
should be called in for an EoT visit corresponding to V32 as soon as possible after discontinuation 
of trial product, FU1 must be scheduled 7 days (+3 days) after discontinuation of trial product and 
FU2 must be scheduled  30 days (+3 days) after discontinuation of trial product. 
Once the two follow-up contacts after discontinuation of trial product are completed the subject 
should be contact[CONTACT_12090] 4 weeks. Information on antidiabetic medication and 
information on potential major cardiovascular events (MACE) and any SAEs occurring since last 
contact [CONTACT_904250]. Phone contacts must be documented in the 
medical record and in the eCRF. The subject should finally come in for a V32A at week [ADDRESS_1268846] body weight 
measured and a blood sample taken to measure HbA 1c, see flow chart (section 2).
Final drug accountability must be done once the subject has discontinued the trial product and the 
premature discontinuation must be recorded in the IWRS through a treatment discontinuation 
session. 
The reason for the premature discontinuation of trial product must be recorded in the eCRF.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268847] aim to undertake procedures 
similar to those for V32, FU1 and FU2 (see section 8.1.5 ) as soon as possible after the last dose of 
trial product.
The end-of-trial form must be completed, and final drug accountability must be performed even if 
the subject is not able to come to the trial site. A treatment discontinuation session must be made in 
the IWRS and the subject should be registered as withdrawn in the eCRF. The case book must be 
signed. 
Although a subject is not obliged to give his/her reason(s) for withdrawing from a trial, the 
investigator must make a reasonable effort to ascertain the reason(s), while fully respecting the 
subject’s rights. Where the reasons are obtained, the primary reason for not completing the trial 
must be specified on the end-of-trial form in the eCRF.
8.2 Laboratory assessments
The laboratory analyses will be handled by a central laboratory. Descriptions of assay methods, 
laboratory supplies and procedures for obtaining samples, handling, transportation and storage of biological samples and information regarding who will perform the assessments, will be described in a trial specific laboratory manual, provided by [CONTACT_2237] (for central laboratory details, see Attachment I ). 
Laboratory samples not drawn on the day of the actual visit should preferably be drawn on another 
day within the visit window, see flow chart (section 2). For some of the samples drawn during the 
trial the subject must be fasting, see the flow chart (section 2) and fasting requirements in section 
8.1.[ADDRESS_1268848] follow the categories:CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 36 of 107
!Normal 
!Abnormal
oWas the result clinically significant? (Yes/No)
The investigator must review all laboratory results for concomitant illnesses and AEs and report 
these according to this protocol (see section 8.3.2 and section 12). The review of laboratory reports 
must be documented either on the documents and/or in the subject’s medical record. The laboratory 
report must be signed and dated by [CONTACT_904251]. 
The investigator should ensure that all laboratory samples for the subject are shipped to the 
laboratory immediately after the samples from V1 and V32 (or V32A for prematurely discontinued 
subjects) have been collected.
All samples will be destroyed on an ongoing basis after the analysis or at the latest at the 
completion of the clinical trial report (CTR).
8.[ADDRESS_1268849] related information
8.3.1 Demography
Demography consists of:
!Date of birth (according to local regulations)
!Sex
!Race (according to local regulations)
!Ethnicity (according to local regulations)
8.3.2 Concomitant illness and medical history
A concomitant illness is any illness that is present at the start of the trial (i.e. at V1) or found as a 
result of a screening procedure. Concomitant illness includes any pre-planned procedures, surgery 
and any intermittent illness (e.g. allergies) that may not be apparent at the time of screening. T2DM
should not be recorded as concomitant illness. 
Any change to a concomitant illness should be recorded during the trial. A clinically significant 
worsening of a concomitant illness must be reported as an AE.
Medical history is a medical event that the subject has experienced in the past.
The information collected for concomitant illness and medical history should include diagnosis, 
date of onset and date of resolution or continuation, as applicable.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 37 of 107
8.3.3 Diabetes history and diabetes complications:
Diabetes history and diabetes complications will be recorded at screening and consists of:
! Date of diagnosis of type 2 diabetes
! Information regarding diabetes complications including date of onset
oDiabetic retinopathy
oDiabetic neuropathy
oDiabetic nephropathy
oMacroangiopathy (including peripheral vascular disease).
Current diabetes treatment is an account in the eCRF where information about current diabetes 
treatment, dose of current diabetes treatment and start date of current diabetes treatment is collected.
Family history of diabetes is an account in the eCRF where information about the family history 
of diabetes is collected.
8.3.4 Hypoglycaemia unawareness
Information on hypoglycaemia unawareness will be recorded at screening according to Clarke’s 
questionnaire, question 823.
The investigator must ask the subject in the following way: “To what extent can you tell by [CONTACT_222668]?” The subject can answer never, rarely, sometimes, often 
or always.
Subjects answering ‘never, rarely or sometimes’ are considered as having impaired awareness of 
hypoglycaemia.
8.3.[ADDRESS_1268850]’s eligibility to continue in the trial, the monitor must be informed.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 38 of 107
8.3.6 Smoking status (tobacco use)
Details of smoking status must be recorded at V1. Smoking is defined as smoking at least one 
cigarette, cigar or pi[INVESTIGATOR_513389]. The collected information should include whether or not the subject 
smokes or has smoked. If the subject smokes or has smoked, record approximate number of years of 
smoking.
8.4 Assessments for efficacy
8.4.1 Body measurements
Height
Height is measured without shoes in centimetres (cm) or inches and rounded to the nearest cm or
inch.
Body weight
Body weight should be measured without shoes and only wearing light clothing in kilograms (kg)
or pounds (lb) with one decimal. The measurements are to be performed in a fasting state, except
for the measurement at V1. Body weight should be assessed with the same equipment throughout 
the trial, if possible.
Body Mass Index (BMI)
BMI will be calculated automatically in the eCRF once height and weight are entered.
Waist circumference
The waist circumference is defined as the minimal abdominal circumference located midway
between the lower rib margin and the iliac crest.
Three consecutive measurements of waist circumference must be performed and entered into the
eCRF. The waist circumference will be measured to the nearest 0.5 cm or 0.2 inch using a non-
stretchable measuring tape (measuring tapes will be provided to the sites by [CONTACT_3454]).
The subject should be measured in a standing position with an empty bladder and wearing light
clothing with accessible waist. The subject should be standing with arms down their side and feet
together. The tape should touch the skin but not compress soft tissue. The subject should be asked
to breathe normally and the measurement should be when the subject is breathing out gently.
8.4.2 Blood samples for efficacy
Blood samples will be drawn in accordance with the flow chart (section 2) and analysed at the
central laboratory to determine levels of the laboratory parameters listed below.  
Glucose metabolism : HbA 1cand FPG.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 39 of 107
HbA 1cand FPG results out of range do not need to be reported as an AE unless the result is
unexpected by [CONTACT_093].
Fasting lipid profile: Cholesterol, HDL cholesterol, LDL cholesterol, VLDL cholesterol, 
triglycerides and free fatty acids.
8.4.3 Fasting plasma glucose (FPG)
FPG is measured in order to evaluate metabolic control. The subject must attend these visits fasting. 
For definition of fasting, refer to section 8.1.1 .  
FPG results ≤ 3.9 mmol/L (70 mg/dL) should not be reported as hypoglycaemic epi[INVESTIGATOR_826640] a
clinical laboratory adverse event (CLAE) at the discretion of the investigator (see section 12.1.).
8.4.4 Self-measured plasma glucose (SMPG)
At V1 subjects will be provided with a BG meter including lancets, plasma-calibrated test strips and 
control solutions as well as instructions for use. The subjects will be instructed in how to use the 
device, the instruction will be repeated as necessary during the trial.
The BG meters use test strips calibrated to plasma values (SMPG values). Therefore, all
measurements performed with capi[INVESTIGATOR_904198], which will be shown on the display of the BG meter.
Subjects should be instructed in how to record the results of the SMPG measurements in the diaries.
Once daily
Subjects should perform OD SMPG measurement in a fasting state prior to breakfast. Diabetes 
medication (including trial products) should be withheld until after the measurement.
9-point profile
Subjects should perform SMPG measurements and record the obtained values for a 9-point profile 
within a week prior to V2, V18 and V32 on a day where the subject does not anticipate unusual 
strenuous exercise. 
Diabetes medication (including trial products) should be withheld until after the pre-breakfast 
SMPG measurement has been performed.
The SMPG values obtained should be recorded in the diary (including actual clock time and date of 
the measurement) at the following time points, always starting with the pre-breakfast measurement:CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 40 of 107
!Before breakfast
![ADDRESS_1268851]
!Before lunch
!90 min after the start of lunch
!Before dinner
!90 min after the start of dinner
!At bedtime
!At 4 am
!Before breakfast the following day
8.5 Assessments for safety
8.5.1 Adverse events (AEs)
All AEs must be collected and reported according the procedures described in section 12.
[IP_ADDRESS] Adverse Events requiring additional data collection in the eCRF
For some AEs the investigator must fill in additional forms in the eCRF. AEs requiring additional 
data collection in the eCRF are:
!Cardiovascular events
!Pancreatitis
!Thyroid disease
!Neoplasms
!Renal failure
!Medication errors
In case any of these events fulfil the criteria for a SAE, please report accordingly. See section 12.2.
Further details of AEs requiring additional data collection in the eCRF can be found in appendix B .
8.5.2 Hypoglycaemic epi[INVESTIGATOR_904199] a nd recorded when a hypoglycaemic epi[INVESTIGATOR_904200].
All plasma glucose values:
!≤ 3.9 mmol/L (70 mg/dL) or
!3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms
should be reported in the diary according to the instructions below throughout the trial from V2 to 
V33.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268852] is recommended to measure plasma glucose 
every15 minutes until the SMPG value is > 3.9 mmol/L (70 mg/dL) and/or symptoms have been 
resolved in accordance to current guidelines24.
A SMPG value ≤ 3.9 mmol/L (70 mg/dL) or hypoglycaemic sympto ms must trigger a 
hypoglycaemic epi[INVESTIGATOR_36197]. Repeated SMPG measurements and/or 
symptoms will per default be considered as  one hypoglycaemic epis ode until a succeeding SMPG 
value is > 3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved. One hypoglycaemic 
epi[INVESTIGATOR_36198]/or symptoms. However, each hypoglycaemic 
epi[INVESTIGATOR_513392] a period of maximum [ADDRESS_1268853] SMPG value and/or symptom. 
If a new low SMPG value is measured or the subject still has symptoms more than [ADDRESS_1268854] reported low SMPG value and/or symptoms it is considered as a new hypoglycaemic 
epi[INVESTIGATOR_36192] a new hypoglycaemic epi[INVESTIGATOR_904201]. 
The record should include the following information:
!Start date and time of the hypoglycaemic epi[INVESTIGATOR_1865]
!The plasma glucose level before treating the epi[INVESTIGATOR_1865] (if available) and any follow up
measurements
The lowest value measured during the hypoglycaemic epi[INVESTIGATOR_904202], the remaining values will be kept as source data.
!Whether the epi[INVESTIGATOR_36202] (Yes/No)
A hypoglycaemic epi[INVESTIGATOR_904203].
!Whether the subject was able to treat him/herself
If the severity of a hypoglycaemic epi[INVESTIGATOR_904204], only one hypoglycaemic epi[INVESTIGATOR_904205].
!Date, time, and dose of last trial product (and other anti-diabetic treatment) administration prior
to the epi[INVESTIGATOR_1865]
!Date and time of last main meal (not including snacks) prior to the epi[INVESTIGATOR_1865]
!Whether the epi[INVESTIGATOR_36205]
!Change in any concomitant illness
!Any sign of fever or other acute disease
!Whether the subject was asleep when the epi[INVESTIGATOR_513398], whether the symptoms of the epi[INVESTIGATOR_904206]: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 42 of 107
The answer to the question: "Was the subject able to treat him/herself?" must be answered "No" for 
anepi[INVESTIGATOR_36208], glucagon, or 
take other corrective actions. Plasma glucose concentrations may not be available during an event, 
but neurological recovery following the return of plasma glucose to normal is considered sufficient 
evidence that the event was induced by a low plasma glucose concentration24.
Oral carbohydrates should not be given if the subject is unconscious.
If the question "Was the subject able to treat him/herself?" is answered "No", the following 
information should be recorded by [CONTACT_423]:
!Who assisted in the treatment of the hypoglycaemic epi[INVESTIGATOR_1865] (i.e. medical person or non-medical
person)
!Where the treatment was administered (in clinic/emergency room/hospi[INVESTIGATOR_36209].  If the
subject was treated in clinic/emergency room/hospi[INVESTIGATOR_307], whether they were transported in an
ambulance or not)
!Type of treatment provided by [CONTACT_215559] (i.e. oral carbohydrates, glucagon, IV glucose or
other)
!Were symptoms alleviated after administration of treatment?
!Factors contributing to the epi[INVESTIGATOR_1865] (i.e. physical activity, missed meal, diet changed, medication
error (i.e. overdose, mix-up between products), miscalculation of insulin dose, other factors not
listed or unknown)
!Did the subject experience seizure?
!Was the subject unconscious/comatose?
!Did the subject experience any of the following symptoms25(layman term used in the diary is 
specified in brackets if different from the protocol term)?
oAutonomic: sweating, trembling, hunger or palpi[INVESTIGATOR_814] (rapid or irregular heart beat)
oNeuroglycopenic: confusion, drowsiness, speech difficulty, visual disturbances, odd
behaviour, impaired balance or incoordination (reduced ability to coordinate movement)
oGeneral malaise: headache or malaise (feeling discomfort/unease)
oOther symptoms?
The Investigator must review the diary at each contact [CONTACT_513452][INVESTIGATOR_1841]. The subject must be questioned whether any of the low values were 
severe i.e. whether the subject was able to self-treat or not. If the subject was not able to self-treat it 
has to be reported as a severe hypo glycaemic epi[INVESTIGATOR_36210] a hypoglycaemic epi[INVESTIGATOR_215510].
Low SMPG values for non-sev ere hypoglycaemic epi[INVESTIGATOR_36212] a hypoglycaemic epi[INVESTIGATOR_36213] 7 days since the SMPG measurement should be reported on a 
hypoglycaemic epi[INVESTIGATOR_904207]. Novo Nordisk will not query CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268855] include: 
!General appearance
!Head, ears, eyes, nose, throat, neck
!Respi[INVESTIGATOR_2133]
!Cardiovascular system
!Gastrointestinal system including mouth
!Musculoskeletal system
!Central and peripheral nervous system
!Skin
!Abdomen
!Lymph node palpation
!Thyroid gland
8.5.[ADDRESS_1268856] be in accordance with the relevant 
exclusion criteria (see section 6.3). At the following visits, the blood pressure should only be 
measured once.
8.5.5 Electrocardiogram (ECG)  
A 12-lead ECG must be performed by [CONTACT_904252]. The ECG must be 
interpreted, signed and dated by [CONTACT_904253]. The ECG 
at screening must be done at the latest at V2 and the results interpreted by [CONTACT_904254].
The evaluation transcribed to the eCRF must follow the categories:CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 44 of 107
!Normal
!Abnormal
oWas the result clinically significant? (Yes/No)
8.5.6 Eye examination
An eye examination (dilated fundoscopy/fundus photography) must be performed by [CONTACT_1275], a local ophthalmologist or an optometrist according to local practise. Results of the eye 
examination must be interpreted, signed and dated by [CONTACT_904255]. 
The evaluation of the results must follow the categories:
!Normal
!Abnormal
oWas the result clinically significant? (Yes/No)
If an eye examination has been performed within [ADDRESS_1268857]´s medical 
records that the procedure was not performed in relation to this trial. 
If an eye examination has been performed within 2 weeks prior to V32 the procedure does not need 
to be repeated, if the results are available for evaluation at V32. 
8.5.7 Blood samples for safety
Blood samples will be drawn in accordance with the flow chart (section 2) and analysed by [CONTACT_904256]:
Haematology: Erythrocytes, haematocrit, haemoglobin, leucocytes, thrombocytes, differential 
count (eosinophils, neutrophils, basophils, monocytes and lymphocytes).
Biochemistry: Amylase, lipase, ALT, AST, alkaline phosphatase, albumin, bilirubin (total), 
creatinine, potassium, sodium, calcium (ionized), urea, GFR (estimated).
Hormones : Blood samples for the measurement of calcitonin concentration will be drawn as per 
flow chart (see section 2). In case any calcitonin value at any time of the trial is ≥10 ng/L the 
algorithm in appendix C  Monitoring of calcitonin must be followed.
Pregnancy test: Females of childbearing potential will have a human chorionic gonadotropin 
(hCG) serum pregnancy test performed according to the flow chart (section 2).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268858] be collected at V1, V18 and V32 to determine the albumin/creatinine ratio , 
see flow chart (section 2). The analysis will be performed by [CONTACT_2237]. 
Urine dipstick test must be performed at the site according to the flow chart, section 2. The 
following parameters will be tested; glucose, ketone, nitrite, pH, protein, leucocyte, and erythrocyte.
Urine pregnancy test using urine dipsticks will be performed at site during the trial for females of 
childbearing potential if a menstrual period is missed or pregnancy is suspected. If a urine test is 
positive, a confirmatory serum-hCG test must be taken and sent to the central laboratory for 
analysis. It should be documented in the eCRF in an unscheduled visit, describing “pregnancy test” 
under “other”. 
8.[ADDRESS_1268859] be documented either on the documents and/or in the subject’s 
medical record.
If clarification of entries or discrepancies in the questionnaires is needed, the subject must be 
questioned and a conclusion made in the subject’s medical record. Care must be taken not to bias 
the subject.
All responses to the questionnaires must be transcribed to the eCRF. 
Novo Nordisk baseline questionnaire
The Novo Nordisk baseline questionnaire; Barriers in Diabetes Treatment must be completed at V2, 
see flowchart, section [ADDRESS_1268860] be completed at V2, V14 and V32, see flowchart, section 
2:
!SF-36v2, standard16
!TRIM-D17
The PRO questionnaires should be completed at the same time point of the visit for both visits, e.g. 
prior to any other trial related activities.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268861] of the 
importance of following the instructions given including taking the trial products as prescribed.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 47 of 107
9 Trial supplies
Trial supplies comprise trial products and auxiliary supplies. Additional details regarding trial 
supplies can be found in the Trial Materials Manual (TMM). 
Trial products must not be dispensed to any person not included in the trial. 
Trial product must not be used:
!If it does not appear clear and colourless
!If it is dropped, damaged or crushed as there is a risk of leakage
!If it has not been stored correctly according to the storage condition on the label
9.1 Trial products
The following trial products are considered as Investigational Medicinal Products (IMPs) and will 
be provided by [CONTACT_3454] A/S, Denmark:
Table 9–1 Investigational medicinal products 
IMPs Strength Dosage formRoute of 
administrationContainer/delivery 
device 
Insulin 
degludec/liraglutide100 units/mL 
+ 3.6 mg/mL
Solution for  
injectionSubcutaneous 
(s.c.)3 mL pre-filled 
PDS290 pen injector
Insulin glargine 100 units/mL 3 mL pre-filled 
SoloStar®
OADs are considered as non-investigational medicinal products (NIMPs) and hence will not be provided by [CONTACT_3454], unless required by [CONTACT_1769]. 
Argentina: All NIMPs, including pi[INVESTIGATOR_051], will be reimbursed by [CONTACT_904257] S.A. NIMPs should be purchased or otherwise delivered to the subjects in accordance 
with local health plans.
Slovakia: Pre-trial OADs and/or rescue medication used during the trial will not be supplied by 
[CONTACT_3454], however these medications will be reimbursed by [CONTACT_904258] s.r.o.
During the 26-weeks treatment period and the 4 weeks follow-up period; the patients de-facto cost 
(actual patient cost, not covered by [CONTACT_217928]/any insurance) of SGLT2i and metformin CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 48 of 107
(mono- or fixed dose combination products) will be reimbursed in accordance with local legislation 
and Ethics Committee approval. Pi[INVESTIGATOR_904208].
9.2 Labelling
The trial products will be labelled in accordance with Annex 1328, local regulations and trial 
requirements.
Each trial site will be supplied with sufficient trial products for the trial on an on-going basis controlled by [CONTACT_8784]. Dispensing unit numbers (DUNs) will be distributed to the trial sites 
according to enrolment and randomisation. 
The investigator must document that direction for use is given to the subject verbally and in writing 
at the first dispensing visit (V2). On all other visits the direction for use must be given in writing.
9.3 Storage 
Storage and in-use conditions of the trial products are outlined in Table 9–2
Table 9–2 Storage conditions for investigational medicinal products
IMPs Storage conditions
(not-in-use)In-use conditions In-use 
time*
Insulin degludec/liraglutide
Store in refrigerator 
(2°C-8°C/36°F-46°F)
Do not freezeProtect from lightStore below 30°C (86°F)
Do not freezeProtect from lightUse within 
3 weeks
Insulin glargine Do not store above 30°C
US: Do not store above 
30°C (86°F)
Do not refrigerateProtect from lightUse within 
4 weeks
* In-use time starts when the product is taken out of the refrigerator at the subject’s homeCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268862] has been stored outside specified conditions (e.g. outside temperature range).
Trial product that has been stored improperly must not be dispensed to any subject before it has 
been evaluated and approved for further use by [CONTACT_3454]. The investigator must take 
appropriate action to ensure correct storage.
9.[ADDRESS_1268863] (used/partly used or unused) ,expi[INVESTIGATOR_904209]-allocated trial product. Non-allocated 
trial products including expi[INVESTIGATOR_904210]. 
Destruction of trial products can be performed on an on-going basis and will be done according to 
local procedures after accountability is finalised and reconciled by [CONTACT_2037]. Destruction of 
products must be documented in the IWRS.
9.5 Auxiliary supplies
The following will be provided by [CONTACT_215571]:
!Directions for Use (DFU) for pen devices
!Needles for pen devices
!BG meters and BG meter auxiliariesCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 50 of 107
10 Interactive web response system (IWRS)
A trial-specific IWRS will be set up which can be accessed at any time via the internet or by [CONTACT_648]. 
Access to the IWRS must be restricted to and controlled by [CONTACT_36301]. 
IWRS is used for: 
!Screening
!Screening failure
!Randomisation
!Medication arrival
!Dispensing
!Treatment discontinuation
!Completion
!Drug accountability
!Data change
It is important that the trial site dispenses the trial products allocated by [CONTACT_904259]:
!Provide the correct trial product (correct DUN) according to randomisation and dispensing 
visits
!Secure available stock at site to cover the drug supply need for all enrolled subjects
!Ensure that no subjects receive trial product that will expi[INVESTIGATOR_513404]
!Secure that drug accountability is possible
IWRS user manuals will be provided to each trial site.
11 Randomisation procedure 
Subjects randomised at V2 will in a 1:1 manner (208 in each arm) get one of the treatments 
described below in combination with previous SGTL2i ± OAD:
!IDegLira added to OAD therapy (SGLT2i ± OAD)  
!IGlar added to OAD therapy (SGLT2i ± OAD)
Pre-trial OAD treatments must include SGLT2i either as monotherapy, or in combination with 
metformin ± DPP4i ± pi[INVESTIGATOR_051]. If a subject is treated with DPP4i these have to be discontinued at randomisation. There will not be applied any stratification on baseline characteristics. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 51 of 107
12 Adverse events, technical complaints and pregnancies
12.1 Definitions
Adverse event 
An adverse event (AE) is any untoward medical occurrence in a subject administered a product, and 
which does not necessarily have a causal relationship with this treatment. An AE can therefore be 
any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or 
disease temporally associated with the use of a product, whether or not considered related to the 
product.
An AE includes:
!A clinically significant worsening of a concomitant illness
!A clinical laboratory adverse event: a clinical laboratory abnormality which is clinically 
significant, i.e. an abnormality that suggests a disease and/or organ toxicity and is of a severity 
that requires active management. Active management includes active treatment or further 
investigations, for example change of medicine dose or more frequent follow-up due to the 
abnormality
The following should notbe reported as AEs:
!Pre-existing conditions, including those found as a result of screening procedures (pre-existing 
conditions should be reported as medical history or concomitant illness)
!Pre-planned procedures unless the condition for which the procedure was planned has worsened 
from the first trial related activity after the subject has signed the informed consent
!Non-serious hypoglycaemia is an AE, but is reported on a hypoglycaemic epi[INVESTIGATOR_36219], see section 8.5.2
The following three definitions are used when assessing an AE:
!Severity 
oMild - no or transient symptoms, no interference with the subject's daily activities
oModerate - marked symptoms, moderate interference with the subject's daily activities
oSevere - considerable interference with the subject's daily activities; unacceptable
!Causality 
Relationship between an AE and the relevant trial product(s): 
oProbable - Good reason and sufficient documentation to assume a causal relationship
oPossible - A causal relationship is conceivable and cannot be dismissed
oUnlikely - The event is most likely related to aetiology other than the trial productCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 52 of 107
!Final outcome
oRecovered/resolved - The subject has fully recovered, or by [CONTACT_36303]-related activity after the 
subject signed the informed consent
oRecovering/resolving - The condition is improving and the subject is expected to recover 
from the event. This term is only applicable if the subject has completed the trial or has died 
from another AE
oRecovered/resolved with sequelae - The subject has recovered from the condition, but with 
lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an SAE 
criterion, the AE must be reported as an SAE
oNot recovered/not resolved - The condition of the subject has not improved and the 
symptoms are unchanged, or the outcome is not known
oFatal - This term is only applicable if the subject died from a condition related to the 
reported AE. Outcomes of other reported AEs in a subject before he/she died should be 
assessed as "recovered/resolved", "recovering/resolving", "recovered/resolved with 
sequelae" or "not recovered/not resolved". An AE with fatal outcome must be reported as an 
SAE
oUnknown - This term is only applicable if the subject is lost to follow-up
Serious adverse event
A SAE is an experience that at any dose results in any of the following:
!Death
!A life-threateningaexperience
!In-patient hospi[INVESTIGATOR_36220]
!A persistent or significant disability or incapacityc
!A congenital anomaly or birth defect
!Important medical events that may not result in death, be life threateningaor require 
hospi[INVESTIGATOR_36221] - based on appropriate medical judgement -
they may jeopardise the subject and may require medical or surgical intervention to prevent one 
of the outcomes listed in the definition of SAEd
Suspi[INVESTIGATOR_904211] "life threatening" in the definition of SAE refers to an event in which the subject was at 
risk of death at the time of the event. It does not refer to an event which hypothetically might have 
caused death if it was more severe.
bThe term "hospi[INVESTIGATOR_11956]" is used when a subject: 
– Is admitted to a hospi[INVESTIGATOR_36222]-patient, irrespective of the duration of physical stay, or 
– Stays at the hospi[INVESTIGATOR_36223] 24 hoursCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268864]'s ability to conduct normal life functions (e.g. following the 
event or clinical investigation the subject has significant, persistent or permanent change, 
impairment, damage or disruption in his/her body function or structure, physical activity and/or 
quality of life).
dFor example intensive treatment in an emergency room or at home of allergic bronchospasm, 
blood dyscrasiasis or convulsions that do not result in hospi[INVESTIGATOR_11956], or development of drug 
dependency or drug abuse.
Non-serious adverse event
A non-serious AE is any AE which does not fulfil the definition of an SAE.Adverse events with additional data collection
AEs with additional data collection are AEs defined as critical for the evaluation of product safety. 
For these AEs the investigator must fill in additional forms in the eCRF.  AEs  requiring additional 
data collection in the eCRF are:
!Cardiovascular events:
oAcute coronary syndrome (MI or hospi[INVESTIGATOR_36193])
oCerebrovascular event (stroke or TIA)
oHeart failure requiring hospi[INVESTIGATOR_063]
!Pancreatitis
!Thyroid disease
!Neoplasms
!Renal failure
!Medication errors
For detailed information on AEs with additional data collection anddefinition of medication errors, 
see Appendix B .
Along with fatal events, certain events will be adjudicated by [CONTACT_904260] (EAC)as described in section 12.7.2 . For further information regarding 
definitions, rationales, and events that will be adjudicated, see Appendix B .
Major adverse cardiovascular event 
A major adverse cardiovascular event (MACE) is any AE which can be categorised into the 
following groups:CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 54 of 107
!Cardiovascular Death
!Myocardial Infarction
!Hospi[INVESTIGATOR_904212]
!Transient Ischemic Attack and Stroke
!Heart Failure Event (requiring hospi[INVESTIGATOR_11956])
!Cardiac procedures
oInterventional Cardiology
oPeripheral Vascular Intervention
oStent Thrombosis
Technical complaint
A technical complaint is any written, electronic, or oral communication that alleges product 
(medicine or device) defects. The technical complaint may be associated with an AE, but does not 
concern the AE itself.
Examples of technical complaints:
!The physical or chemical appearance of trial products (e.g. discoloration, particles or
contamination)
!The packaging material (e.g. leakage, cracks, rubber membrane issues or errors in labelling text)
!Problems related to devices (e.g. to the injection mechanism, dose setting mechanism, push
button or interface between the pen and the needle)
12.[ADDRESS_1268865]-treatment follow-up periods. Please be aware that hypoglyc aemic epi[INVESTIGATOR_904213] e.g. hypoglycaemic epi[INVESTIGATOR_904214] (V2). Subjects discontinuing trial product prematurely (see section 6.4) will be 
contact[CONTACT_457] 4th week and asked for information about antidiabetic medication, MACE and 
SAEs. These subjects should finally come in for a V32A at week 26, only to assess antidiabetic 
medication, MACE, SAEs and a blood sample to measure HbA 1c.
The events must be recorded in the applicable CRF forms in a timely manner, see timelines below 
and Figure 12–[ADDRESS_1268866] be asked about AEs and technical 
complaints, for example by [CONTACT_7939]: "Have you experienced any problems since the last contact?"CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268867] be reported by [CONTACT_36306]. Novo Nordisk assessment of expectedness is performed according to the following 
reference documents:
!IDegLira: Current version of the Company Core Data Sheet (CCDS) or any updates hereof
!IGlar: European Summary of Product Characteristics (SmPC) current version or any updates
hereof11
All AEs must be recorded by [CONTACT_49738]. The investigator should report the 
diagnosis, if available. If no diagnosis is available, the investigator should record each sign and 
symptom as individual AEs using separate AE forms.
For SAEs, a SIF must be completed in addition to the AE form. If several symptoms or diagnoses 
occur as part of the same clinical pi[INVESTIGATOR_1103], one SIF can be used to describe all the SAEs.
For AEs requiring additional data collection and for AEs requiring adjudication, a specific event 
form in addition to the AE form must be completed.
The AE form for a non-serious AE not fulfilling the additional data collection criteria should be 
signed when the event is resolved or at the end of the trial.
Timelines for initial reporting of AEs:
The investigator must complete the following forms in the eCRF within the specified timelines:
!SAEs : The AE form within 24 hours and the SIF within 5 calendar days of the investigator's
first knowledge of the SAE. Both forms must be signed within 7 calendar days from the date theinformation was entered in the eCRF
!SAEs with additional data collection: in addition to above, also the specific event form within
14 calendar days of the investigator's first knowledge of the AE
!Non –serious AEs with additional data collection : The AE form, and specific event form
within 14 calendar days of the investigator’s first knowledge of the event
!Events for adjudication : Event Adjudication Document Collection Form must be completed
within [ADDRESS_1268868] details (fax, telephone, e-mail and address) are provided in the investigator trial master file.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 56 of 107
An AE is observed 
and reported It is an SAE
complete:
!AE form ≤ 24 hours
!SIF ≤ 5 calendars days
It is a non-serious AE
complete:
!AE formFulfilling 
seriousness 
criteria?
Additional data 
collection 
requeried?Additional data 
collection 
required or fatal 
outcome?Complete ≤ 14 calendar days:
!Specific event form
No additional forms to be 
completedYes
No
Complete ≤ 14 calendar days: 
!Specific event formYesNo NoYes
Is the AE 
category 
selected for 
adjudication?Complete ≤ 14 calendar 
days:!Adjudication form 
Upload Source Data within 
4 weeksYes
AE: Adverse Event
SIF: safety information form
All timelines are from the investigator’s
first knowledge of the event
Addtional data collection described in chapter 8.5
Events for adjudication described in chapter 12.7NoFatal outcome
Figure 12–[ADDRESS_1268869]-related S[LOCATION_003]Rs by [CONTACT_3454]:
Novo Nordisk will notify the investigator of trial product-related suspected unexpected serious 
adverse reactions (S[LOCATION_003]Rs) in accordance with local requirements and GCP2.In addition, the 
investigator will be informed of any trial-related SAEs that may warrant a change in any trial procedure.
In accordance with regulatory requirements, Novo Nordisk will inform the regulatory authorities, including EMA, of trial product-related S[LOCATION_003]Rs. In addition, Novo Nordisk will inform the IRBs/IECs of trial product-related S[LOCATION_003]Rs in accordance with local requirement and GCP
2, unless 
locally this is an obligation of the investigator.
Novo Nordisk products used as concomitant medication:
If a SAE  is considered to have a causal relationship with a Novo Nordisk marketed product used as 
concomitant medication in the trial, it is important that the suspected relationship is reported to 
Novo Nordisk, e.g. in the alternative aetiology section on the SIF. Novo Nordisk may need to report 
this adverse event to relevant regulatory authorities.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268870] be reported to Novo Nordisk according to the following:
!SAEs: All SAEs must be followed until the outcome of the event is “recovered/resolved”,
“recovered/resolved with sequelae” or “fatal”, and until all queries have been resolved. Cases of
chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE)
may be closed with the outcome “recovering/resolving” or “not recovered/not resolved”. Cases
can be closed with the outcome of “recovering/resolving” when the subject has completed the
follow-up period and is expected by [CONTACT_36308]. The SAE follow-up information
should only include new (e.g. corrections or additional) information and must be reported
within 24 hours of the investigator's first knowledge of the information. This is also the case for
previously non-serious AEs which subsequently become SAEs.
!Non-serious AEs: Non-serious AEs must be followed until the outcome of the event is
“recovering/resolving”, “recovered/resolved” or “recovered/resolved with sequelae” or until the
end of the follow-up period stated in the protocol, whichever comes first, and until all queriesrelated to these AEs have been resolved. Cases of chronic conditions, cancer or AEs ongoing at
time of death (where death is due to another AE) may be closed with the outcome
“recovering/resolving” or “not recovered/not resolved”. Cases can be closed with the outcome
of “recovering/resolving” when the subject has completed the follow-up period and is expected
by [CONTACT_36308].
The investigator must ensure that the worst case severity and seriousness of an event is kept 
throughout the trial. A worsening of an unresolved AE must be reported as follow up with re -
assessment of severity and/or seriousness of the event.
Queries or follow-up requests from Novo Nordisk must be responded to within [ADDRESS_1268871].
12.4 Technical complaints and technical complaint samples
12.4.1 Reporting of technical complaints 
All technical complaints on any of the following products: 
!IDegLira (100 units/mL + 3.6 mg/mL), 3 mL pre-filled PDS290 pen
!Novo Nordisk needles for prefilled pen
!IGlar (100 units/mL), 3 mL pre-filled Solostar
®,
which occur from the time of first usage of the product until the time of the last usage of the 
product, must be collected and reported to Customer Complaint Center, Novo Nordisk. 
Contact [CONTACT_8972] (fax, e-mail and address) are provided in Attachment I to the protocol.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268872] complete the technical complaint form in the eCRF within the following 
timelines of the trial site obtaining knowledge of the technical complaint:
!Technical complaint assessed as related to an SAE within 24 hours
!All other technical complaints within [ADDRESS_1268873] the technical complaint sample and notify the monitor within 5 
calendar days of obtaining the sample at trial site. The monitor must coordinate the shipment to 
Customer Complaint Center, Novo Nordisk (the address is provided in Attachment I ) and ensure 
that the sample is sent as soon as possible. A print or copy of the technical complaint form must be sent with the sample.
The investigator must ensure that the technical complaint sample contains the batch or lot number 
and, if available, the DUN.
If the technical complaint sample is unobtainable, the investigator must specify on the technical 
complaint form why it is unobtainable. 
Storage of the technical complaint sample must be done in accordance with the conditions 
prescribed for the product. The shipment of the technical complaint sample should be done in 
accordance with the same conditions as for storage (see section 9).
12.[ADDRESS_1268874](s).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268875] report information about the pregnancy, pregnancy outcome, and health of 
the newborn infant(s), as well as AEs in connection with the pregnancy, and AEs in the foetus and 
newborn infant.
The following must be collected and reported by [CONTACT_36309] - electronically 
(e.g. in PDF format), or by [CONTACT_36310]:
1. Reporting of pregnancy information
Information about the pregnancy and pregnancy outcome/health of the newborn infant(s) has to be 
reported on Maternal Form 1A and 1B, respectively. 
When the pregnancy outcome is abnormal (i.e. congenital anomalies, foetal death including 
spontaneous abortion and/or any anomalies of the foetus observed at gross examination or during 
autopsy), and/or when a congenital anomaly is diagnosed within the first month, further information 
has to be reported for the female subject on Maternal Form 2. In addition, information from the 
male partner has to be reported on the Paternal Form, after an informed consent has been obtained 
from the male partner. 
Initial reporting and follow-up information must be reported within 14 calendar days of the 
investigator's first knowledge of initial or follow-up information. 
2. Reporting of AE information
The investigator has to report AEs in connection with the pregnancy as well as in the foetus and 
newborn infant(s). The SAEs that must be reported include abnormal outcome, such as foetal death 
(including spontaneous abortion), and congenital anomalies (including those observed at gross 
examination or during autopsy of the foetus), as well as other pregnancy complications fulfilling the 
criteria of an SAE.
Forms and timelines for reporting AEs:
Non-serious AEs: 
!Paper AE form* within 14 calendar days of the investigator's first knowledge of the initial or 
follow-up information to the non-serious AE.
SAEs: 
!Paper AE form* within 24 hours of the investigator's first knowledge of the SAE
!Paper SIF within 5 calendar days of the investigator's first knowledge of the SAE
!SAE follow-up information to the AE form and/or SIF within 24 hours of the investigator's 
first knowledge of the follow-up informationCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 60 of 107
* It must be clearly stated in the AE diagnosis field on the AE form if the event occurred in the
subject, foetus or newborn infant.
Any queries or follow-up requests from Novo Nordisk to non-serious AEs, SAEs and pregnancy 
forms must be responded to by [CONTACT_19452] [ADDRESS_1268876].
12.5.2 Pregnancies in female partners of male subjects (only applicable for US)
Male subjects must be instructed to notify the investigator if their female partner becomes pregnant 
during the trial, except in the screening period. At the last scheduled visit, male subjects must be 
asked if their female partner has become pregnant.
If a female partner has become pregnant during the trial, the investigator must follow-up on the 
pregnancy outcome and until the new-born infant is one month of age, irrespective of whether the 
trial is completed or not. The investigator must ask the male subject and assess, if the pregnancy 
outcome is normal or abnormal. 
When the pregnancy outcome is normal this information is recorded in the subject's medical record 
only, no further information is collected and reported to Novo Nordisk. When the pregnancy 
outcome is abnormal (i.e. congenital anomalies, foetal death including spontaneous abortion and/or 
any anomalies of the foetus observed at gross examination or during autopsy), the following must 
be reported by [CONTACT_136760] (e.g. in PDF format) or by [CONTACT_6791]:
1. Reporting of pregnancy information
Information from the male subject has to be reported on the Paternal Form. Furthermore,
information from the female partner (including information about the pregnancy outcome and
health status of the infant until the age of one month) has to be reported on the Maternal Forms
1A, 1B and 2, after an informed consent has been obtained from the female partner.
Initial reporting and follow-up information must be reported within 14 calendar days of the
investigator's first knowledge of initial or follow-up information.
2. Reporting of AE information
The following AEs in the foetus and newborn infant have to be reported:
oNon-serious AEs evaluated as possible/probably related to the father's treatment with the
trial product(s)
oSAEs in the foetus and newborn infant - whether or not related to the father's treatment with
the trial product(s). This includes an abnormal outcome - such as foetal death (including 
spontaneous abortion) and congenital anomalies (including those observed at gross 
examination or during autopsy of the foetus)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 61 of 107
Forms and timelines for reporting AEs:
Please see section 12.5.1 , point 2, “Forms and timelines for reporting AEs”.
Any queries or follow-up requests from Novo Nordisk to non-serious AEs, SAEs and pregnancy 
forms must be responded to by [CONTACT_19452] [ADDRESS_1268877].
12.6 Precautions and/or overdose
During treatment with insulin ther e is a risk of hypoglycaemia.
Symptoms of hypoglycaemia usually occur suddenly and may include cold sweat, nervousness or 
tremor, anxious feelings, unusual tiredness, confusion, difficulty in concentrating, excessive hunger, 
temporary vision changes, headache, nausea and palpi[INVESTIGATOR_332]. Severe hypoglycaemia may lead to 
unconsciousness.
Hypoglycaemic epi[INVESTIGATOR_513407]. Attention should be given to the fact that the action profile of the insulin component in 
IDegLira is flat and of somewhat longer duration than currently marketed long-acting insulin 
preparations. It may therefore take several hours longer before stable normal blood glucose is 
achieved after a hypogly caemic epi[INVESTIGATOR_513408].
Symptoms of minor hypoglycaemia should be treated with ingestion of carbohydrates. Severe 
hypoglycaemia resulting in loss of consciousness must be treated according to best medical practice 
(e.g. 25 mL of 50% dextrose solution given intravenously, or 0.5-1 mg of glucagon given s.c. or 
intramuscularly).
From clinical trials and marketed use of Victoza®overdoses up to 40 times the recommended 
maintenance dose (72 mg) have been reported. Events reported included severe nausea and severe 
vomiting. None of the reports included severe h ypoglycaemia. All subject s recovered without 
complications.
When initiating treatment with IDegLira, the subject may in some cases experience loss of 
fluids/dehydration, due to vomiting, nausea or diarrhoea. It is important to avoid dehydration by 
[CONTACT_215574].
For further information see the IDegLira IB10or any update hereof.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 62 of 107
12.7 Committees related to safety
12.7.1 Novo Nordisk safety committee
Novo Nordisk will constitute an internal IDegLira safety committee to perform ongoing safety 
surveillance. The IDegLira safety committee may recommend unblinding of any data for further 
analysis, and in this case an independent ad hoc group will be established in order to maintain the 
blinding of the trial personnel.
12.7.2 Event adjudication committee (EAC)
An independent external EAC is established to perform qualitative validation of selected AEs 
according to pre-defined diagnostic criteria. The validation is based on review of pre-defined 
clinical data related to the specific AE. The events are reviewed by [CONTACT_36312] a blinded manner.
The following AEs will be adjudicated in this trial:
!Fatal events
!Acute coronary syndrome (MI or hospi[INVESTIGATOR_36193])
!Cerebrovascular event (stroke or TIA)
!Heart failure requiring hospi[INVESTIGATOR_063]
!Pancreatitis
!Thyroid disease requiring thyroidectomy and thyroid neoplasms
!Neoplasms (all kinds of abnormal growth) – excluding thyroid neoplasms
Event adjudication will be performed for AEs in randomised subjects including AEs with an onset 
date during the screening period. Event adjudication will not be performed for AEs in screening 
failures.
The EAC is composed of permanent members who cover required medical specialities. The EAC 
members must disclose any potential conflicts of interest and must be independent of Novo 
Nordisk. The role of the EAC is solely to adjudicate events in a blinded manner. The EACs will 
have no authorisations to impact on trial conduct, trial protocol or amendments.
The EAC will review translated copi[INVESTIGATOR_904215] (for example X-ray, ECGs, ultrasound images, discharge summaries, 
pathology reports, and death certificates). The EAC can evaluate an event not initially reported as 
an AE for adjudication, to be adjudicated. The investigator must provide source documentation as 
soon as possible, once the request from Novo Nordisk or the event adjudication vendor is received.
All AEs will be screened by [CONTACT_904261]. If 
needed, the investigator will be asked to provide additional information such as an alternative 
aetiology.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268878] be reported according to section 12.2. In addition the specific 
adjudication form should be completed within 14 calendar days of the investigator's first 
knowledge of the AE, and all relevant predefined documents provided within 4 weeks in 
accordance with the event adjudication site manual.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268879] or an assessment has not been done and will not be available, or if the question is 
irrelevant (e.g. is not applicable), the investigator must indicate this according to the data entry 
instructions.
The following will be provided as paper CRFs :
!Pregnancy forms
!AE forms (These must be used when access to the eCRF is revoked or if the eCRF is
unavailable)
!SIFs (only to be used if eCRF is unavailable)
!Technical complaint forms (only to be used if eCRF is unavailable or the TC concerns a product
not allocated to a subject)
On the paper CRF forms the investigator must print legibly, using a ballpoint pen. The investigator 
must ensure that all questions are answered, and that no empty data blocks exist. It must be ensured 
that no information is recorded outside the data blocks. If a test/assessment has not been done and 
will not be available, the investigator must indicate this by [CONTACT_565] “ND” (not done) in the 
appropriate answer field in the CRF. If the question is irrelevant (e.g. is not applicable) the 
investigator must indicate this by [CONTACT_565] “NA” (not applicable) in the appropriate answer field. 
Further guidance can be obtained from the instructions in the CRF.
The investigator must ensure that all information is consistent with the source documentation. By 
[CONTACT_36321], the investigator confirms that the information in 
the eCRF and related forms is complete and correct.
13.1 Corrections to case report forms
Corrections to the CRF data may be made by [CONTACT_36322]’s delegated staff. 
An audit trail will be maintained in the CRF application containing as a minimum: the old and the 
new data, identification of the person entering the data, date and time of the entry and reason for the 
correction.
If corrections are made by [CONTACT_093]’s delegated staff after the date the investigator has signed 
the case book, the case book must be signed and dated again by [CONTACT_093].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268880] be entered 
within 24 hours after the site visit/phone contact [CONTACT_853299].
The PRO questionnaires and the baseline questionnaire will be completed by [CONTACT_904262].
At the end of trial the investigator must ensure that all remaining data have been entered into the 
eCRF no later than [ADDRESS_1268881]’s last visit at the site. In addition, queries must be 
resolved immediately in order to ensure the planned lock of the database.
Site specific eCRF data (in an electronic readable format) will be provided to the trial site before 
access to the eCRF is revoked. This data must be retained at the trial site.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268882] monitoring visit will be performed as soon as possible after FSFV at 
the trial site and no later than 4 weeks after. The monitoring visit intervals will depend on the 
outcome of the remote monitoring of the CRFs, the trial site's recruitment rate and the compliance 
of the trial site to the protocol and GCP, but will not exceed [ADDRESS_1268883] access to source documents (original documents, data and 
records). Direct access includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are important to the evaluation of the trial. If the electronic medical record does 
not have a visible audit trail, the investigator must provide the monitor with signed and dated 
printouts. In addition the relevant trial site staff should be available for discussions at monitoring 
visits and between monitoring visits (e.g. by [CONTACT_756]). All data must be verifiable in source 
documentation other than the CRF.
For all data recorded the source document must be defined in a source document agreement at each 
trial site. There must only be one source defined at any time for any data element.
The investigator is required to make a reasonable effort to obtain necessary additional information 
from external sources e.g. primary physician and other hospi[INVESTIGATOR_600]/departments to document the 
subjects’ eligibility. 
For SMPG measurements; only the values entered in the diary should be monitored as source data, 
although the BG meter can log a number of SMPG readings. 
Source data generated by [CONTACT_36323]; any correction must be explained, signed and dated 
by [CONTACT_36324]. The original diaries and PROs must be collected by [CONTACT_904263].
The monitor will ensure that the CRFs are completed and that paper CRFs are collected. The 
following data will be source data verified for screening failures: 
!Date for obtaining informed consent
!Screen failure reason
Monitors must review the subject's medical records and other source data (e.g. the diaries and 
PROs) to ensure consistency and/or identify omissions compared to the CRF. If discrepancies are 
found, the investigator must be questioned about these. A follow-up letter (paper or electronic) will CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 67 of 107
be sent to the investigator following each monitoring visit. This should address any action to be 
taken.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268884] Operating Procedures and IT architecture documentation. The use and 
control of these systems are documented.
Investigators working on the trial may use their own electronic systems to capture source data.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 69 of 107
17 Statistical considerations
Novo Nordisk will analyse and report data from all sites together.
All efficacy endpoints and PRO endpoints will be summarised using the full analysis set (FAS) and 
safety endpoints will be summarised using the safety analysis set (SAS).
All statistical analyses of efficacy and safety endpoints will be based on the full analysis set (FAS) 
unless otherwise specified. Confirmatory analyses will include on-treatment data and available 
retrieved (V32A) data.
Unless otherwise specified, all continuous measurements will be summarised descriptively at each 
visit by [CONTACT_904264]-treatment observed data. Endpoints are summarised by [CONTACT_339708], 
standard deviation (SD), median, and minimum and maximum value. Selected endpoints, e.g. 
endpoints that are analysed log-transformed, will be reported with geometric mean and coefficient 
of variation in place of mean and SD. For measurements over time, mean values will be plotted to 
explore the trajectory over time. Observed data will be used as the basis for plotting data if not 
otherwise specified. For endpoints that are summarised with geometric mean, the geometric mean 
values will be plotted. Mean profiles for the primary and continuous confirmatory secondary 
endpoints by [CONTACT_904265]. In addition, selected endpoints will be summarised by [CONTACT_62866][INVESTIGATOR_904216], box and mean change from baseline over time plots.
The primary objective is to confirm the effect of IDegLira in terms of glycaemic control in subjects 
with T2DM on previous treatment with SGLT2i ± OAD therapy. The primary estimand for the 
primary objective will be the difference in change from baseline in HbA 1cafter 26 weeks between 
T2DM subjects randomised to IDegLira and IGlar, both in combination with SGLT2i ± OAD, 
regardless of whether subjects remained on initially a ssigned treatment or not until week 26. This 
estimand is a de facto estimand addressing effectiveness. With the aim of comparing treatment 
strategies this estimand is considered clinically relevant. It resembles the ITT principle. For the 
confirmatory secondary endpoints de facto estimands addressing effectiveness are chosen as 
primary estimand too.
The secondary estimand for the primary objective will be the difference in change from baseline in 
HbA 1cafter 26 weeks between T2DM subjects randomised to IDegLira and IGlar, both in 
combination with SGLT2i ± OAD, attributable to randomised treatment, if all randomised subjects 
had tolerated and adhered to treatment until week 26. This estimand is a de jure estimand 
addressing efficacy. In the non-inferiority setting this estimand has higher assay sensitivity than an 
effectiveness estimand. The estimand is considered clinically relevant since it provides information 
to treating clinicians about the glycaemic efficacy attributable to IDegLira for the purpose of CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 70 of 107
treating individual subjects with T2DM. For the confirmatory secondary endpoints de jure 
estimands addressing efficacy are chosen as secondary estimand too.
Only endpoints derived after 26 weeks will be analysed statistically. The expected percentage of 
missing data is around 15%. In accordance with guidance29endpoints will be assessed at frequent 
visits and also on subjects who prematurely discontinue treatment. If an assessment has been made both at screening and randomisation, and if not otherwise specified, the value from the randomisation visit will be used as the baseline value. If the value measured at the randomisation visit is missing and the assessment also has been made at screening, then the screening value will be used as the baseline value.
Laboratory values below the lower limit of quantification (LLOQ) will be set to ½LLOQ.
The test strategy is hierarchical testing in order to control the familywise Type I error. Inferences 
will be based on the primary analyses of the primary estimands. The trial will be powered with 
respect to the primary objective and endpoint.
Presentation of results from a statistical analysis will include the estimated mean treatment effects 
using LSMean for absolute values, and change from baseline where applicable. The LSMean is 
either obtained by [CONTACT_11369]’s rule weighing together LSMeans from multiple imputation estimations 
or obtained directly from estimation of a parameterized statistical model. In addition, estimated 
mean treatment difference (or ratio) will be presented together with the two-sided 95% confidence 
interval and corresponding two-sided p-value.
In the statistical models explanatory factors will be parameterized as follows:
!Treatment: IDegLira, IGlar
!Pre-trial OAD: SGLT2i ± pi[INVESTIGATOR_051](pio), SGLT2i + metformin(met) ± pio, SGLT2i +
DPP4i ± pio, SGLT2i + met + DPP4i ± pio
!Region: Europe (Finland, Hungary, Russia, Slovakia, Slovenia, Spain, Switzerland), North
America (CA, [LOCATION_003]), South America (Argentina), Asia (India)
!Visit: Planned visits for actual endpoint according flow-chart
The impact of protocol deviations and outliers may be investigated further in sensitivity analyses if 
deemed relevant.
17.[ADDRESS_1268885] of IDegLira in terms of glycaemic control 
in subjects with T2DM on previous treatment with SGLT2i ± OAD therapy. This will be done by [CONTACT_345960]: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 71 of 107
comparing the difference in change from baseline in HbA 1cafter 26 weeks to a non-inferiority
margin of 0.3% for IDegLira versus IGlar, both arms on continued SGLT2i ± OAD therapy. 
The non-inferiority margin of 0.3% is due to guidance30,31, a treatment effect −0.85% 
[−1.04;−0.66] 95%CIof IGlar versus placebo reported in a placebo controlled clinical trial32in 
T2DM subjects, and the effect of IGlar stated to be clinically equal to NPH33. With the superiority 
of IGlar to placebo and IGlar established as being as efficacious as NPH, a non-inferiority margin of 0.3% is considered to give sufficient assay sensitivity in this trial.
Formally, let D be the mean treatment difference (IDegLira – IGlar) in change from baseline in 
HbA 1c. The null-hypothesis of IDegLira inferior by 0.3% or more will be tested against the 
alternative hypothesis of non-inferiority (IDegLira inferior by [CONTACT_21316] 0.3%) as given by
H0: D≥0.3%   against   H A: D < 0.3%.
Non-inferiority will be considered confirmed if the upper bound of the two-sided 95% confidence 
interval for D (mean treatment difference in change from baseline in HbA 1c) is strictly below 0.3%. 
This is equivalent to using a one-sided test of size 2.5%, i.e. the Type I error rate is controlled at 
2.5% one-sided.
Accordingly, the sample size is calculated using a t-statistic under the assumptions of a one-sided 
test of size 2.5%, a mean treatment difference of 0.0%, a standard deviation of 1.0%, a non-
inferiority margin of 0.3%, and that 15% of the randomised subjects will be excluded from the PP 
analysis set. These assumptions are based on experience from the phase 3a development programs
for IDegLira and insulin degludec. With the 1:1 randomisation scheme the sample size is set to 208 
subjects per treatment arm; in total 416 subjects will be randomised. This will ensure a nominal 
power of 80% for confirming the primary objective based on PP.
Considering inferior efficacy retention for IDegLira as opposed to IGlar amongst the anticipated 
15% of subjects discontinuing randomised treatment, the expected treatment difference may be 
adjusted by [CONTACT_904266]
0.85×0.0% + 0.15×0.3% = 0.045%. A total of [ADDRESS_1268886] 74% (see Table 17–1 )CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 72 of 107
Table 17–1 Power for various rates of discontinuation
Adjusted treatment difference (% discontinued)
SD 0.000 (0%) 0.045 (15%) 0.060 (20%) 0.075 (25%)
0.9 0.924 0.822 0.774 0.720
1.0 0.863 0.737 0.685 0.629
1.1 0.792 0.655 0.603 0.548
1.2 0.720 0.580 0.530 0.479
Power is computed under the assumption of 208 subjects in either arm, 1:1 randomization, and a penalty of the NI 
margin 0.3% in treatment difference for discontinuing subjects. SD: standard deviation.
For the confirmatory secondary endpoints body weight and hypoglycaemic epi[INVESTIGATOR_904217] 75% and 60% respectively under assumptions of moderate treatment 
effects: a treatment difference of 1 kg in weight change in favour of IDeg Lira, and a hypoglycaemic 
epi[INVESTIGATOR_904218] 1.8 event/PYE and rate ratio of 0.[ADDRESS_1268887] been observed for IDegLira in the phase 3a development programme. The order of 
hypotheses in the hierarchical testing procedure reflects this.
17.2 Definition of analysis sets
The following analysis sets are defined in accordance with the ICH-E9 guidance34.
Full analysis set (FAS ):includes all randomised subjects. In exceptional cases, subjects may be 
eliminated from the full analysis set. In such cases the elimination will be justified and documented. 
The statistical evaluation of the full analysis set will follow the ITT principle and subjects will 
contribute to the evaluation “as randomised”.
Per-protocol (PP) analysis set: includes all subjects in the full analysis set who fulfils the following 
criteria:
!Have not violated any inclusion criteria
!Have not fulfilled any exclusion criteria
!Have a non-missing HbA 1cat screening or randomisation
!Have at least one non-missing HbA 1cafter 12 weeks of exposure
!Have at least 12 weeks of exposure
Subjects will contribute to the evaluation “as treated”.
Safety analysis set (SAS): includes all subjects receiving at least one dose of the investigational 
product or comparator. Subjects in the safety set will contribute to the evaluation “as treated”.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 73 of 107
Completer analysis set (CAS ): includes all randomised subjects who have completed the trial 
without discontinuation from randomised treatment. Subjects in the completer analysis set will 
contribute to the evaluation “as randomised”.
Randomised subjects who are lost to follow up and where no exposure information of the 
investigational product or comparators is available after randomisation will be handled as 
unexposed.
Before data are released for statistical analysis, a review of all data will take place to identify 
protocol deviations that could potentially affect the results. Any decision to exclude any subject or 
observation from the statistical analysis is the joint responsibility of the members of the study 
group. The subjects or observations to be excluded, and the reasons for their exclusion must be 
documented and signed by [CONTACT_36331]. The subjects and observations 
excluded from analysis sets, and the reason for this, will be described in the clinical trial report.
17.3 Primary endpoint
17.3.1 Primary statistical analysis primary estimand
Multiple imputation – jump to reference – retrieved data – NI penalty
The primary objective of this trial is to confirm the effect of IDegLira in terms of glycaemic control 
in subjects with T2DM on previous treatment with SGLT2i ± OAD therapy. 
The primary estimand for the primary objective will be the difference in change from baseline in 
HbA 1cafter 26 weeks between T2DM subjects randomised to IDegLira and IGlar, both in 
combination with SGLT2i ± OAD, regardless of whether subjects remained on initially assigned 
treatment or not until week 26.The treatment difference is to be compared to a non-inferiority
margin of 0.3%.
Formally, let D be the mean treatment difference (IDegLira – IGlar) in change from baseline in 
HbA 1c. The null-hypothesis of IDegLira inferior by 0.3% or more will be tested against the 
alternative hypothesis of non-inferiority (IDegLira inferior by [CONTACT_21316] 0.3%) as given by
H0: D≥0.3%   against   H A: D < 0.3%.
Non-inferiority will be considered confirmed if the upper bound of the two-sided 95% confidence 
interval for D (mean treatment difference in change from baseline in HbA 1c) is strictly below 0.3%. 
This is equivalent to using a one-sided test of size 2.5%, i.e. the Type I error rate is controlled at 
2.5% one-sided.
The primary estimand will be estimated based on the FAS using all post baseline HbA 1c
measurements obtained at planned visits up to and including week 26, and data retrieved at week 26 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 74 of 107
(V32A) from subjects prematurely discontinued from randomised treatment. To estimate this 
estimand for evaluation of non-inferiority of HbA 1c, a pattern mixture model approach35will be 
adopted. It mimics an ITT scenario where withdrawn and prematurely discontinued subjects from 
the investigational treatment (IDegLira) arm not having a week 26 measurement are assumed to be switched to a treatment inferior to comparator (IGlar) or any other treatment received after premature treatment discontinuation. This corresponds to a jump to reference (J2R) principle where a penalty in terms of the NI margin is added to withdrawn or prematurely discontinued subjects in the IDegLira arm. Observe that the J2R principle and use of retrieved (V32A) data in analyses will equalise treatment effects and in turn assay sensitivity in the non-inferiority setting may be jeopardized. The penalty of the non-inferiority margin
36is to remedy this. Multiple copi[INVESTIGATOR_014] (1000 
copi[INVESTIGATOR_014]) of the full dataset will be generated by [CONTACT_904267] a subgroup of subjects in the trial. This will be done as follows:
!As a first step, all post-randomisation HbA 1cvalues for prematurely discontinued subjects in
the investigational treatment group (IDegLira) not having retrieved (V32A) data are set to
missing
!In the second step, intermittent missing values are imputed using a Markov Chain Monte Carlo
(MCMC) method, in order to obtain a monotone missing data pattern. This imputation is done
for each treatment group separately and 1000 copi[INVESTIGATOR_215520]. Subjects
from either group with retrieved (V32A) data will now have a non-missing data pattern
!In the third step, for each of the [ADDRESS_1268888] planned HbA 1cmeasurement visit after randomisation (V10) based on the
control group (IGlar) and subjects with retrieved (V32A) data in the investigational group
(IDegLira). The estimated parameters, and their variances, from this model are used to impute
missing values at the first planned HbA 1cmeasurement visit after randomisation (V10) for
subjects in both treatment groups, based on their pre-trial OAD, region and HbA 1cat baseline
!In the fourth step, for each of the 1000 copi[INVESTIGATOR_136691], missing HbA 1cvalues at the
second planned HbA 1cmeasurement visit after randomisation (V14) are imputed in the same
way as in the previous step, now based on an ANOVA model with pre-trial OAD and region as
factors, and the HbA 1cvalues at baseline and at previous planned HbA 1cmeasurement visits as
covariates, fitted to the control group (IGlar) and subjects with retrieved (V32A) data in the
investigational group (IDegLira)
!This fourth step is then repeated sequentially over visits where HbA 1cmeasurement is planned,
adding one visit in each step until the last planned visit (V32)
!In the sixth step a penalty equal to the non-inferiority margin 0.3% is added to the EOT HbA 1c
value for any prematurely discontinued subject in the investigational group (IDegLira),
irrespective of the EOT value being retrieved (V32A) data or an imputed value from the
sequential imputation steps (step 3 to 5)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 75 of 107
!In the seventh step, for each of the 1000 complete data sets, the change from baseline to the
EOT visit (V32) is analysed using an ANOVA model with treatment, pre-trial OAD and region
as factors and baseline HbA 1cvalue as a covariate
!In the eighth step, the estimates and standard errors for the [ADDRESS_1268889] error using Rubin’s rule37.From these pooled estimates the 
confidence interval for the treatment difference and the associated p-value are calculated
17.3.2 Sensitivity analyses primary estimand
Any marked difference between the primary statistical analysis and sensitivity analyses will be 
commented upon in the CTR.
MMRM – retrieved data
A mixed model for repeated measurement (MMRM) with an unstructured covariance matrix will be 
applied for the statistical analysis. The MMRM model accounts for missing data by [CONTACT_904268]. That is, the trajectory of treatment discontinued subjects is assumed to be 
as for those subjects on similar treatment that complete treatment. All observed and retrieved 
(V32A) data will be included in the analysis. Thus this model operates under a different assumption on missingness and includes more observed data. The latter implies that any treatment effect up 
until premature discontinuation is taken into account.
The MMRM model will include treatment, pre-trial OAD, region and visit as fixed factors and the 
corresponding baseline value as a covariate. Interactions between visit and all factors and the 
covariate are also to be included in the model. This model will be referred to as the standard 
MMRM model.
Multiple imputation – copy reference– retrieved data – NI penalty
In this analysis withdrawn and prematurely discontinued subjects from the investigational treatment 
(IDegLira) arm not having a week 26 measurement are assumed to respond as if treated with a 
treatment inferior to comparator (IGlar) or any other treatment received after premature treatment 
discontinuation from the time of treatment discontinuation.
The analysis is similar to the primary analysis except that observed values for prematurely 
discontinued IDegLira subjects are not set missing (step 1 is left out). Observe that for IDegLira 
now only missing data after premature discontinuation are imputed by [CONTACT_904269] 
(step 3 to 5) and this principle is named copy reference (CR); intermittent missing data are imputed 
by [CONTACT_85222] (step 2). Thus this analysis is to include more observed values and applying the 
sequential ANOVAs at a later point in the visit structure. The latter implies that any treatment effect 
up until premature discontinuation is taken into account.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 76 of 107
Multiple imputation – jump to reference – retrieved data – NI penalty – tippi[INVESTIGATOR_11300]
A tippi[INVESTIGATOR_904219]. Subjects 
who prematurely discontinue from the IDegLira arm are assumed to have received a treatment 
inferior to IGlar or any other treatment received after premature treatment discontinuation. The 
extent of the inferiority (also termed the ‘penalty’) will be gradually increased to evaluate at which 
point (penalty) IDegLira is no longer non-inferior to IGlar.
Multiple imputation – jump to reference – retrieved data – NI penalty – CAS
This is a repeat of the primary analysis restricted to the CAS.
Multiple imputation – jump to reference – retrieved data – NI penalty – PP
This is a repeat of the primary analysis restricted to the PP analysis set.
17.3.3 Primary statistical analysis secondary estimand
MMRM
The secondary estimand for the primary objective is difference in change from baseline in HbA 1c
after 26 weeks between T2DM subjects randomised to IDegLira and IGlar, both in combination 
with SGLT2i ± OAD, attributable to randomised treatment, if all randomised subjects had tolerated 
and adhered to treatment until week 26.
This analysis is a repeat of the standard MMRM this time leaving out retrieved (V32A) data.
17.3.4 Sensitivity analyses secondary estimand
ANOVA – LOCF imputation
This analysis is an ANOVA with treatment, pre-trial OAD and region as factors and baseline value 
as covariate based on the FAS and with missing data imputed by [CONTACT_317875].
17.4 Secondary endpoints
17.4.1 Confirmatory secondary endpoints
The confirmatory secondary endpoints of the tria l are tested for superiority of IDegLira to IGlar.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 77 of 107
In order to control the overall Type I error, a hierarchical testing procedure will be used. If non-
inferiority in glycaemic control (change from baseline in HbA 1c) is concluded in the primary 
statistical analysis of the primary estimand, testing proceeds down the following hierarchy as long 
as superiority at a given stage is confirmed based on the primary statistical analysis of the primary 
estimand:
1. Superiority in weight change
2. Superiority in number of treatment-emergent (severe or BG confirmed symptomatic)
hypoglycaemic epi[INVESTIGATOR_1841]
3. Superiority in glycaemic control (change from baseline in HbA 1c)
4. Superiority in insulin dose (total daily dose [U])
The following paragraphs detail the hypotheses and statistical analyses of the confirmatory 
secondary endpoints.
[IP_ADDRESS] Primary statistical analyses primary estimand
Body weight
Let D Wbe the mean treatment difference (IDegLira – IGlar) in change from baseline in body 
weight. The null-hypothesis of IDegLira not superior will be tested against the alternative 
hypothesis of superiority as given by
H0: DW≥ [ADDRESS_1268890]   H A: D W< [ADDRESS_1268891] procedure was not stopped and if the upper 
bound of the two-sided 95% confidence interval for D W(mean treatment difference in change from 
baseline in weight) is strictly below [ADDRESS_1268892] of size 2.5%, 
i.e. the Type I error rate is controlled at 2.5% one-sided. The change from baseline in body weight 
after 26 weeks will be analysed with the J2R pattern mixture model for HbA 1c, substituting body 
weight for HbA 1cand leaving out the non-inferiority penalty (step 6).
Treatment-emergent hypoglycaemic epi[INVESTIGATOR_904220] (IDegLira/IGlar) of the rate of treatment-emergent severe or BG confirmed 
symptomatic hypoglycaemic epi[INVESTIGATOR_51953] [ADDRESS_1268893] the alternative hypothesis of superiority as given by
H0: RR≥[ADDRESS_1268894]   H A: RR < 1.
Superiority will be considered confirmed if the test procedure was not stopped and if the upper 
bound of the two-sided 95% confidence interval for RR (rate ratio of rate of treatment-emergent 
severe or BG confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_51953]-treatment) is strictly below 1. 
This is equivalent to using a one-sided test of size 2.5%, i.e. the Type I error rate is controlled at CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 78 of 107
2.5% one-sided. The number of hypoglycaemic epi[INVESTIGATOR_111366] a multiple 
imputation technique for count data under the J2R principle as follows.
For prematurely discontinued subjects the number of events in the missing period (time of 
premature discontinuation to planned TE period [max of [ADDRESS_1268895] TE exposure time observed in the trial]) will be imputed using a multiple imputation technique
38,and assuming that 
all subjects have an event rate in the period before and after premature discontinuation corresponding to the event rate in the control group (IGlar). This will be done as follows:
!As a first step, a Bayes negative binomial model is fitted to the event rate data to obtain the
posterior distribution of model parameters
!In the second step, based on the estimated parameters for comparator (IGlar) in this model, the
number of events in the missing period is imputed for all prematurely discontinued subjects.I.e. pre and post discontinuation event rates in the conditional distribution used for imputation
are as for comparator (IGlar). Multiple copi[INVESTIGATOR_014] (1000 copi[INVESTIGATOR_014]) of a complete data set are
generated by [CONTACT_111424]
!In the third step, for each of the complete data sets, the number of events is analysed using a
negative binomial model
!In the fourth step, the estimates and standard deviations for the [ADDRESS_1268896] deviation using Rubin’s rule37. From these pooled estimates 
the confidence interval for the treatment ratio and the associated p-value are calculated
The negative binomial model will have a log-link function, and the logarithm of the time period, in 
which a hypoglycaemic epi[INVESTIGATOR_513414]-emergent, will be used as offset. The model 
will include treatment, pre-trial OAD and region as factors. 
Glycaemic control
As above, let D be the mean treatment difference (IDegLira – IGlar) in change from baseline in 
HbA 1c. The null-hypothesis of IDegLira not superior will be tested against the alternative 
hypothesis of superiority as given by
H0: D≥0%   against   H A: D < 0%.
Superiority will be considered confirmed if the test procedure was not stopped and if the upper 
bound of the two-sided 95% confidence interval for D (mean treatment difference in change from 
baseline in HbA 1c) is strictly below 0%. This is equivalent to using a one-sided test of size 2.5%, i.e. 
the Type I error rate is controlled at 2.5% one-sided. The change from baseline in HbA 1cafter 26 
weeks will be analysed with the J2R pattern mixture model for HbA 1cbut leaving out the non-
inferiority penalty (step 6).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 79 of 107
Insulin dose
Let D Dbe the mean treatment difference (IDegLira – IGlar) in insulin dose after [ADDRESS_1268897] the alternative hypothesis of 
superiority as given by
H0: DD≥ [ADDRESS_1268898]   H A: D D< [ADDRESS_1268899] procedure was not stopped and if the upper 
bound of the two-sided 95% confidence interval for D D(mean treatment difference in insulin dose 
after 26 weeks) is strictly below [ADDRESS_1268900] of size 2.5%, i.e. 
the Type I error rate is controlled at 2.5% one-sided. The insulin dose after 26 weeks will be 
analysed with the J2R pattern mixture model for HbA 1c, substituting insulin dose for HbA 1c, leaving 
out the non-inferiority penalty (step 6) and using baseline HbA 1cas covariate as there is no baseline 
dose. That is, in the sequential ANOVAs (step 3 to 5) both insulin dose at previous visits and 
baseline HbA 1cwill be included as covariates whilst in the EOT ANOVA (step 7) only baseline 
HbA 1cwill be included as covariate.
[IP_ADDRESS] Sensitivity analyses primary estimand
Continuous endpoints, body weight, HbA 1cand insulin dose – multiple imputation – copy
reference– retrieved data
These analyses are repeats of the primary analyses using the CR principle in place of the J2R
principle, just as for the CR sensitivity analysis of the primary estimand of the primary objective.
Continuous endpoints body weight, HbA 1cand insulin dose – multiple imputation – jump to 
reference – retrieved data – tippi[INVESTIGATOR_904221] a treatment inferior to IGlar or any other treatment 
received after premature treatment discontinuation. The extent of the inferiority will be gradually 
increased to evaluate at which point (penalty) IDegLira is no longer superior to IGlar.
Count endpoint hypoglycaemic epi[INVESTIGATOR_1841] – multiple imputation – copy reference
This is a repeat of the primary analysis using the CR principle in place of the J2R principle. More 
specifically, in this analysis IDegLira subjects are assumed to have the event rate of the IDegLira 
arm prior to premature discontinuation and the event rate of IGlar after premature discontinuation. The method follows the multiple imputation J2R for count data above, but in the second step pre 
discontinuation rates are the respective groups rates whilst post discontinuation rate is the rate of 
comparator (IGlar).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 80 of 107
Count endpoint hypoglycaemic epi[INVESTIGATOR_1841] – multiple imputation – jump to reference – tippi[INVESTIGATOR_904222] a repeat of the multiple imputation J2R above, now varying a penalty on the post 
discontinuation event rate until IDegLira is no longer superior to IGlar.
[IP_ADDRESS] Primary statistical analyses secondary estimand
Continuous endpoints body weight, HbA 1cand insulin dose – MMRM
This is the same analysis as for the primary objective. For insulin dose baseline HbA 1cwill be used 
as covariate.
Count endpoint hypoglycaemic epi[INVESTIGATOR_904223].
[IP_ADDRESS] Sensitivity analyses secondary estimand
Continuous endpoints body weight, HbA1c and insulin dose – multiple imputation – jump to
reference – retrieved data
These analyses are identical to the primary analyses of the primary estimand and serve to evaluate 
the MAR assumption.
17.4.2 Supportive secondary endpoints
The supportive secondary endpoints will be addressed in terms of the primary estimand only.
[IP_ADDRESS] Efficacy endpoints
HbA 1cresponder after 26 weeks (yes/no)
Two dichotomous endpoints (responder=yes/non-responder=no) will be defined based on whether a 
subject has met a specific target level after 26 weeks:
!HbA 1c< 7.0 %
!HbA 1c≤6.5 %
Analysis of each the two responder endpoints will be based on a logistic regression model with 
treatment, pre-trial OAD and region as fixed factors and baseline HbA 1cvalue as a covariate, 
hereafter referred to as the standard logistic regression model. 
For each of the multiple copi[INVESTIGATOR_014] (1000) of the full dataset of the primary analysis of the primary 
estimand (multiple imputation J2R with retrieved data, NI penalty section 17.3.1 ) the responder 
endpoints are derived without using the non-inferiority penalty (step 6) and analysed with the 
standard logistic regression model. Estimates are pooled using Rubin’s rule.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 81 of 107
HbA 1cresponder endpoints without weight gain after 26 weeks
Responder for HbA 1cwithout weight gain after 26 weeks will be defined as
!HbA 1c< 7.0% and change in body weight from baseline ≤0k g
!HbA 1c≤6.5% and change in body weight from baseline ≤0k g
Theses endpoint will be analysed as the HbA 1cresponder endpoints, now using also the multiple 
copi[INVESTIGATOR_904224] (section 17.4.1 ), and including baseline weight too as covariate 
in the standard logistic regression model.
HbA 1cresponder endpoints without treatment-emergent severe or BG confirmed 
symptomatic hypoglycaemic epi[INVESTIGATOR_11645] 26 weeks
Responder for HbA 1c without treatment-emergent severe or BG confirmed symptomatic 
hypoglycaemic epi[INVESTIGATOR_11645] 26 weeks will be defined as
!HbA 1c< 7.0% and without treatment-emergent severe or BG confirmed symptomatic
hypoglycaemic epi[INVESTIGATOR_339663] 12 weeks of treatment
!HbA 1c≤6.5% and without treatment-emergent severe or BG confirmed symptomatic
hypoglycaemic epi[INVESTIGATOR_339663] 12 weeks of treatment
Theses endpoints will be analysed as the HbA 1cresponder endpoints, where subjects with less than 
12 weeks of treatment conservatively will be set to being non-responder.
HbA 1cresponder endpoints without treatment-emergent severe or BG confirmed 
symptomatic hypoglycaemic epi[INVESTIGATOR_904225] 26 weeks
Responder for HbA 1c without treatment-emergent severe or BG confirmed symptomatic 
hypoglycaemic epi[INVESTIGATOR_904225] 26 weeks will be defined as 
!HbA 1c< 7.0%without treatment-emergent severe or BG confirmed symptomatic during the last
12 weeks of treatment, and change in body weight from baseline ≤0k g
!HbA 1c≤6.5% without treatment-emergent severe or BG confirmed symptomatic during the last
12 weeks of treatment, and change in body weight from baseline ≤0k g
Theses endpoints will be analysed as the composite HbA 1cand weight responder endpoints, where 
subjects with less than [ADDRESS_1268901] circumference will be analysed by [CONTACT_111012] J2R. 
Fasting plasma glucose change from baseline after 26 weeks
Change from baseline in FPG will be analysed by [CONTACT_111012] J2R. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 82 of 107
Fasting lipid profile after 26 weeks
Cholesterol, LDL cholesterol, HDL cholesterol, VLDL cholesterol, triglycerides and free fatty acids 
will be analysed separately by [CONTACT_111012] J2R. In these statistical analyses, the endpoint 
will be log-transformed and so will the corresponding baseline covariate.
Self-measured plasma glucose (SMPG) 9-point profile change from baseline after 26 weeks 
The following six endpoints from the 9-point SMPG profile will be defined:
!9-point profile (individual SMPG values). [One endpoint]
!Mean of the 9-point profile, defined as the area under the profile (calculated using the 
trapezoidal method) divided by [CONTACT_36336]. [One endpoint]
!Prandial plasma glucose increments (from before meal to [ADDRESS_1268902], lunch 
and dinner). The mean increment over all meals will be derived as the mean of all available 
meal increments. [Four endpoints]
A linear mixed effect model will be fitted to the 9-point SMPG profile data. The model will include 
treatment, pre-trial OAD, time (within 9-point profile), the interaction between treatment and time, 
the interaction between pre-trial OAD and time as fixed factors, and subject as random effect. From 
the model mean profile by [CONTACT_904270]. 
Change from baseline in mean of the 9-point profile and prandial increment endpoints will be 
analysed separately by [CONTACT_111012] J2R.
Blood pressure (systolic and diastolic) change from baseline after 26 weeks
Change from baseline in systolic and diastolic blood pressure will be analysed separately by 
[CONTACT_111012] J2R.
[IP_ADDRESS] Safety endpoints
Adverse events during [ADDRESS_1268903] recent version of the Medical Dictionary for Regulatory 
Activities.
A treatment-emergent AE (TEAE) is defined as an event that has onset date on or after the first day 
of exposure to randomised treatment and no later than [ADDRESS_1268904] drug date, then this 
event should also be considered as a TEAE. Major adverse cardiovascular events (MACEs) are 
considered treatment-emergent until [ADDRESS_1268905] day of randomised treatment.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268906] one event (N), the percentage of 
subjects with at least one event (%), the number of events (E) and the event rate per 100 years of 
exposure (R).
Summaries of TEAEs and of serious TEAEs will be presented as an overview including all AEs, 
serious AEs, number of deaths, AEs by [CONTACT_926], AEs by [CONTACT_339710]. 
Furthermore summary tables based on system organ class and preferred terms are made for:
!All TEAEs
!Serious TEAEs
!TEAEs possibly or probably related to trial product
!Severe, moderate and mild TEAEs
!TEAEs reported by [CONTACT_339711]
!TEAEs with preferred term that are experienced by [CONTACT_2669] 5% (1%) of the subjects in any 
treatment arm or by [CONTACT_2669] 5% (1%) of all subjects
A listing for non-TEAEs with onset date before the first day of exposure to randomised treatment 
will be presented. A listing will also be presented for non-TEAEs collected after the treatment-
emergent period according to the definition of TEAE.
Additional summaries will be displayed for MACEs collected between the end of treatment (V32) 
and the last follow-up visit (V32A) for subjects who discontinue trial product prematurely.
Hypoglycaemic epi[INVESTIGATOR_51953] 26 weeks
For the definition and classification of hypoglycaemic epi[INVESTIGATOR_904226] [IP_ADDRESS] .
Data on treatment-emergent hypoglycaemic epi[INVESTIGATOR_826667] (N), the percentage of subjects with at least one event (%), the 
number of events (E) and the event rate per 100 years of exposure (R).
Separate summaries are made by [CONTACT_826706][INVESTIGATOR_1841], severe or BG confirmed hypoglycaemic epi[INVESTIGATOR_1841], and the ADA 
(American Diabetes Association) classification of hypoglycaemia. The summaries are made for all 
and nocturnal (between 00:01 and 05.59 both inclusive) epi[INVESTIGATOR_339655].
Number of nocturnal treatment-emergent severe or BG confirmed symptomatic hypoglycaemic 
epi[INVESTIGATOR_51953] 26 weeks will be analysed using the same J2R multiple imputation model as used 
for the treatment-emergent severe or BG confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_1841].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 84 of 107
Clinical evaluation (ECG, eye examination and physical examination) change from baseline 
after 26 weeks
Eye examination (fundoscopy/fundusphotography) and 12-lead ECG findings will be summarised 
descriptively, including:
!Summaries for each visit
!Shift tables from baseline to after 26 weeks
Pulse rate change from baseline after 26 weeks
Change from baseline in pulse rate will be analysed by [CONTACT_111012] J2R.
Laboratory assessments (Biochemistry, Haematology, Calcitonin and urine analysis)
All laboratory parameters will be summarised descriptively including
!Summaries by [CONTACT_765]
!Shift tables from baseline to after 26 weeks
!Proportion of subjects with measurements outside reference range by [CONTACT_57485]
!Box plots by [CONTACT_339718]
!Listings of individual values outside reference ranges (abnormal values)
For lipase and amylase the following rule applies in the evaluation of the result:
!If the amylase or lipase baseline (at screening) value is > 3×upper normal range (UNR) the
information will be regarded as medical history for that subject
[IP_ADDRESS] Classification of hypoglycaemia
Treatment-emergent: hypoglycaemic epi[INVESTIGATOR_36239]-emergent if the onset of 
the epi[INVESTIGATOR_720710], and no later than [ADDRESS_1268907].
Nocturnal hypoglycaemic epi[INVESTIGATOR_1841]: are epi[INVESTIGATOR_1841] o ccurring between 00:01 and 05.59 both inclusive.
Hypoglycaemic epi[INVESTIGATOR_513417] (see Figure 17–1 ) and the ADA classification of hypoglycaemia (see Figure 17–2 ).
Novo Nordisk classification of hypoglycaemia
In normal physiology, symptoms of hypoglycaemia occur below a plasma glucose level of 3.1 
mmol/L (56 mg/dL)39.Therefore, Novo Nordisk has included hypoglycaemia with plasma glucose 
levels below this cut-off point in the definition of BG confirmed hypoglycaemia.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 85 of 107
Novo Nordisk uses the following classification (see Figure 17–1 ) in addition to the ADA 
classification: 
!Severe hypoglycaemia according to the ADA classification
!Symptomatic BG confirmed hypoglycaemia: An epi[INVESTIGATOR_904227] <3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia
!Severe or BG confirmed symptomatic hypoglycaemia: An epi[INVESTIGATOR_904228] 
the ADA classification24or BG confirmed by a plasma glucose value <3.1 mmol/L (56 mg/dL) 
withsymptoms consistent with hypoglycaemia
Figure 17–1 Novo Nordisk classification of hypoglycaemiaCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 86 of 107
ADA classification24of hypoglycaemia
!Severe hypoglycaemia: An epis ode requiring assistance of another person to actively
administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose
concentrations may not be available during an event, but neurological recovery following the
return of plasma glucose to normal is considered sufficient evidence that the event was induced
by a low plasma glucose concentration
!Asymptomatic hypoglycaemia: An epi[INVESTIGATOR_720728], but with a measured plasma glucose concentration ≤ 3.9 mmol/L (70 mg/dL)
!Documented symptomatic hypoglycaemia: An epi[INVESTIGATOR_720729] a measured plasma glucose concentration ≤ 3.9 mmol/L
(70 mg/dL)
!Pseudo-hypoglycaemia: An epi[INVESTIGATOR_720730] a measured plasma glucose concentration > 3.9
mmol/L (70 mg/dL) but approaching that level
!Probable symptomatic hypoglycaemia: An epi[INVESTIGATOR_720731] a plasma glucose determination but that was presumably caused by [CONTACT_904271] ≤ 3.9 mmol/L (70 mg/dL)
Figure 17–2 ADA classification of hypoglycaemiaCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 87 of 107
17.5 Health economics and/or patient reported outcomes
The following questionnaires will be used to compare PROs between treatments:
!Medical outcomes study 36-item short form (SF-36v2, standard)16
!Treatment related impact measure (TRIM-D)17
For each questionnaire, the summary scores will be summarised descriptively by [CONTACT_904272] J2R.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 88 of 107
18 Ethics
The trial will be conducted in compliance with ICH GCP2and applicable regulatory requirements, 
and in accordance with the Declaration of Helsinki3. 
The subjects will have the right to withdraw from the trial at any time, without giving a specific reason.
18.1 Benefit-risk assessment of the trial
All subjects included in the trial will be treated with IDegLira or IGlar, both in combination with 
previous SGTL2i ± OAD, in order to improve their glycaemic control.
Subjects will be transferred to a treatment regimen (fixed ratio combination of IDegLira or IGlar) 
anticipated to be better than or equal to the treatment they received prior to entering the trial. All participating subjects will need to spend some extra time as additional visits to the clinic are required, and some of the required tests performed during the trial are outside the normal practice. 
When randomised the subjects will get one of the treatments described above in combination with 
previous SGTL2i ±OAD. By [CONTACT_904273]-trial OAD treatments must include SGLT2i either as 
monotherapy, or in combination with metformin ± DPP4i ±pi[INVESTIGATOR_051]. If a subject is treated with 
DPP4i these have to be discontinued at randomisation, since subjects may be randomised to an injectable treatment including a GLP-[ADDRESS_1268908]. It has previously been reported that subjects on DPP4i in need of improved glycaemic control have acquired this by [CONTACT_904274] 
from DPP4i to a GLP-[ADDRESS_1268909] the investigator 
in case of any concerns regarding trial participation.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 89 of 107
18.1.1 Clinical risk profile of IDegLira and risk mitigations for this trial
[IP_ADDRESS] Identified risks
Hypoglycaemia
Hypoglycaemia is a pharmacological effect from insulin administration. The addition of liraglutide 
to IDeg has shown to reduce the requirement of exogenous insulin and hence minimise the risk of 
hypoglycaemia.
Immunogenicity (allergic reactions)
All peptide/protein based drugs have an inherent risk of allergic reactions. Allergic reactions are 
well known class effects for insulins and GLP-1 receptor agonists. Subjects with previous allergic 
reactions to IDeg or liraglutide will be excluded from the trial.
Pancreatitis
An association between the use of GLP-1 receptor agonists and pancreatitis has been suggested 
based on case reports received in clinical trials and during marketed use of drugs from this class. Even though a final conclusion regarding a causal relationship has not been established
41a causal 
relationship is possible, and acute pancreatitis is therefore considered an identified risk for all GLP- 
1 receptor agonists. Subjects with history of pancreatitis (acute or chronic) will be excluded from the trial as a precaution.
There have been few clinical reported events of acute pancreatitis (inflammation of the pancreas) 
presenting with persistent severe abdominal pain (usually accompanied by [CONTACT_492]) with 
liraglutide treatment. As a consequence of the known events of acute pancreatitis, Novo Nordisk 
will analyse blood samples for amylase and lipase during the trial to monitor the subjects’ safety. 
Furthermore, participating subjects should be informed of the characteristic symptoms of acute 
pancreatitis. If pancreatitis is suspected, IDegLira and other potentially suspected medicinal 
products will be discontinued. All cases of pancreatitis will be evaluated by [CONTACT_904275]. 
Gastrointestinal adverse events
Gastrointestinal adverse events are considered class effects for GLP-[ADDRESS_1268910] frequently reported events in patients treated with IDegLira. The titration of 
IDegLira is slow and has previously shown to result in a lower frequency of gastrointestinal adverse 
effects. The dose of the liraglutide component in the start dose of IDegLira in the present trial is 0.36 mg, which is less than the starting dose of liraglutide when administered as the mono-
component (Victoza
®). CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 90 of 107
[IP_ADDRESS] Potential risks
Altered Renal Function
Dehydration due to known gastrointestinal effects associated with GLP-[ADDRESS_1268911] safety laboratory surveillance.
Medullary Thyroid Cancer (C-Cell Carcinogenicity)
Thyroid C-cell carcinogenicity has been reported in rats and mice treated with GLP-1 receptor 
agonistsin non-clinical studies. Based on these findings, monitoring of serum calcitonin will be 
performed approximately every 3 months in the present trial. Subjects with thyroid disease will be closely monitored and in case of elevated calcitonin a recommendation for follow-up is included in Appendix C  inthe protocol. Subjects with a personal or family history of medullary thyroid 
carcinoma and subjects with multiple endocrine neoplasia type 2 syndrome or/and subjects with a 
calcitonin value > 50 ng/L will be excluded from the trial. 
Neoplasms
Epi[INVESTIGATOR_513426] T2DM are at higher risk for many forms of 
cancer. Moreover, evidence from observational studies indicates that some medications used to treat 
hyperglycaemia are associated with either increased or reduced risk of cancer. It is thus important to 
demonstrate, that new antidiabetic therapi[INVESTIGATOR_904229] 
T2DM population.
Neoplasms will be followed closely. All neoplasms will be adjudicated externally by [CONTACT_36320].
Pancreatic cancer
Pancreatic cancer is included as a potential risk, due to the focus on the potential association with 
GLP-1-based therapi[INVESTIGATOR_014]. There is currently no support from non-clinical investigations or clinical trials that GLP-1 receptor agonists increase the risk of pancreatic cancer
42. GLP-1 receptor agonists 
treatment shall be withdrawn in patients with suspi[INVESTIGATOR_1884]/diagnosed pancreatic cancer and appropriate treatment and monitoring shall be initiated.
Epi[INVESTIGATOR_513426] T2DM are at significantly higher risk for many 
forms of cancer43,44.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268912] an increased risk of cardiovascular disorders, and it is a major 
comorbidity factor in this population. 
The following cardiovascular events will be followed closely: acute coronary syndrome, 
cerebrovascular event, heart failure requiring hospi[INVESTIGATOR_063], revascularisation procedures and 
cardiac arrhythmia. In addition, selected cardiovascular events will be adjudicated by [CONTACT_131461].
Lack of efficacy due to anti-IDeg or anti-liraglutide antibody formation
Consistent with the potentially immunogenic properties of protein and peptide pharmaceuticals, 
patients may develop anti-insulin degludec and anti-liraglutide antibodies following treatment with 
liraglutide and IDeg. Antibody formation seems to be of no consequence for the efficacy and the 
safety of liraglutide or current insulin preparations.
Medication errors, including errors with transfer from injectable diabetes therapy
Medication errors may occur due to the lack of training before initiating IDegLira therapy, patient’s 
unawareness of difference between IDegLira and other injectable diabetes therapy (insulin or GLP-
1 receptor agonists) or distraction during preparation for injection. Mixing up IDegLira with 
different types of insulin may result in hypo- and/or hyperglycaemia. Mixing up IDegLira with a 
GLP-[ADDRESS_1268913] may result in gastrointestinal disorders.  Investigators should mitigate this risk by 
[CONTACT_904276]. 
[IP_ADDRESS] Other safety considerations
In reproduction and development toxicity studies liraglutide has been shown to be teratogenic in 
rats and rabbits including reduced growth and major abnormalities at systemic exposures below 
human exposure at the maximum recommended human dose (MRHD) of 1.8 mg/day. The US 
Victoza®Prescribing Information includes the Pr egnancy Category C (US FDA Pharmaceutical 
Pregnancy Categories: “Animal reproduction studies have shown an adverse effect on the foetus 
and there are no adequate and well-controlled studies in humans, but potential benefits may warrant 
use of the drug in pregnant women despi[INVESTIGATOR_47853]”). Due to this pregnant women and 
women with the intention to become pregnant, are excluded from the trial.
Dorsal skin sarcomas at the injection site were significantly increased in male mice at the highest 
dose of 3 mg/kg/day. These fibrosarcomas were attributed to the high local concentration of drug 
near the injection site. The liraglutide concentration in the clinical formulation (6 mg/ml) is 10-
times higher than the concentration in the formulation used in the carcinogenicity study (0.6 
mg/ml). The observed increase in skin sarcomas in high-dose male mice is of unknown relevance 
for human safety.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268914] level (NOAEL) was not observed. These tumours were not seen 
in monkeys treated for [ADDRESS_1268915] tolerated SGLT2i treatment for 90 days we minimize the risk of adverse events in this 
regards. Furthermore, IDegLira is titrated slowly and thus the risk of gastrointestinal side effect is 
minimal
45.
18.1.[ADDRESS_1268916]. This trial has been designed to mitigate potential risks, such as risk of dehydration, 
associated with SGLT2i treatment. The development programme has not identified any risks 
associated with the use of IDegLira that are not already known from IDeg or liraglutide; for further 
information please see section 3. The benefits are therefore concluded to outweigh the risks, and the 
proposed use of IDegLira in this trial is considered warranted.
Areas of special interest with regards to safety of trial products are described in detail in the IDeg 
NN1250 IB9current version or any updates hereof, the liraglutide local approved labelling current 
version or any updates hereof and/or the IDegLira NN9068 IB10current version or any updates 
hereof. 
18.[ADDRESS_1268917] comply with applicable 
regulatory requirement(s) and adhere to ICH GCP2and the requirements in the Declaration of 
Helsinki3.
Before any trial-related activity, the investigator must give the subject verbal and written 
information about the trial and the procedures involved in a form that the subject can read and 
understand. 
The subjects must be fully informed of their rights and responsibilities while participating in the 
trial as well as possible disadvantages of being treated with the trial products.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268918]’s willingness to continue 
participating in the trial, the investigator must inform the subject in a timely manner, and a revised 
written subject information must be provided and a new informed consent must be obtained.
In this trial additional informed consent must be obtained if: 
!A female subject becomes pregnant during the trial, the male partner should be asked to sign a
separate informed consent form (when abnormality is found in the foetus or new-born infant).
!A male subject report that his female partner becomes pregnant during the trial, the female
partner should be asked to sign a separate informed consent form (only applicable for the US).
In addition, all subjects will be asked to sign a separate informed consent form in order to give 
permission to collect cardiovascular information in case the subject withdraws. The subject will be 
asked to sign this additional informed consent when entering the trial and the cardiovascular 
information will be collected at the time of the initial planned EOT.
18.[ADDRESS_1268919]’s data will be handled 
as follows:
!Data already collected and data collected at the end-of-trial visit will be retained by [CONTACT_904277], entered into the database and used for the trial report.
!Safety events will be reported to Novo Nordisk and regulatory authorities according to
local/national requirements.
If data is used, it will always be in accordance with local regulations and IRBs/IECs.
18.[ADDRESS_1268920] may receive information provided to the site by [CONTACT_3454], an example of this may 
be a “thank you for your participation letter” after completion of the trial. Further the subject may 
receive letters during the trial. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268921] be sent to IRB/IEC for approval/favourable opi[INVESTIGATOR_17950].
18.5 Premature termination of the trial and/or trial site
Novo Nordisk, the IRBs/IECs or a regulatory authority may decide to stop the trial, part of the trial 
or a trial site at any time, but agreement on procedures to be followed must be obtained.
If a trial is suspended or prematurely terminated, the investigator must inform the subjects promptly 
and ensure appropriate therapy and follow-up. The investigator and/or Novo Nordisk must also 
promptly inform the regulatory authorities and IRBs/IECs and provide a detailed written 
explanation. 
If, after the termination of the trial, the benefit-risk analysis changes, the new evaluation must be 
provided to the IRBs/IECs in case it has an impact on the planned follow-up of subjects who have 
participated in the trial. If it has an impact, the actions needed to inform and protect the subjects 
should be described.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268922] be documented and explained in a protocol deviation by [CONTACT_18030], date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the eCRF or via listings from the clinical database. 
Documentation on protocol deviations must be kept in the investigator's trial master file and 
sponsor trial master file.
[ADDRESS_1268923] to audits conducted by [CONTACT_36341]/IECs. Audits and inspections may take place during or after the trial. The investigator and the site staff as well as Novo Nordisk staff 
have an obligation to cooperate and assist in audits and inspections. This includes giving auditors 
and inspectors direct access to all source documents and other documents at the trial site relevant to 
the clinical trial. This includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are relevant to the evaluation of the trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268924] be available 
to Novo Nordisk:
!Regulatory approval and/or acknowledgement of notification as required
!Approval/favourable opi[INVESTIGATOR_36254]/IECs clearly identifying the documents reviewed as
follows: protocol, any protocol amendments, subject information/informed consent form, any
other written information to be provided to the subject and subject recruitment materials
!List of IRB/IEC members and/or constitution (or a general assurance number/statement of
compliance)
!Curricula vitae of investigator and sub-investigator(s) (current, dated and signed - must include
documented GCP training or a certificate)
!Signed receipt of Investigator's Brochure or Summary of Product Characteristics
!Signed and dated Agreement on Protocol
!Signed and dated agreement on protocol amendment, if applicable
!Contract, signed by [CONTACT_1755]/or appropriate parties on behalf of the investigator’s
site and Novo Nordisk
!Source document agreement
!Central laboratory certification and normal ranges
!Insurance statement, if applicable
!Financial disclosure form from investigator and sub-investigator(s)
Only applicable for US trial sites: 
!For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of
Financial Conflict of Interest
!For US trial sites: FDA form [ADDRESS_1268925] be completed and signed by [CONTACT_904278] 1572
For US sites:
!Intended for US sites
!Conducted under the IND
!All US investigators, as described above, will sign FDA Form 1572CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 97 of 107
For sites outside the US:
!Intended for participating sites outside of the US
!Not conducted under the IND
!All investigators outside of the US will not sign FDA form 1572
Novo Nordisk will analyse and report data from all sites together if more than one site is involved in 
the trial.
By [CONTACT_12142], each investigator agrees to comply fully with ICH GCP2, applicable 
regulatory requirements and the Declaration of Helsinki3.
By [CONTACT_12142], each investigator also agrees to allow Novo Nordisk to make investigator's name [CONTACT_136821] 
[CONTACT_36344].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268926] of the trial at his/her site. If any tasks are delegated, 
the investigator must maintain a log of appropriately qualified persons to whom he/she has 
delegated specified trial-related duties. The investigator must ensure that there is adequate training 
for all staff participating in the conduct of the trial. It is the investigator's responsibility to supervise 
the conduct of the trial and to protect the rights, safety, and well-being of the subjects.
A qualified physician, who is an investigator or a sub-investigator for the trial, must be responsible 
for all trial-related medical decisions.
The investigator must ensure adequate supervision of the conduct of the trial at the trial site. 
The investigator will follow instructions from Novo Nordisk when processing data.
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data 
produced) in the investigator trial master file. The documents including the subject identification 
code list should be kept in a secure locked facility, so no unauthorized persons can get access to the 
data. 
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. The investigator 
must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safety measures have been taken.
During any period of unavailability, the investigator must delegate responsibility for medical care of 
subjects to a specific qualified physician who will be readily available to subjects during that time.
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk. 
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268927], if deemed necessary by [CONTACT_3454]. Provided that certain 
conditions are fulfilled, Novo Nordisk may grant access to information obtained during this trial to 
researchers who require access for research projects studying the same disease and/or trial product 
studied in this trial.
Novo Nordisk may publish on its clinical trials website a redacted CTR for this trial.
One investigator will be appointed by [CONTACT_18036] (signatory 
investigator) on behalf of all participating investigators. The signatory investigator will be appointed based upon the criteria defined by [CONTACT_904279]
46.
23.[ADDRESS_1268928] for Clinical Trial Disclosure
18.
Novo Nordisk reserves the right to defer the release of data until specified milestones are reached, 
for example when the CTR is available. This includes the right not to release the results of interim 
analyses, because the release of such information may influence the results of the entire trial.
At the end of the trial, one or more scientific publications may be prepared collaboratively by [CONTACT_1275](s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or 
communication for up to [ADDRESS_1268929] intellectual property.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 100 of 107
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. All authors will be given the relevant 
statistical tables, figures, and reports needed to evaluate the planned publication. In the event of any 
disagreement on the content of any publication, both the investigators' and Novo Nordisk opi[INVESTIGATOR_36255].
Where required by [CONTACT_18038], the investigator from each trial site will be named in an 
acknowledgement or in the supplementary material, as specified by [CONTACT_18038]. 
Novo Nordisk maintains the right to be informed of plans by [CONTACT_36347], presentation, communication or other information concerning the 
investigation described in this protocol. Any such communication must be submitted in writing to 
Novo Nordisk before submission for comments. Comments will be given within four weeks from 
receipt of the planned communication. 
23.1.1 Authorship
Authorship of publications should be in accordance with the Uniform Requirements of the 
International Committee of Medical Journal Editors46(sometimes referred to as the 
Vancouver Criteria).
The investigator(s) offered authorship will be asked to comment and approve the publication. No 
permission to publish will be granted to any clinical research organisation (CRO) involved in the 
trial described in this protocol. 
23.1.2 Site-specific publication(s) by [CONTACT_1697](s)
For a multi-centre clinical trial, analyses based on single-site data usually have significant statistical 
limitations and frequently do not provide meaningful information for healthcare professionals or 
subjects, and therefore may not be supported by [CONTACT_3454]. It is a Novo Nordisk policy that 
such individual reports do not precede the primary manuscript and should always reference the 
primary manuscript of the trial.
Novo Nordisk reserves the right to prior review of such publications. Further to allow for the 
primary manuscript to be published as the first, Novo Nordisk asks for deferment of publication of 
individual site results until the primary manuscript is accepted for publication. As Novo Nordisk wants to live up to the industry publication policy, submission of a primary publication will take 
place no later than [ADDRESS_1268930] their own research subjects' data.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268931]'s medical records must be kept for the maximum period permitted by [CONTACT_5035][INVESTIGATOR_307], 
institution or private practice.
The investigator must agree to archive the documentation (this includes both electronic and paper-
based records) pertaining to the trial in an archive after completion or discontinuation of the trial if 
not otherwise notified. The investigator should not destroy any documents without prior permission 
from Novo Nordisk. If the investigator cannot archive the documents at the trial site, Novo Nordisk 
can refer the investigator to an independent archive provider that has a system in place to allow only 
the investigator to access the files.
The investigator must be able to access his/her trial documents without involving Novo Nordisk in 
any way. Site-specific CRFs and other subject data (in an electronic readable format or as paper 
copi[INVESTIGATOR_17951]) will be provided to the investigator before access is revoked to the systems and/or 
electronic devices supplied by [CONTACT_3454]. These data must be retained by [CONTACT_21655]. If the 
provided data (e.g. the CD-ROM) is not readable during the entire storage period, the investigator 
can request a new copy. A copy of all data will be stored by [CONTACT_3454].
Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for as long as the 
product is on the market plus 20 years. 
The files from the trial site/institution must be retained for 15 years after the completion of the trial, 
or longer if required by [CONTACT_36348]. In any case trial files cannot be 
destroyed until the trial site/institution is notified by [CONTACT_3454]. The deletion process must 
ensure confidentiality of data and must be done in accordance with local regulatory requirements.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 102 of 107
25 Institutional Review Boards/Independent Ethics Committees and 
regulatory authorities
IRB/IEC:
Written approval or favourable opi[INVESTIGATOR_36256]/IEC prior to commencement of 
the trial.
During the trial, the investigator or Novo Nordisk, as applicable, must promptly report the 
following to the IRB/IEC, in accordance with local requirements: updates to Investigator's 
Brochure, unexpected SAEs where a causal relationship cannot be ruled out, protocol amendments 
according to local requirements, deviations to the protocol implemented to eliminate immediate 
hazards to the subjects, new information that may affect adversely the safety of the subjects or the 
conduct of the trial (including new benefit-risk analysis in case it will have an impact on the 
planned follow-up of the subjects), annually written summaries of the trial status, and other 
documents as required by [CONTACT_1036]/IEC.
The investigator must ensure submission of the clinical trial report synopsis to the IRB/IEC, 
according to local requirements.
Protocol amendments must not be implemented before approval or favourable opi[INVESTIGATOR_36257], unless necessary to eliminate immediate hazards to the subjects.
The investigator must maintain an accurate and complete record of all submissions made to the 
IRB/IEC. The records must be filed in the investigator trial master file and copi[INVESTIGATOR_36258].
Regulatory Authorities:
Regulatory authorities will receive the clinical trial application, protocol amendments, reports on 
SAEs, and the clinical trial report according to national requirements.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268932] liability for its products, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown 
negligence.
Novo Nordisk assumes no liability in the event of negligence, or any other liability of the sites or 
investigators conducting the trial, or by [CONTACT_18033].
Novo Nordisk accepts liability in accordance with:
Russia: Federal Law of 12 April 2010 No. 61-FZ "On Medicinal Drugs' Cerculation
Switzerland: Federal Act on Medicinal Products and Medical Devices of (HMG/TPA) 15 
December 2000 and Ordinance on Clinical Trials in Human Research (KlinV/ClinO) of 20 
September 2013CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 104 of 107
27 References
1 The Criteria Committee Of The [LOCATION_001] Heart Association. Nomenclature and Criteria for 
Diagnosis of Diseases of the Heart and Great Vessels. Little, Brown & Co., 1994.
2 International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: Guideline 
for Good Clinical Practice E6 (R1), Step 4. [ADDRESS_1268933] amended by [CONTACT_941] 64th WMA General Assembly, Fortaleza, Brazil. World Medical Association. 20 A.D.
4 American Diabetes Association. Standards of medical care in diabetes--2015. Diabetes Care 
2015; [ADDRESS_1268934] 1-17.
5 [LOCATION_006] Prospective Diabetes Study ([LOCATION_006]PDS) Group. Intensive blood-glucose control with 
sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes ([LOCATION_006]PDS 33). Lancet 1998; 352(9131):837-853.
[ADDRESS_1268935] of intensive 
treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 1993; 329(14):977-986.
7 Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management 
of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38(1):140-149.
[ADDRESS_1268936] and 
basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014; 384(9961):2228-2234.
9 Novo. Investigator's Brochure, Insulin degludec (10th Edition).  
10 Investigator's Brochure, NN9068 insulin degludec/liraglutide (7th Edition). Novo Nordisk 
A/S. 2015.
11 Lantus
®- Summary of Product Characteristics.  28 Jul 2015. 
12 Food and Drug Administration. Lantus®- U.S. Label information.  17 Jul 2015. 
13 Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 
diabetes. Drug Des Devel Ther 2014; 8:1335-1380.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 105 of 107
14 Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K et al. Long-term efficacy of 
dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012; 156(6):405-415.
15 Wysham CH, Woo VC, Matheiu C, Desai M, Alba M, Capuano G et al. Canagliflozin 
(CANA) added on to Dipeptidyl Peptidase-4 Inhibitors or Glucagon-Like Peptide-1 (GLP-1) Agonists With or Without Other Antihyperglycemic Agents (AHAs) in type 2 Diabetes Mellitus (T2DM). Diabetes Care [62 (supplement 1)], A217-A364. 2013. 
[ADDRESS_1268937], RI, [LOCATION_003]: QualityMetric Icorporated; 2007. QualityMetric Icorporated 2007.
[ADDRESS_1268938] of treatment in diabetes: the Treatment-Related Impact Measures for Diabetes and Devices (TRIM-Diabetes and TRIM-Diabetes Device). Health Qual Life Outcomes 2009; 7:83.
18 Novo Nordisk A/S. http://novonordisk-trials.com/website/content/how-we-disclose-trial-
information.aspx.   
19 De Angelius C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. New England Journal of Medicine 2004; 351(12):1250-1251.
[ADDRESS_1268939] of 2007: 
http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFD 
CAct/SignificantAmendmentstotheFDCAct/FoodandDrugAdministrationAmendmentsActof2 
007/default.htm. 
21 The European Parliament and the Council of the European Council. Directive 2001/20/EC of 
the European Parliament and of the Council of [ADDRESS_1268940] of clinical trials on medicinal products for human use, article 11. Official Journal of the European Communities. May 2001.  2001. 
22 The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human 
and veterinary use and establishing a European Medicines Agency, article 57. Official Journal 
of the European Communities. April 2001. 
23 Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced 
awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic 
frequency and associated symptoms. Diabetes Care 1995; 18(4):517-522.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268941] ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L et al. Hy poglycemia  and 
diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013; 36(5):1384-1395.
25 McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. Diabet 
Med 2001; 18(9):690-705.
26 U.S.Department of Health and Human Services, Food and Drug Administration, Center for 
Drug Evaluation and Research (CDER), Center for biologics Evaluation and Research 
(CBER), Center for Devices and Radiological Health (CDRH). Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. December 2009. http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf . 
27 Stull DE, Leidy NK, Parasuraman B, Chassany O. Optimal recall periods for patient-reported 
outcomes: challenges and potential solutions. Curr Med Res Opin 2009; 25(4):929-942.
28 European Commision. The Rules Governing Medicinal Products in the European Union, 
Volume 4, Annex 13, Investigational Medicinal Products. Brussels, February 2010. 1 Feb 2010.
29 National Research Council (US) Panel on Handling Missing Data, Committee on National 
Statistics DoBaSSaE. The Prevention and Treatment of Missing Data in Clinical Trials. The National Academies Press, 2010.
30 U.S.Department of Health and Human Services. Guidance (draft) for Industry Diabetes 
Mellitus: Developi[INVESTIGATOR_111391]. Food and Drug Administration, February 2008.  
31 European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). 
Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus (CPMP/EWP/1080/00 Rev. 1). 14 May 2012.  
32 Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S et al. Liraglutide vs insulin 
glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52(10):2046-2055.
33 Wang F, Carabino JM, Vergara CM. Insulin glargine: a systematic review of a long-acting 
insulin analogue. Clin Ther 2003; 25(6):1541-77, discussion.
34 International Conference on Harmonisation, ICH Expert Working Group. ICH Harmonised 
Tripartite Guideline. Statistical Principles for Clinical Trials E9 (step 4 version 5). 5 February 1998.  CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 107 of 107
35 O'Kelly M, Ratitch B. Clinical Trials with Missing Data: A Guide for Practitioners. 2014.
36 Koch GG. Comments on 'Current issues in non-inferiority trials' by [CONTACT_19617] R. Fleming, 
Statistics in Medicine, DOI: 10.1002/sim.2855. Stat Med 2008; 27(3):333-342.
37 Little RJA, Rubin D.B. Statistical analysis with missing data. [LOCATION_001]: John Wiley & Sons, 
1987.
38 Keene ONea. Missing data sensitivity analysis for recurrent event data using controlled 
imputation. Pharm Stat 2014; 13:258-264.
[ADDRESS_1268942] 1987; 79(3):777-781.
40 Pratley RE, Nauck MA, Bailey T, Montanya E, Filetti S, Garber AJ et al. Efficacy and safety 
of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care 2012; 35(10):1986-1993.
41 Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T et al. Pancreatic safety 
of incretin-based drugs--FDA and EMA assessment. N Engl J Med 2014; 370(9):794-797.
42 Assessment report for GLP-1 based therapi[INVESTIGATOR_014], 25 July 2013 (EMA/474117/2013).  2013. 43 Chodick G, Heymann AD, Rosenmann L, Green MS, Flash S, Porath A et al. Diabetes and 
risk of incident cancer: a large population-based cohort study in Israel. Cancer Causes Control 2010; 21(6):879-887.
44 Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA. Risk of cancer in a large 
cohort of U.S. veterans with diabetes. Int J Cancer 2011; 128(3):635-643.
[ADDRESS_1268943] HW, Linjawi S, Poulsen P et al. Efficacy and safety of a 
fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol 2014; 2(10):885-893.
46 Clever L, Colaianni LA, Davidoff F, Horton R, Kassirer JP, Angell M et al. Uniform 
requirements for manuscripts submitted to biomedical journals. New Engl J Med 1997; 336(4):309-315.CONFIDENTIAL
Protocol Appendix A
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 1 of 8
Appendix A: Titration Guideline
Trial ID: NN9068-4229
DUALTMIX - Add-on to SGLT2i
A clinical trial comparing glycaemic control and safety of 
insulin degludec/liraglutide (IDegLira) versus insulin 
glargine (IGlar) as add-on therapy to SGLT2i in subjects 
with type 2 diabetes mellitus 
Trial phase: 3b
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
partiesCONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Appendix A
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268944] of in-text tables
Page
Table 1 Adjustment of IDegLira or IGlar ......................................................................................... ..........5CONFIDENTIAL
Protocol Appendix A
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 3 of 8
1 Introduction
The goal of insulin therapy is to achieve near normoglycaemia, i.e. to reach a pre-defined HbA 1c
level with a low rate of hy pogly caemic epi[INVESTIGATOR_904230]. Several trials 
have shown that this is difficult to achieve, unless plasma glucose (PG) values are intensively monitored and the insulin dose(s) frequently adjusted
1-6.
To ensure treatment uniformity between the sites, as well as to ensure that subjects receive an 
optimal treatment, titration algorithms have been developed specifying recommended dose 
adjustments at different PG levels.
It is recognised that treatments differ between different regions and countries. Likewise, specific 
titration guidelines may not be applicable in certain clinical situations. It is important that other 
information, such as symptoms of hypo- or hyperglycaemia, previous response to dose adjustments, 
other glucose measurements and other indicators of the subject’s level of glycaemic control, is 
taken into consideration when decisions on dosing are made. The investigator should always use his 
clinical judgement to avoid safety hazards. The investigator is responsible for the treatment of the 
subjects and can therefore overrule the guideline.
To optimise and maintain glycaemic control, the investigator should, throughout the trial be at least 
in weekly contact [CONTACT_904280]’s welfare.CONFIDENTIAL
Protocol Appendix A
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 4 of 8
2 Treatment regimens
At randomisation the subjects will be randomised 1:1 into two parallel treatment arms:
!IDegLira OD + SGLT2i ± OAD
!IGlar OD + SGLT2i ± OAD
First dosing of IDegLira or IGlar should take place on day of randomisation or on the day following 
randomisation.
Maximum dose of IDegLira is 50 dose steps (50U of insulin degludec and 1.8 mg of liraglutide). 
There is no maximum dose of IGlar.
Subjects should continue their SGLT2i ± metformin ± pi[INVESTIGATOR_904231]-trial doses.
2.1 Injection area
IDegLira should be injected subcutaneously into the thigh, upper arm (deltoid region) or the 
abdomen. 
IGlar should be administered subcutaneously according to local labelling.
The chosen region should be the same throughout the trial. Rotation of injection sites within a given 
region is recommended.
2.2 Time of injection
IDegLira should be injected once daily at any time of the day, but should approximately be the 
same time of the day throughout the trial. 
IGlar should be injected once daily according to local labelling.CONFIDENTIAL
Protocol Appendix A
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 5 of 8
3 Initiation and titration
3.1 Initiation of IDegLira or IGlar
Subjects randomised to IDegLira will start on 10 dose steps, consisting of 10U insulin 
degludec/0.36 mg liraglutide once daily.
Subjects randomised to IGlar will start on 10U of insulin glargine once daily.
3.2 Titration of IDegLira or IGlar
The doses of IDegLira or IGlar should be adjusted twice weekly on fixed days (Mondays and 
Thursdays). 
Dose adjustment will be based on the mean of three pre-breakfast SMPG values measured on the 
day of the titration and the two days prior to the titration in accordance with Table 1 .
!Monday, Tuesday and Wednesday doses will be determined, based on the mean fasting
glucose values, obtained on Saturday, Sunday and Monday
!Thursday, Friday, Saturday and Sunday doses will be determined, based on the mean fasting
glucose values, obtained on Tuesday Wednesday and Thursday
Table [ADDRESS_1268945] SMPG Dose adjustment
mmol/L mg/dL Dose steps/U
< 4.0 < 72 -2
4.0∀5.0 72 – 90 0
> 5.0 > 90 +2
If one or more SMPG values are missing, the dose adjustment should be performed on the 
remaining SMPG value(s). 
3.[ADDRESS_1268946] the IDegLira or IGlar doses are based on all relevant information as described in Section 1. A 
reason for deviating from the algorithm should be entered into the eCRF.CONFIDENTIAL
Protocol Appendix A
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 6 of 8
4 Data collection
The following titration data from the diaries should be entered into the eCRF for all subjects within 
24 hours on weekdays after each site visit/phone contact:
!Daily SMPG values
!Daily date, time and dose of IDegLira or IGlar
!Hypoglycaemic epi[INVESTIGATOR_1841]
!Prescribed dose of IDegLira or IGlar
!Reasons for deviations from the titration guideline, if applicable.CONFIDENTIAL
Protocol Appendix A
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 7 of 8
5 Review procedure
Surveillance of titration data will be performed centrally by [CONTACT_197684]. It 
is important that data regarding dose titration is entered into the eCRF within 24 hours (on 
weekdays). If delays occur, action cannot be taken in due time before the subject’s next site 
visit/phone contact. The aim is to reduce the time periods in which a subject may receive 
suboptimal treatment.
The data listed in section 4will be reviewed by [CONTACT_41194] 24 hours (on weekdays). The 
reviewer may contact [CONTACT_826726].
When the investigator receives an inquiry, a response should be received at Novo Nordisk within 24 
hours (on weekdays). 
During the trial HbA 1cwill be monitored by [CONTACT_826727]. Novo Nordisk may be in contact [CONTACT_190063] (visit or phone contact) to discuss 
progress in glycaemic control and titration of individual subjects based on SMPGs and HbA 1c. This 
will be done in an unbiased and whenever possible in a blinded manner.CONFIDENTIAL
Protocol Appendix A
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 8 of 8
6 References
1 Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-
week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51(3):408-416.
2 Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, 
randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29(6):1269-1274.
3 Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. 
Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clinical Therapeutics 2006; 28(10):1569-1581.
4 Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or 
human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26(11):3080-3086.
5 Garber AJ, King AB, Del PS, Sreenan S, Balci MK, Munoz-Torres M et al. Insulin degludec, an 
ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379(9825):1498-1507.
6 Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L et al. Insulin degludec, an ultra-
longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379(9825):1489-1497.CONFIDENTIAL
Protocol Appendix B
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 1 of 10
Appendix B: Events with additional data collection and events 
requirin g adjudication 
Trial ID: NN9068-4229
DUALTMIX - Add-on to SGLT2i
A clinical trial comparing glycaemic control and safety of 
insulin degludec/liraglutide (IDegLira) versus insulin glargine 
(IGlar) as add-on therapy to SGLT2i in subjects with type 2 
diabetes mellitus
Trial phase: 3b
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
partiesCONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Appendix B UTN: U1111-1168-9343 Date: 20 November 2015 Status: Final Novo Nordisk
Trial ID: NN9068-[ADDRESS_1268947] No.: 2015-001596-48 Version: 2.0 Page: 2 of 10
1 Events with additional data collection and events requiring adjudication 
Events with additional 
data collection and/or 
events requiring 
adjudication Definitions Rationale Event Adjudication 
Committee
Fatal events All fatal events must be reported  including all-cause 
mortality: 
!Cardiovascular death
!Non-cardiovascular death
!Undetermined cause of deathAnFDA guidance document1  requests that 
Sponsors demonstrate the cardiovascular 
safety profile of any new therapy for type 2 
diabetes in order to ensure, that the new therapy does not increase the cardiovascular 
risk to an unacceptable extent.All events will be 
adjudicated
Acute coronary syndrome:
!Myocardial
infarction 
!Hospi[INVESTIGATOR_904232] (MI) must be 
reported:
!Spontaneous MI (including re-infarction and
MI associated with stent thrombosis)
!Percutaneous coronary intervention (PCI)
related MI
!Coronary artery by[CONTACT_10956] (CABG)
related MI 
!Silent MI
All events with symptoms of unstable angina requiring 
hospi[INVESTIGATOR_513433].AnFDA guidance document1requests that 
Sponsors demonstrate the cardiovascular safety profile of any new therapy for type 2 diabetes in order to ensure, that the new 
therapy does not increase the cardiovascular 
risk to an unacceptable extent.All events will be 
adjudicated
Cerebrovascular event (stroke or transient 
ischemic attack)Stroke (ischaemic, haemorrhagic or undetermined) is 
defined as an acute epi[INVESTIGATOR_904233], caused by [CONTACT_513466], spi[INVESTIGATOR_36232], or retinal vascular injury.
Transient Ischemic Attack (TIA) is defined as a 
transient (<24 hours) epi[INVESTIGATOR_904234], spi[INVESTIGATOR_1831], or 
retinal ischemia, without acute infarction.AnFDA guidance document1requests that 
Sponsors demonstrate the cardiovascular 
safety profile of any new therapy for type 2 
diabetes in order to ensure, that the new therapy does not increase the cardiovascular risk to an unacceptable extent.All events will be 
adjudicated
Protocol Appendix B UTN: U1111-1168-9343 Date: 20 November 2015 Status: Final Novo Nordisk
Trial ID: NN9068-[ADDRESS_1268948] No.: 2015-001596-48 Version: 2.0 Page: 3 of 10
Events with additional 
data collection and/or 
events requiring 
adjudication Definitions Rationale Event Adjudication 
Committee
Heart failure requiring 
hospi[INVESTIGATOR_513436] a new epi[INVESTIGATOR_904235].An FDA guidance document1requests that 
Sponsors demonstrate the cardiovascular safety profile of any new therapy for type [ADDRESS_1268949] a 24 hour 
stay, will be 
adjudicated
Pancreatitis Two of the following three diagnostic criteria fulfilling 
the diagnosis of acute pancreatitis: 
!Severe acute upper abdominal pain
!Elevated blood levels of pancreatic enzymes
(lipase and/or amylase) > 3xUNR
!Characteristic imaging finding (ultrasound,
computerised axial tomography (CT),
magnetic resonance imaging (MRI)
Chronic pancreatitis will be defined by [CONTACT_513467] (ultrasound, CT, MRI) with abnormal 
pancreatic function tests or characteristic histological 
findings.Treatment with GLP-1 agonists has been 
associated with acute pancreatitis. 
Pancreatitis (including necrotising 
pancreatitis) is an identified risk according to 
the Company Core Data Sheet (CCDS) for 
liraglutide, a component of IDegLira. Novo 
Nordisk therefore monitors these events 
closely.All events will be 
adjudicated
Thyroid disease All disorders of thyroid gland (incl. thyroid neoplasms) 
must be reported.
Please refer to the protocol for further details on the Thyroid C-cells carcinogenicity has been 
reported in rats and mice treated with GLP-1 
receptor agonists in non-clinical studies.All thyroid neoplasms 
will be adjudicated.
Thyroid disorders 
Protocol Appendix B UTN: U1111-1168-9343 Date: 20 November 2015 Status: Final Novo Nordisk
Trial ID: NN9068-[ADDRESS_1268950] No.: 2015-001596-48 Version: 2.0 Page: 4 of 10
Events with additional 
data collection and/or 
events requiring 
adjudication Definitions Rationale Event Adjudication 
Committee
assessments. which require 
thyroidectomy will be 
adjudicated
Neoplasm All types of neoplasms (i.e. all new growth incl. 
polyps, warts etc.) must be reported including:
!Malign neoplasm
!In situ neoplasm
!Benign neoplasm
!Neoplasms of uncertain or unknown
behaviour
(Please note: for operational reasons thyroid neoplasms will be reported as a thyroid disease and should not be 
reported as a Neoplasm)Neoplasm is an event we follow closely for 
GLP-1 analogues due to non-clinical findings 
in rats and mice treated with GLP-1 agonists.All neoplasm events, 
irrespective of 
malignancy stage ,will 
be adjudicated
Renal failure !All events of renal failure should be reported,
including events fulfilling one of the following
three diagnostic criteria, fulfilling the diagnosis of
acute renal failure:
!Increase in serum creatinine ≥ 0.3 mg/dL within
48 hours
!Increase in serum creatinine to ≥ 1.5 times
baseline within 7 days
!Urine volume < 0.5 mL/kg/h for 6 hoursLiraglutide (a component of IDegLira) and 
SGLT2i have been associated with 
dehydration/volume depletion. Severe 
dehydration/volume depletion per se can be 
associated with development of renal impairment and acute renal failure. Therefore 
renal impairment and acute renal failure are 
followed closely.  No adjudication 
Protocol Appendix B UTN: U1111-1168-9343 Date: 20 November 2015 Status: Final Novo Nordisk
Trial ID: NN9068-[ADDRESS_1268951] No.: 2015-001596-48 Version: 2.0 Page: 5 of 10
Events with additional 
data collection and/or 
events requiring 
adjudication Definitions Rationale Event Adjudication 
Committee
Medication errors 
concerning trial products1. Administration of wrong drug or use of wrong
device. Note: Use of wrong DUN is not
considered a medication error unless it results
in administration of wrong drug.
2. Wrong route of administration, such as
intramuscular instead of subcutaneous
3. Administration of an overdose with the
intention to cause harm (e.g., suicide attempt)
Accidental administration of a lower or higher dose 
than intended . That is a dose that deviates by [CONTACT_26813] ± 20% of the intended dose; however the 
administered dose must deviate from the intended dose 
to an extent where clinical consequences for the trial 
subject were likely to happen as judged by [CONTACT_1275], although they did not necessarily occur.Medication errors are captured to collect 
information which may be used to improve 
the design, name [CONTACT_513478]/or information which may have an 
impact on product labelling (for example 
information about substantial overdoses).No adjudication
Protocol Appendix B
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 6 of 10
2 Adverse Events Requiring Additional Data Collection in the eCRF
2.1 Cardiovascular events:
Cardiovascular events that are suspected as being related to one of the three categories below 
should be reported on the designated form in the eCRF:
2.1.[ADDRESS_1268952] be reported if 
available:
!Duration of symptoms
!Changes in ECG
!Collection of cardiac biomarkers
!Cardiac imaging
!Cardiac stress testing
!Angiography
!Use of thrombolytic drugs
!Coronary revascularisation
2.1.2 Cerebrovascular events, e.g. transient ischemic attack (TIA), stroke
If a cerebrovascular event is observed during the trial, this must be recorded as an AE and on a 
specific cerebrovascular event form in the eCRF. The following information must be reported if 
available:
!Type of event (e.g. TIA, Stroke)
!Contributing condition
!Neurologic signs and symptoms
!History of neurologic disease
!Imaging supporting the condition
!Treatment given for the condition
2.1.3 Heart failure requiring hospi[INVESTIGATOR_237169] (admission to an in-patient unit or a visit to an 
emergency department that results in at least a 24 hour stay) is observed during the trial, this must CONFIDENTIAL
Protocol Appendix B
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268953] be reported if available: 
!Signs and symptoms of heart failure
!NYHA Class2
!Supportive imaging
!Supportive laboratory measurements
!Initiation or intensification of treatment for this condition
2.[ADDRESS_1268954] be reported if 
available : 
!Signs and symptoms of pancreatitis
!Specific laboratory test supporting a diagnosis of pancreatitis:
!Amylase
!Lipase
!ALT and AST
!Bilirubin
!Alkaline Phosphatase
!Imaging performed and consistency with pancreatic disease
!Complications to the event
!Relevant risk factors for pancreatic disease including:
!History of gall-stones
!History of pancreatitis
!Family history of pancreatitis
!Trauma
2.[ADDRESS_1268955] level (NOAEL) was not observed. These tumours were not seen 
in monkeys treated for [ADDRESS_1268956] been found.
Subjects scheduled for thyroidectomy (partial or total) for any reason during the trial, must be 
instructed to inform the investigator prior to their operation. If an event of thyroid disease, including CONFIDENTIAL
Protocol Appendix B
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268957] be reported if available: 
!History of thyroid disease
!Signs and symptoms leading to investigations of thyroid disease
!Specific laboratory tests describing thyroid function including:
!Thyroid stimulating hormone (TSH)
!Total and free T3 and T4 and Free Thyroid Index
!Calcitonin
!Thyroid Peroxidase antibodies
!Thyroglobulin and Thyroglobulin antibody
!TSH receptor antibody
!Diagnostic imaging performed and any prior imaging supporting the disease history
!Pathologic examinations
!Treatment given for the condition
!Risk factors identified
!Family history of thyroid disease
2.4 Neoplasms
All events of neoplasm (excluding thyroid neoplasm, but including malignant neoplasm, in situ 
neoplasm and benign neoplasm) must be recorded as an AE and on a specific neoplasm event form 
in the eCRF. The following information must be reported if available:
!Type of neoplasm
!Symptoms leading to identification of event
!Diagnostic imaging
!Pathological examination results
!Treatment for the event
!Participation in screening programs
!Risk factors associated to the event
2.5 Renal failure
If an event of renal failure is observed during the trial the following additional information should 
be reported if available:
!Signs and symptoms of renal failure
!Specific laboratory test supporting a diagnosis of renal failure
!Imaging performed supporting the diagnosis
!Kidney biopsy resultsCONFIDENTIAL
Protocol Appendix B
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 9 of 10
!Relevant risk factors associated to the event
2.6 Medication errors
If a medication error is observed during the trial the following additional information should be 
obtained: 
!Trial product(s) involved
!Classification of medication error:
!Wrong drug(s) administered
!Wrong route of administration
!Wrong dose administered
!Whether the subject experienced any hypoglycaemic epi[INVESTIGATOR_36192]/or a dverse event(s) as a result
of the medication error
!Suspected primary reason for the medication errorCONFIDENTIAL
Protocol Appendix B
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 10 of 10
3 References
1 Hicks KA, Hung HMJ, Mahaffey KW, Mehran R, Nissen SE, Strockbridge NL et al. 
Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials (DRAFT).   20 Aug 2014. 
2 The Criteria Committee of the [LOCATION_001] Heart Association. Nomenclature and Criteria 
forDiagnosis of Diseases of the Heart and Great Vessels . 9th ed., 253-256. 1994. [LOCATION_011], Mass: 
Little, Brown & Co.CONFIDENTIAL
Protocol Appendix C
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 1 of 5
Appendix C: Monitoring of calcitonin
Trial ID: NN9068-4229
DUALTMIX - Add-on to SGLT2i
A clinical trial comparing glycaemic control and safety of 
insulin degludec/liraglutide (IDegLira) versus insulin glargine 
(IGlar) as add-on therapy to SGLT2i in subjects with type 2 
diabetes mellitus
Trial phase: 3b
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
partiesCONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Appendix C
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 2 of 5
1 Background
Treatment with GLP-1(glucagon-like peptide-1) receptor agonists has shown to be associated with 
thyroid C-cell changes in rodents but not in non-human primates. The human relevance of this 
finding is unknown. However, based on the findings in rodents, monitoring of serum calcitonin (a 
sensitive biomarker for C-cell activation) is currently being performed in clinical trials with insulin 
degludec/liraglutide (IDegLira).
While there is general agreement on the clinical interpretation of substantially elevated calcitonin 
levels (greater than 100 ng/L) as likely indicative of C-cell neoplasia, the interpretation of values 
between upper normal range (5.0 and 8.4 ng/L for women and men, respectively) and 100 ng/L is 
less clear with regards to indication of disease. 
There are several known confounding factors affecting calcitonin levels, e.g.:
!renal dysfunction
!smoking
!autoimmune thyroiditis
!several drug classes (e.g. proton pump inhibitors, beta-blockers, H 2-blockers and
glucocorticoids)
Physiology of C-cell activation in various clinical conditions and in different patient populations 
(i.e. with various co-morbidities) is poorly understood. There may be various clinical conditions not 
identified so far which mildly or moderately affect calcitonin secretion by C-cells.CONFIDENTIAL
Protocol Appendix C
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 3 of 5
2 Calcitonin monitoring
A blood sample will be drawn at pre-specified trial visits for measurement of calcitonin. Subjects 
with a calcitonin value ≥ 50 ng/L cannot be randomised according to protocol section 6.3. In case a 
subject has a calcitonin value ≥ 10 ng/L the algorithm outlined in Figure 1 and described below 
should be followed. The algorithm applies for all calcitonin values including screening values.
Figure 1 Flow of calcitonin monitoring
CONFIDENTIAL
Protocol Appendix C
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 4 of 5
2.1 Calcitonin ≥ 100 ng/L  
Action: The subject (even if a screen failure) must immediately be referred to a thyroid specialist 
for further evaluation and the trial product must be discontinued (see section 6.[ADDRESS_1268958]). The subject can remain in the trial; however, all medications 
suspected to relate to this condition must be discontinued until diagnosis has been established. 
Background : These values were found in 9 (0.15%) of a population of 5817 patients with thyroid 
nodular disease1.All of these patients were diagnosed with MTC (medullary thyroid cancer) 
resulting in a positive predictive value of 100 %.
Diagnostic evaluation should include: 
!thyroid ultrasound
!fine needle aspi[INVESTIGATOR_36260] >1 cm
!potentially surgery with neck dissection
In case a subject is diagnosed with MTC, it is common clinical practice to explore the family 
history of MTC or MEN2 (multiple endocrine neoplasia type 2) and perform a genetic test for RET 
proto-oncogene mutation.
2.2 Calcitonin ≥ 50 and < 100 ng/L
Action: The subject (even if a screen failure) should be referred to a thyroid specialist for further 
evaluation and the trial product should be discontinued. The subject can remain in the trial however; 
all medications suspected to relate to this condition should be discontinued until appropriate 
treatment has been initiated. 
Background: These values were found in 8 (0.14%) of the population of 5817 patients with thyroid 
nodular disease1.Twoof these subjects were diagnosed with MTC and two were diagnosed with C-
cell hyperplasia, resulting in a positive predictive value of a C-cell anomaly of 50%.
Diagnostic evaluation should include: 
!thyroid ultrasound examination
!if available no contraindication, a pentagastrin stimulation test. Subjects with positive
pentagastrin stimulation tests should be considered to undergo surgery
!if pentagastrin is not available, thyroid ultrasound and fine needle aspi[INVESTIGATOR_904236]
2.3 Calcitonin ≥ 10 and < 50 ng/L
Action: The subject can continue in the trial on trial product. Continue sampling of calcitonin 
according to the protocol. If the subject is a screen failure or if the value is from the last sample 
taken in the trial, the subject should be referred to a thyroid specialist for further evaluation.CONFIDENTIAL
Protocol Appendix C
CONFIDENTIALDate: 20 November 2015 Novo Nordisk
Trial ID: NN9068-4229 Version: 2.0
UTN: U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 5 of 5
Background: Calcitonin values from 20-50 ng/L were found in up to 1% of subjects of the 
population of 5817 patients with thyroid nodular disease1. The predictive value of a C-cell anomaly 
for this calcitonin level was 8.3%. However, the likelihood of having a medullary carcinoma >1 cm with calcitonin in this range is extremely low.
For calcitonin values 10-20 ng/L Costante et al1identified 216 (3.7%) patients. One patient out of 
the 216 had a subsequent basal (unstimulated) calcitonin of 33 ng/L, and had C-cell hyperplasia at surgery. Two other studies used a cut-off of CT > 10 ng/L to screen for C-cell disease, but they do not provide sufficient information on patients with basal CT >10 and <20 ng/L to allow conclusions
2,3.
3 References
1 Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S et al. Predictive value of 
serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007; 92(2):450-455.
2 Scheuba C, Kaserer K, Moritz A, Drosten R, Vierhapper H, Bieglmayer C et al. Sporadic 
hypercalcitoninemia: clinical and therapeutic consequences. Endocr Relat Cancer 2009; 16(1):243-253.
3 Verga U, Ferrero S, Vicentini L, Brambilla T, Cirello V, Muzza M et al. Histopathological and 
molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia? Endocr Relat Cancer 2007; 14(2):393-403.CONFIDENTIAL
Global and country key Novo Nordisk staff
Attachments I and II (if applicable) to the protocol are located in the Trial Master File.
Content: Global key staff and Country key staffCONFIDENTIALDate: Novo Nordisk
Version:
Status:IDegLira
Trial ID: NN9068-4229Clinical Trial Report
Appendix 16.1.1 0DUFK  2018

)LQDOCONFIDENTIAL
Protocol amendment Nº 1
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9068-4229 Version: 1.0
UTN: U111 -1168-9343 Status: Final
EudraCT No: 2015-001596-48 Page: 1o f  4
Substantial amendment nº 1 to proto col version 2.0 dated on 20-
Nov-2015. .
Trial ID: NN9068 -4229
DUALTMIX - Add-on to SGLT2i
A clinical trial comparing glycaemic control and 
safety of insulin degludec/liraglutide (IDegLira) 
versus insulin glargine (I Glar) as add- on therapy to 
SGLT2i in subjects with type 2 diabetes mellitus.
Trial phase: 3b
Applicable to Spain
Author
,
Clinical Operations Spain
CMR Spain, CDC Europe
This confidential document is the proper ty of Novo Nordisk. No unpublished information contained 
herein may be disclosed without prior written approv al from Novo Nordisk. Access to this document 
must be restricted to relevant parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties. 
 
 
 
 
Redacted protocol 
Includes redaction of personal identifiable information only. 
 
 
 
. 
 
 
Protocol amendment Nº 1
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9068-4229 Version: 1.0
UTN: U111 -1168-9343 Status: Final
EudraCT No: 2015-001596-48 Page: 2o f  4
Table of contents   
    Page 
Table of contents ............................................................................................................. .................................. 2
1Introduction including rationale for the substantial amendment ......................................................... 3
2Changes ....................................................................................................................... ............................... 4
Appendix A Approval of final substantial amendment nº 1 
Appendix B Agreement on final substantial amendment nº 1 CONFIDENTIAL
Protocol amendment Nº 1
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9068-4229 Version: 1.0
UTN: U111 -1168-9343 Status: Final
EudraCT No: 2015-001596-48 Page: 3o f  4
1Introduction including rationale for the substantial 
amendment 
Based on the recommendation of Spanish HA (A EMPS) that the protocol should contain detailed 
information on the required level of contraception tak ing into account the possible toxicity of the 
investigational drug. And also we should consid er recommendations on contraception in clinical 
trials by [CONTACT_536490] (CFTG1), the protocol has been revised with regards to 
the exclusion criteria nº 4 changing from “females of childbearing potential not using adequate 
contraceptive methods” to “females of childbearing potential not using highly effective 
contraceptive methods”.
According to CFTG contraceptive methods defined as “highly effective” (methods that can achieve 
a failure  rate of less than 1% per year when used consistently and correctly) are: 
•Combined (estrogen and progestogen contain ing) hormonal contraception associated with 
inhibition of ovulation (oral, intravaginal or transdermal) 
•Progestogen-only hormonal contraception asso ciated with inhibition of ovulation (oral, 
injectable or implantable) 
•Intrauterine device (IUD) 
•Intrauterine hormone-releasing system (IUS) 
•Bilateral tubal occlusion 
•Vasectomised partner 
•Sexua l abstinence 
1http://www.hma.eu/fileadmin/dateien/Human_Medicines/01- 
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf CONFIDENTIAL
Protocol amendment Nº 1
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9068-4229 Version: 1.0
UTN: U111 -1168-9343 Status: Final
EudraCT No: 2015-001596-48 Page: 4o f  4
2Changes 
The protocol has been changed accordingly. Remove d text is strikethrough and new text is shown 
in italics: 
6.[ADDRESS_1268959]-feeding or intend to become pregnant or of 
childbearing potential not using adequate highly effective  contraceptive methods 
(highly effective  adequate contraceptive measures as required by [CONTACT_904281]) 
Spain : Highly effective methods are de fined as established use of: 
xoral, injectable, transdermal, implantable or intravaginal hormonal methods 
of contraception associated with inhibition of ovulation 
xplacement of an intrauterine device 
xfemale sterilisation
xmale sterilisation (where partner is sole partner of subject) 
xtrue abstinence (when in line wi th preferred and usual lifestyle) CONFIDENTIAL
Protocol Amendment 2
CONFIDENTIALDate: 28 November 2016 Novo Nordisk
Trial ID: NN9068-4229 Version: 1.0
UTN:U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 1 of 19
Protocol Amendment
No. 2
to Protocol, final version 2.0
dated 20 November 2015
Trial ID: NN9068-4229
DUALTMIX - Add-on to SGLT2i
A clinical trial comparing glycaemic control and safety of insulin 
degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on 
therapy to SGLT2i in subjects with type 2 diabetes mellitus 
Trial phase: 3b
Applicable to all countries
Amendment originator:
, 
Trial Operations, Insulin and Devices
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties. 
 
 
 
 
Redacted protocol 
Includes redaction of personal identifiable information only. 
 
 
. 
 
 
Protocol Amendment 2
CONFIDENTIALDate: 28 November 2016 Novo Nordisk
Trial ID: NN9068-4229 Version: 1.0
UTN:U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268960] of abbreviations ....................................................................................................... ...............5
2.2 Section 1 Summary........................................................................................................... .............5
2.3 Section 2 Flowchart ......................................................................................................... ..............6
2.4 Section 6.5 Rescue criteria................................................................................................. ..........11
2.5 Section 8.1.3 Screening failures ............................................................................................ ......11
2.6 Section 8.1.4 Ra ndomisation (V2)............................................................................................ ...[ADDRESS_1268961].............................................................11
2.8 Section 8.2 Laborat ory assess ments .......................................................................................... ..12
2.9 Section 8.4.1 Body measurements............................................................................................. ..12
2.10 Section 8.5.2 Hypogl ycaemic epi[INVESTIGATOR_1841] ....................................................................................... 12
2.11 Section 8.5.5 Electro cardiogram (ECG) ...................................................................................... 12
2.12 Section 8.6.1 Qu estionnaires ............................................................................................... ........12
2.13 Section 9.1 Trial products................................................................................................. ...........13
2.14 Section 9.4 Drug accountability  and destruction .........................................................................13
2.15 Section 12.1 Definitions ................................................................................................... ...........13
2.16 Section 12.2 Reporting of adverse events................................................................................... .14
2.17 Section 12.5.1 Pregnancies in female subjects ............................................................................14
2.18 Section 13.2 Case report form flow......................................................................................... ....14
2.19 Section 17.3.1 Primary statistical analysis prima ry estimand......................................................14
2.20 Section 17.3.2 Sensitivity an alyses primary estimand.................................................................15
2.21 Section [IP_ADDRESS] Primary statistical analyses primary estimand..................................................15
2.22 Section [IP_ADDRESS] Sensitivity an alyses primary estimand..............................................................16
2.23 Section [IP_ADDRESS] Sensitivity an alyses seconda ry estimand ..........................................................17
2.24 Section [IP_ADDRESS] Eff icacy endpoints ........................................................................................ ....17
2.25 Section [IP_ADDRESS] Saf ety endpoints.......................................................................................... ......18
2.26 Section 17.5 Health economics and/ or patient reported  outcomes ..............................................18
2.27 Section 18.1 Benefit-risk assessment of the trial.........................................................................1 8
2.28 Section [IP_ADDRESS] Iden tified risks .......................................................................................... ........18
2.29 Appendix A: Titr ation Guideline............................................................................................ .....18CONFIDENTIAL
Protocol Amendment 2
CONFIDENTIALDate: 28 November 2016 Novo Nordisk
Trial ID: NN9068-4229 Version: 1.0
UTN:U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 3 of 19
1 Introduction including rationale for the protocol amendment
In this protocol amendment:
!Any new text is written in italics.
!Any text deleted from the protocol is written using strike through.
1.1 Rationale for the amendment
This amendment has been prepared in order to:
1. Update List of abbreviations
2. Update the flowchart:
!deletion of footnote 7 – as not applicable in final eCRF
!update of flowchart and protocol section 8.[ADDRESS_1268962] cm or inch as not 
applicable in final eCRF  
8. In section 8.5.2 insert “>” in front of 3.9 mmol/L.
In addition, in the 5thbullet in order to align with the diary, specify that date, time, and dose of 
last anti-diabetic treatment should not be collected  in connection with  a hypoglycaemic event 
between V32 and V33 
9. In section 8.5.[ADDRESS_1268963] more than 14 days after the ECG is obtained. In addition delete 
whom the ECG should be obtained by
10. In section 8.6.1, align with the PRO questionnaire that site staff can fill in the headings on the 
questionnaire forms and review the questionnaire for empty fields and potential adverse events
11. In Summary and section 9.1 specify that SGLT2i and metformin not necessarily “will be” but 
“can be” reimbursed in accordance with local legislation and Ethics Committee approval
12. In section 12.1 update serious adverse event with current protocol template text and definition 
of Major Adverse Cardiovascular Events (MACE) 
13. In section 12.2 specify that “fasting body weight” should be measured at V32A CONFIDENTIAL
Protocol Amendment 2
CONFIDENTIALDate: 28 November 2016 Novo Nordisk
Trial ID: NN9068-4229 Version: 1.0
UTN:U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 4 of 19
14. In section 12.5.1 specify forms to be completed 
15. Update made to section 13.2 in order to align with other parts of the protocol
16. In section 17 statistical terminologies of “jump to reference” and “copy reference” have been 
abolished and updated with established terminologies “multiple imputation conditional” and 
“multiple imputation unconditional” 
17. In section 18.1 align text with other parts of the protocol
18. Update section 18.1.1 with “acute gallstone disease” in accordance with update to IDegLira 
Minimum Mandatory Safety Text
19. Make typographical changes
20. In appendix A: align with section 5.3 the wording regarding starting dose of IDegLira and 
specification of dose adjustmentCONFIDENTIAL
Protocol Amendment 2
CONFIDENTIALDate: 28 November 2016 Novo Nordisk
Trial ID: NN9068-4229 Version: 1.0
UTN:U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268964] of abbreviations
CR
J2R
ANOVA
CAS
ITT
MCMC
NI
PPcopy reference  
jump to reference
analysis of variance
completer analysis set
intention to treat
Markov Chain Monte Carlo 
non-inferiority
per-protocol
2.2 Section 1 Summary
Trial products:
The subject’s de-facto cost of SGLT2i and metformin (mono- or fixed dose combination products) 
willcanbe reimbursed in accordance with local legislation and Ethics Committee approval.CONFIDENTIAL
Protocol Amendment 2 UTN:U1111-1168-9343 Date: 28 November 2016 Status: Final Novo Nordisk
Trial ID: NN9068-[ADDRESS_1268965] No.: 2015-001596-48 Version: 1.0 Page: 6 of 19
2.3 Section 2 Flowchart 1
Trial Periods Screen Rand Treatment EoT Follow-up Pre-disc1
Trial site visit (V)
Phone contact (P)2V1 V2 P3 V4 P5 V6 P7 V8 P9 V10P11
P12
P13 V14P15
P16
P17 V18P19
P20
P21 V22P23
P24
P25 V26P27
P28
P29
P30
P31 V32FU1
V33FU2
P34 PX V32A
Timing of visit (weeks)≤ [ADDRESS_1268966] 
trial 
productEvery 
4 
weeks 26
Visit window (days) ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±[ADDRESS_1268967] RELATED
INFO/ASSESSMENTS
Informed consent X
In/exclusion criteria X X
Randomisation X
Pre-discontinuation of 
trial productX X X X X X X X X X X X X X X X X X
Rescue criteria X X X X X X X X X X X X X X
Withdrawal of consent X X X X X X X X X X X X X X X X X X X X4X
Demography5X
Concomitant illness X
Medical history X
Diagnosis of diabetes X
Diabetes complications X
                                                
1Subjects discontinuing trial product prematurely will be asked to attend the end of treatment (EoT) visit and the two follow up visits after discontinuation corresponding to V32, V33 and 
P34. After the follow-up period the subject should have phone contacts scheduled every 4 weeks (PX) until the additional premat ure discontinuation follow-up visit (V32A) performed at 
week 26. See section 2.7for further details.
2A phone contact [CONTACT_904245] a trial site visit e.g. if further titration is needed.
3Corresponding to previous visit date plus [ADDRESS_1268968] prematurely.
5Collection of sex and date of birth, race and ethnicity only if applicable by [CONTACT_1769].
Protocol Amendment 2 UTN:U1111-1168-9343 Date: 28 November 2016 Status: Final Novo Nordisk
Trial ID: NN9068-[ADDRESS_1268969] No.: 2015-001596-48 Version: 1.0 Page: 7 of 19
Trial Periods Screen Rand Treatment EoT Follow-up Pre-disc1
Trial site visit (V)
Phone contact (P)2V1 V2 P3 V4 P5 V6 P7 V8 P9 V10P11
P12
P13 V14P15
P16
P17 V18P19
P20
P21 V22P23
P24
P25 V26P27
P28
P29
P30
P31 V32FU1
V33FU2
P34 PX V32A
Timing of visit (weeks)≤ [ADDRESS_1268970] 
trial 
productEvery 
4 
weeks 26
Visit window (days) ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±[ADDRESS_1268971] circumference X X X
Glucose metabolism
HbA1c X X X X X X X X X
Fasting plasma glucose8X X X X X X X
Lipi[INVESTIGATOR_805] X X X
Self measured plasma 
glucose (SMPG)
                                                
6Only anti-diabetic medication will be collected.
7If no insulin is taken by [CONTACT_423], please enter “0” in the eCRF
7Body weight should be measured fasting except at V1, see section 8.1.[ADDRESS_1268972] attend visits fasting, see section 8.1.1
Protocol Amendment 2 UTN:U1111-1168-9343 Date: 28 November 2016 Status: Final Novo Nordisk
Trial ID: NN9068-[ADDRESS_1268973] No.: 2015-001596-48 Version: 1.0 Page: 8 of 19
Trial Periods Screen Rand Treatment EoT Follow-up Pre-disc1
Trial site visit (V)
Phone contact (P)2V1 V2 P3 V4 P5 V6 P7 V8 P9 V10P11
P12
P13 V14P15
P16
P17 V18P19
P20
P21 V22P23
P24
P25 V26P27
P28
P29
P30
P31 V32FU1
V33FU2
P34 PX V32A
Timing of visit (weeks)≤ [ADDRESS_1268974] 
trial 
productEvery 
4 
weeks 26
Visit window (days) ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±3
Once daily9X X X X X X X X X X X X X X
9-point profile10X X X
SAFETY
Adverse events X X X X X X X X X X X X X X X X X X X X X X X11X11
Hypoglycaemic epi[INVESTIGATOR_1841] X X X X X X X X X X X X X X X
Technical complaints X X X X X X X X X X X X X X X
ECG X X12
Eye examination X13X14
Physical examination X X
Vital signs X X X X
Biochemistry X X X X X X
Haematology X X X X
Hormones (calcitonin) X X X X
Urinalysis 
(albumin:creatinine ratio)X X X
Urine dipstick X X X
                                                
9Subjects should measure "self measured plasma glucose" prior to breakfast. Diabetes medication should be withheld until after th e SMPG measurement.
109-point profile should be measured within one week prior to the site visit (on a day where unusual strenuous exercises is not a nticipated).
11Only AE information for potential major adverse cardiovascular events (MACE) and SAE information will be collected.
12ECG obtained within [ADDRESS_1268975] the screening assessment if resul ts are available for evaluation at V2. 
14Eye examination performed within 2 weeks prior to V32 is acceptable if results are available for evaluation at V32.
Protocol Amendment 2 UTN:U1111-1168-9343 Date: 28 November 2016 Status: Final Novo Nordisk
Trial ID: NN9068-[ADDRESS_1268976] No.: 2015-001596-48 Version: 1.0 Page: 9 of 19
Trial Periods Screen Rand Treatment EoT Follow-up Pre-disc1
Trial site visit (V)
Phone contact (P)2V1 V2 P3 V4 P5 V6 P7 V8 P9 V10P11
P12
P13 V14P15
P16
P17 V18P19
P20
P21 V22P23
P24
P25 V26P27
P28
P29
P30
P31 V32FU1
V33FU2
P34 PX V32A
Timing of visit (weeks)≤ [ADDRESS_1268977] 
trial 
productEvery 
4 
weeks 26
Visit window (days) ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±3
Pregnancy test15X (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) X
OTHER ASSESSMENTS
Barriers in Diabetes 
Treatment questionnaireX
PRO questionnaires
TRIM-D X X X
SF-36v2 X X X
TRIAL MATERIAL
Dispensing trial product X X X X X X X
IWRS call X X X X X X X X X
Dosing dates16X X
Drug accountability X X X X X X X X
REMINDERS
Hand-out ID card X
Discontinue DPP4i X
Training in trial product 
and pen handling.X X X X X X X
Dispense directions for X X X X X X X
                                                
15For women of childbearing potential a blood sample pregnancy test must be performed at V1 and V32. Additionally, a urine pregna ncy test should be performed at site if pregnancy is 
suspected or if a menstrual period is missed. If the subject reports missing menstrual period at a phone contact, the subject wi ll have to attend the site for an unscheduled visit as soon as 
possible to have an urine pregnancy test performed. If positive a confirmatory serum hCG test should be sent to the central lab oratory. If required by [CONTACT_1769], pregnancy test may be 
performed regularly.
16First and last dates and doses as recorded in patient diaries.
Protocol Amendment 2 UTN:U1111-1168-9343 Date: 28 November 2016 Status: Final Novo Nordisk
Trial ID: NN9068-[ADDRESS_1268978] No.: 2015-001596-48 Version: 1.0 Page: 10 of 19
Trial Periods Screen Rand Treatment EoT Follow-up Pre-disc1
Trial site visit (V)
Phone contact (P)2V1 V2 P3 V4 P5 V6 P7 V8 P9 V10P11
P12
P13 V14P15
P16
P17 V18P19
P20
P21 V22P23
P24
P25 V26P27
P28
P29
P30
P31 V32FU1
V33FU2
P34 PX V32A
Timing of visit (weeks)≤ [ADDRESS_1268979] 
trial 
productEvery 
4 
weeks 26
Visit window (days) ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±[ADDRESS_1268980] in 
BG meterX
Attend visit fasting X X X X X X X X
Make appointment for eye 
examinationX
Sign off Casebook X17X
End of trial 
(subject completion)X17X
                                                
17Not applicable for subjects that have prematurely discontinued trial product.
Protocol Amendment 2
CONFIDENTIALDate: 28 November 2016 Novo Nordisk
Trial ID: NN9068-4229 Version: 1.0
UTN:U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268981] SMPG values taken on three consecutive days or if any of the FPG samples 
analysed by [CONTACT_826683]:
!15.0 mmol/L (270 mg/dL) from after baseline to week 6
!13.3 mmol/L (240 mg/dL) from week 7 to week 12
!11.1 mmol/L (200 mg/dL) from week [ADDRESS_1268982] for any reason is not eligible for the trial or are not randomised within 14 
calendar days after the screening visit (V1), the subject will be considered a screening failure. For 
screening failures the screening failure form in the eCRF must be completed with the reason for not 
continuing in the trial. Serious and non-serious AEs from screening failures must be transcribed by [CONTACT_215546]. Follow-up of SAEs must be carried out according to section 12.3. 
Screening failures experiencing an AE that would otherwise qualify for adjudication (see section 
12.7) will not be adjudicated as no trial product has been administered. 
2.6 Section 8.1.4 Randomisation (V2)
Randomisation must NOT take place more than 14 calendar days after V1 (screening). All results 
from screening assessments, including laboratory results, ECG and eye examination must be 
available and reviewed by [CONTACT_904249]/exclusion criteria must be carefully 
reviewed to ensure the subject is eligible prior to the randomisation. 
2.[ADDRESS_1268983] 
should be contact[CONTACT_12090] 4 weeks. Information on antidiabetic medication and
information on potential major cardiovascular events (MACE) and any SAEs occurring since last 
contact [CONTACT_904250]. Phone contacts must be documented in the 
medical record and in the eCRF. The subject should finally come in for a V32A at week [ADDRESS_1268984] fasting body 
weight measured and a blood sample taken to measure HbA 1c, see flow chart (section 2).CONFIDENTIAL
Protocol Amendment 2
CONFIDENTIALDate: 28 November 2016 Novo Nordisk
Trial ID: NN9068-4229 Version: 1.0
UTN:U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268985] at the 
completion of the clinical trial report (CTR). However in case of abnormal haematology analysis 
test results, part of the sample may be kept for up to 2 years.
2.9 Section 8.4.1 Body measurements
Height is measured without shoes in centimetres (cm) or inches. and rounded to the nearest cm or 
inch.
2.10 Section 8.5.2 Hypoglycaemic epi[INVESTIGATOR_688133] a hypogl ycaemic epi[INVESTIGATOR_36190].
All plasma glucose values:
!≤ 3.9 mmol/L (70 mg/dL) or
!>3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms 
5thbullet:
!Date, time, and dose of last trial product (and other anti-diabetic treatment, except between V32 
and V33 ) administration prior to the epi[INVESTIGATOR_1865]
2.11 Section 8.5.5 Electrocardiogram (ECG)
A 12-lead ECG must be performed. by [CONTACT_904252]. The ECG must be 
interpreted, signed and dated by [CONTACT_904282]. The ECG at screening must be done at the latest at V2 and 
the results interpreted by [CONTACT_904283]. can be 
obtained at the latest at V2. The result of the ECG must be available to the investigator prior to 
randomisation. The ECG must not be obtained more than 2 weeks prior to V2; in that case a re-
assessment is necessary.
2.[ADDRESS_1268986] be documented either on the documents and/or in the subject’s medical record.CONFIDENTIAL
Protocol Amendment 2
CONFIDENTIALDate: 28 November 2016 Novo Nordisk
Trial ID: NN9068-4229 Version: 1.0
UTN:U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 13 of 19
2.13 Section 9.1 Trial products
During the 26-weeks treatment period and the 4 weeks follow-up period; the patients de-facto cost 
(actual patient cost, not covered by [CONTACT_217928]/any insurance) of SGLT2i and metformin 
(mono- or fixed dose combination products) canwill be reimbursed in accordance with local 
legislation and Ethics Committee approval. Pi[INVESTIGATOR_904208].
2.[ADDRESS_1268987] always be reported as a SAE using the important medical event 
criterion if no other seriousness criteria are applicable:
!suspi[INVESTIGATOR_36225] 
!risk of liver injury defined as ALT or AST >3 x upper normal limit and total bilirubin >2 x 
upper normal limit, where no alternative aetiology exists (Hy's law)
Major adverse cardiovascular event 
A major adverse Anycardiovascular event (MACE) is any AE which can be categorised into the 
following groups will be evaluated as a potential Major Adverse Cardiovascular Event (MACE) :
!Cardiovascular Death
!Myocardial Infarction
!Hospi[INVESTIGATOR_904212] 
!Transient Ischemic Attack and Stroke 
!Heart Failure Event (requiring hospi[INVESTIGATOR_11956])
!Cardiac procedures
oInterventional Cardiology
oPeripheral Vascular Intervention 
oStent Thrombosis
A MACE is defined as:
!Cardiovascular Death
!Non-fatal Myocardial Infarction
!Non-fatal StrokeCONFIDENTIAL
Protocol Amendment 2
CONFIDENTIALDate: 28 November 2016 Novo Nordisk
Trial ID: NN9068-4229 Version: 1.0
UTN:U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268988]-treatment follow-up periods. Please be aware that hypoglyc aemic epi[INVESTIGATOR_904213] e.g. hypoglycaemic epi[INVESTIGATOR_904214] (V2). Subjects discontinuing trial product prematurely (see section 6.4) will be 
contact[CONTACT_457] 4th week and asked for information about antidiabetic medication, MACE and 
SAEs. These subjects should finally come in for a V32A at week 26, only to assess antidiabetic 
medication, MACE, SAEs, fasting body weight and a blood sample to measure HbA 1c.
2.17 Section 12.5.1 Pregnancies in female subjects
Forms and timelines for reporting AEs:
Non-serious AEs: 
!Paper AE form* within 14 calendar days of the investigator's first knowledge of the initial or 
follow-up information to the non-serious AE.
SAEs: 
!Paper AE form* within 24 hours of the investigator's first knowledge of the SAE
!Paper SIF within 5 calendar days of the investigator's first knowledge of the SAE
!SAE follow-up information to the AE form and/or SIF within 24 hours of the investigator's 
first knowledge of the follow-up information
* It must be clearly stated in the AE diagnosis field on the AE form if the event occurred in the 
subject, foetus or newborn infant. If the AE occurred in the foetus or newborn infant, the AE can 
only be reported on paper AE and SIF.
2.[ADDRESS_1268989] be 
entered within 24 hours after the site visit/phone contact [CONTACT_853299].
2.19 Section 17.3.1 Primary statistical analysis primary estimand
Multiple imputation – unconditional jump to reference – retrieved data – NI penalty
The primary estimand will be estimated based on the FAS using all post baseline HbA 1c
measurements obtained at planned visits up to and including week 26, and data retrieved at week 26 
(V32A) from subjects prematurely discontinued from randomised treatment. To estimate this 
estimand for evaluation of non-inferiority of HbA 1c, a pattern mixture model approach35will be CONFIDENTIAL
Protocol Amendment 2
CONFIDENTIALDate: 28 November 2016 Novo Nordisk
Trial ID: NN9068-4229 Version: 1.0
UTN:U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 15 of 19
adopted based on sequential modelling using the conditional approach described generally in 
section 7.3.1 and the conditional approach specifically in section 7.4.2 in the book by O’Kelly and 
Ratitch35. A penalty in terms of the NI margin is added to withdrawn or prematurely discontinued 
subjects in the IDegLira arm. It mimics an ITT scenario where withdrawn and prematurely 
discontinued subjects from the investigational treatment (IDegLira) arm not having a week 26 
measurement are assumed to be switched to a treatment inferior to comparator (IGlar) or any other 
treatment received after premature treatment discontinuation. This corresponds to a jump to 
reference (J2R) principle where a penalty in terms of the NI margin is added to withdrawn or 
prematurely discontinued subjects in the IDegLira arm. Observe that the imputation method J2R 
principle and use of retrieved (V32A) data in analyses will equalise treatment effects and in turn 
assay sensitivity in the non-inferiority setting may be jeopardized. The penalty of the non-inferiority 
margin36is to remedy this. Multiple copi[INVESTIGATOR_014] (1000 copi[INVESTIGATOR_014]) of the full dataset will be generated by 
[CONTACT_904267] a subgroup of subjects in the trial. 
2.20 Section 17.3.2 Sensitivity analyses primary estimand
Multiple imputation – conditional jump to reference – retrieved data – NI penalty
The analysis is similar to the primary analysis except that observed values for prematurely 
discontinued IDegLira subjects are not set missing (step 1 is left out). Observe that for IDegLira 
now only missing data after premature discontinuation are imputed by [CONTACT_904269] 
(step 3 to 5) and this corresponds to the conditional sequential modelling approach described in 
section 7.4.3 in the book by O’Kelly and Ratitch35principle is named copy reference (CR); 
intermittent missing data are imputed by [CONTACT_85222] (step 2). 
Multiple imputation – unconditional jump to reference– retrieved data – NI penalty – tippi[INVESTIGATOR_904237] – unconditional jump to reference– retrieved data – NI penalty – CAS
Multiple imputation – unconditional jump to reference– retrieved data – NI penalty – PP
2.21 Section [IP_ADDRESS] Primary statistical analyses primary estimand
Body weight – multiple imputation – unconditional – retrieved data
The change from baseline in body weight after 26 weeks will be analysed with the multiple 
imputation unconditional sequential J2R pattern mixture model for HbA 1c, substituting body weight 
for HbA 1cand leaving out the non-inferiority penalty (step 6).CONFIDENTIAL
Protocol Amendment 2
CONFIDENTIALDate: 28 November 2016 Novo Nordisk
Trial ID: NN9068-4229 Version: 1.0
UTN:U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 16 of 19
Treatment-emergent hypoglycaemic epi[INVESTIGATOR_1841] – multiple imputation – method 1
The number of hypoglycaemic epi[INVESTIGATOR_111366] a multiple imputation technique for 
count data under the J2R principle as follows.
Glycaemic control – multiple imputation – unconditional – retrieved data
The change from baseline in HbA 1cafter 26 weeks will be analysed with the multiple imputation 
unconditional sequential J2R pattern mixture model for HbA 1cbut leaving out the non-inferiority 
penalty (step 6).
Insulin dose – multiple imputation – unconditional – retrieved data
The insulin dose after 26 weeks will be analysed with the multiple imputation unconditional 
sequential J2R pattern mixture model for HbA 1c, substituting insulin dose for HbA 1c, leaving out 
the non-inferiority penalty (step 6) and using baseline HbA 1cas covariate as there is no baseline 
dose. 
2.22 Section [IP_ADDRESS] Sensitivity analyses primary estimand
Continuous endpoints, body weight, HbA 1cand insulin dose – multiple imputation –
conditional copy reference– retrieved data
These analyses are repeats of the primary analyses using the conditional approach CR principle in 
place of the unconditional approach J2R principle, just as for the conditional CR sensitivity 
analysis of the primary estimand of the primary objective.
Continuous endpoints body weight, HbA 1cand insulin dose – multiple imputation –
unconditional jump to reference– retrieved data – tippi[INVESTIGATOR_904238] – multiple imputation – method [ADDRESS_1268990] discontinuation rate is the 
rate of comparator (IGlar).
Count endpoint hypoglycaemic epi[INVESTIGATOR_1841] – multiple imputation – method 1 jump to reference–
tippi[INVESTIGATOR_904239] a repeat of method [ADDRESS_1268991] 
discontinuation event rate until IDegLira is no longer superior to IGlar.CONFIDENTIAL
Protocol Amendment 2
CONFIDENTIALDate: 28 November 2016 Novo Nordisk
Trial ID: NN9068-4229 Version: 1.0
UTN:U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 17 of 19
2.23 Section [IP_ADDRESS] Sensitivity analyses secondary estimand
Continuous endpoints body weight, HbA1c and insulin dose – multiple imputation –
unconditional jump to reference– retrieved data
2.24 Section [IP_ADDRESS] Efficacy endpoints
For each of the multiple copi[INVESTIGATOR_014] (1000) of the full dataset of the primary analysis of the primary 
estimand ( unconditional multiple imputation J2R with retrieved data, NI penalty section 2.19) the 
responder endpoints are derived without using the non-inferiority penalty (step 6) and analysed with 
the standard logistic regression model. Estimates are pooled using Rubin’s rule37.
Waist circumference change from baseline after [ADDRESS_1268992] circumference will be analysed by [CONTACT_904284]2R. 
Fasting plasma glucose change from baseline after 26 weeks
Change from baseline in FPG will be analysed by [CONTACT_904285]2R.
Fasting lipid profile after 26 weeks
Cholesterol, LDL cholesterol, HDL cholesterol, VLDL cholesterol, triglycerides and free fatty acids 
will be analysed separately by [CONTACT_904286] J2R. In these statistical analyses, 
the endpoint will be log-transformed and so will the corresponding baseline covariate.
Self-measured plasma glucose (SMPG) 9-point profile change from baseline after [ADDRESS_1268993] model will be fitted to the 9-point SMPG profile data. The model will include 
treatment, pre-trial OAD, time (within 9-point profile), the interaction between treatment and time, 
the interaction between pre-trial OAD and time as fixed factors, and subject as random effect , 
where measurements within subjects will be assumed correlated as specified by a compound 
symmetric covariance matrix . From the model mean profile by [CONTACT_904287]. 
Change from baseline in mean of the 9-point profile and prandial increment endpoints will be 
analysed separately by [CONTACT_904286] J2R.
Blood pressure (systolic and diastolic) change from baseline after 26 weeks
Change from baseline in systolic and diastolic blood pressure will be analysed separately by 
[CONTACT_904286] J2R.CONFIDENTIAL
Protocol Amendment 2
CONFIDENTIALDate: 28 November 2016 Novo Nordisk
Trial ID: NN9068-4229 Version: 1.0
UTN:U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: 18 of 19
2.25 Section [IP_ADDRESS] Safety endpoints
Hypoglycaemic epi[INVESTIGATOR_51953] 26 weeks
Number of nocturnal treatment-emergent severe or BG confirmed symptomatic hypoglycaemic 
epi[INVESTIGATOR_51953] 26 weeks will be analysed using the same (method 1) J2R multiple imputation 
model as used for the treatment-emergent severe or BG confirmed symptomatic hypoglycaemic 
epi[INVESTIGATOR_1841].
Pulse rate change from baseline after 26 weeks
Change from baseline in pulse rate will be analysed by [CONTACT_904286] J2R.
2.26 Section 17.5 Health economics and/or patient reported outcomes
For each questionnaire, the summary scores will be summarised descriptively by [CONTACT_904288]
J2R.
2.[ADDRESS_1268994] , if the level of glycaemic control exceeds acceptable limits during trial participation. 
2.28 Section [IP_ADDRESS] Identified risks 
Acute gallstone disease
Cases of gallstones (cholelithiasis) and inflammation of the gallbladder (cholecystitis) have been 
reported from clinical trials with IDegLira. Both cholelithiasis and cholecystitis have possible 
clinical implications for the patients as the events might lead to hospi[INVESTIGATOR_513440]. If cholelithiasis is suspected, treatment should be discontinued and gallbladder 
examination and appropriate clinical follow-up should be initiated. If acute gallstone disease is 
confirmed, the trial product must be permanently discontinued.
2.29 Appendix A: Titration Guideline
Section 3.1 Initiation of IDegLira or IGlar
Forsubjects randomised to IDegLira will the recommended start dose is on 10 dose steps, 
consisting of 10U insulin degludec/0.36 mg liraglutide once daily.CONFIDENTIAL
Protocol Amendment 2
CONFIDENTIALDate: 28 November 2016 Novo Nordisk
Trial ID: NN9068-4229 Version: 1.0
UTN:U1111-1168-9343 Status: Final
EudraCT No.: 2015-001596-48 Page: [ADDRESS_1268995] be adjusted twice weekly on fixed days (Mondays and 
Thursdays). CONFIDENTIAL